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Summary 
This thesis deals with sequential and adaptive methods for clinical trials, and how such 
methods can be used to achieve eﬃcient clinical trial designs. The eﬃciency gains that 
can be achieved through non-adaptive group sequential methods are well established, 
while the newer adaptive methods seek to combine the best of the classical group 
sequential framework with an approach that gives increased ﬂexibility. 
Our results show that the adaptive methods can provide some additional eﬃciency, 
as well as increased possibilities to respond to new internal and external information. 
Care is however needed when applying adaptive methods. While sub-optimal rules for 
adaptation can lead to ineﬃciencies, the logistical challenges can also be considerable. 
Eﬃcient non-adaptive group sequential designs are often easier to implement in 
practice, and have for the cases we have considered been quite competitive in terms of 
eﬃciency. 
The four problems that are presented in this thesis are very relevant to how clinical 
trials are run in practice. The solutions that we present are either new approaches 
to problems that have not previously been solved, or methods that are more eﬃcient 
than the ones currently available in the literature. Several challenging optimisation 
problems are solved through numerical computations. The optimal designs that are 
achieved can be used to benchmark new methods proposed in this thesis as well as 
methods available in the statistical literature. 
The problem that is solved in Chapter 5 can be viewed as a natural extension to 
the other problems. It brings together methods that we have used to the design of 
individual trials, to solve the more complex problem of designing a sequence of trials 
that are the core part of a clinical development program. The expected utility that is 
maximised is motivated by how the development of new medicines works in practice. 
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CHAPTER 1 
Introduction 
1.1 Development of new medicines 
Over the past decades, great advances have been made in medicine. There are, however, 
many conditions that remain without satisfactory treatment options. Moreover, there 
may be room for further improvements in areas where important progress has already 
been achieved. New drugs have for example been successful in treating cardiovascular 
risk factors like elevated cholesterol and hypertension, with associated reductions in 
cardiovascular events such as myocardial infarction and stroke. Despite this progress, 
cardiovascular disease remains one of the most important causes of death around the 
world. In other areas, the drugs that are available can slow the progression of a 
disease somewhat, without actually providing a cure. Further improvement through 
new medicines may then still be possible, in terms of reduced mortality or improved 
quality of life. 
There are clearly many areas of unmet medical need, where new medicines could 
provide important improvements to the life of patients. Before a new medicine 
can be made publicly available, it must be shown to be safe and eﬃcacious in the 
patient population where it will be used. Randomised clinical trials, where patients 
are randomly assigned to one of several treatment groups, are considered to be the 
most reliable way to evaluate a new experimental drug. They make it possible to 
make causal inference about the treatment eﬀect, and assess the beneﬁts and risks 
of diﬀerent treatment regimens. Such risk/beneﬁt assessments form the basis for 
regulatory authorities when deciding whether to approve a new drug. 
Whenever possible from a logistical perspective, it is desirable that randomised 
clinical trials are double-blind. In a double-blind trial, neither the patient nor 
the investigator knows to which treatment group the patient has been randomised. 
The intention is to remove the possibility for the investigator to approach patients 
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diﬀerently, depending on to which treatment group the patients have been randomised. 
Making sure that a trial is double-blind is thought to reduce bias and increase the 
scientiﬁc credibility of the results. 
Conducting a double-blind randomised clinical trial can present diﬃcult ethical 
issues. In some situations it may for example be considered unethical to randomise 
patients to placebo, particularly for conditions where a safe and eﬃcacious treatment 
is already available for public use. As stated in the declaration of Helsinki, it 
is fundamental that patients make informed decisions about whether they wish to 
participate in a clinical trial, both initially and throughout the duration of the trial 
(World Medical Association, 2008). This process is referred to as patients giving their 
informed consent to participating in the trial. Patients providing their informed consent 
is one of the key principles of good clinical practice, which should be followed for a 
clinical trial to be credible. The International Conference for Harmonisation (ICH) 
Guideline E6 aims to protect the ethical and scientiﬁc quality of clinical trials and is a 
good source for further information about such matters (ICH, 1996). 
Clinical trials have traditionally been divided into four phases. The characteristics 
of each phase can diﬀer between therapeutic areas, but can broadly be outlined as 
follows: 
•	 Phase I clinical trials aim at making an initial assessment of the safety, tolerability, 
pharmacokinetics, and pharmacodynamics of a drug. They often include a small 
group of healthy volunteers, but in some therapeutic areas such as oncology, 
patients are involved already in this early phase. 
•	 Phase II clinical trials typically include more subjects than phase I trials, but are 
still of moderate size. An important part of phase II is to evaluate both eﬃcacy 
and safety aspects of the drug at diﬀerent dose levels. Based on phase II data, a 
decision about whether to progress to phase III has to be made. At the end of 
phase II, it is also decided which dose(s) to bring forward to phase III. 
•	 The objective of phase III clinical trials is to demonstrate that an experimental 
drug is eﬃcacious and safe. This is the phase where the statistical framework 
of hypothesis testing is most rigorously applied. If the programme of phase III 
trials is successful, submissions for regulatory approval are made to regulatory 
agencies around the world. Phase III clinical trials often include a large number 
of patients recruited at many centres in diﬀerent countries. They are costly to 
run and may have a long treatment duration and follow-up. 
•	 Phase IV clinical trials are conducted after a drug has received regulatory 
approval. Some Phase IV trials are required by regulatory authorities and may 
be referred to as post marketing surveillance trials. In other cases the focus may 
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be on life cycle management activities, which aim to broaden the indication of 
the drug and increase sales. 
The main focus of this thesis will be on sequential and adaptive methods used in 
phase III clinical trials. In addition, we shall study the joint planning of phase II and 
phase III trials in Chapter 5. In a phase III clinical trial, the primary objective is often 
to conﬁrm that the experimental drug is eﬃcacious compared to control. Suppose that 
the true treatment eﬀect is θE for the experimental drug and θC for the control, and 
that a positive value of θE or θC implies that the treatment has been beneﬁcial to 
the patient. The treatment eﬀect θ = θE − θC can then be  assessed in a  statistical  
hypothesis test framework, where the null hypothesis H0 : θ ≤ 0, is tested against the 
alternative hypothesis H1 : θ > 0. It is a regulatory requirement to control the type I 
error, the probability of falsely rejecting the null hypothesis, at some pre-speciﬁed 
level α. Regulators typically require α ≤ 0.025 for one-sided tests, which corresponds 
to allowing α ≤ 0.05 for two-sided tests. It is also desirable to make sure that the power 
at a certain value of the treatment eﬀect, θ = δ say, is at least 1 − β. The choices of β 
and δ are not as strictly controlled by regulators. The type II error β can be viewed 
as the sponsor’s risk of an eﬃcacious treatment not achieving a statistically signiﬁcant 
result. Common choices for β are β = 0.1 and  β = 0.2. 
In this thesis we are concerned with methods for making the design of clinical trials 
more eﬃcient. Given α, β, δ and some additional assumptions, we can calculate the 
number of patients needed to satisfy the power requirement in a ﬁxed sample trial. 
Unfortunately, this number is often rather high, which makes phase III trials very 
expensive. The increased costs of drug development over the last decade are discussed 
by DiMasi et al. (2003). They estimate the average cost spent prior to approval of a new 
drug to be approximately US$ 800 million. This underlines the importance of eﬃcient 
clinical trials, so that more treatments can be tested, approved and made available to 
patients. One way to make clinical trials more eﬃcient is to apply group sequential 
methods, which will be discussed in the next section. 
1.2 Group sequential designs 
1.2.1 Background 
In the early literature about sequential methods, data were typically assumed to be 
monitored continuously, i.e. for every patient. There was an early focus on applications 
in quality control, which gained importance during World War II when it was essential 
to make sure that ammunition was of appropriate quality. For testing the simple 
null hypothesis θ = θ0 against the alternative θ = θ1, Wald (1945, 1947) introduced 
the sequential probability ratio test (SPRT). In the SPRT, the likelihood ratio of the 
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accumulated data, under θ = θ1 and θ = θ0, is compared to critical values A and B. 
The test is stopped to reject H0 if the likelihood ratio is larger than A and to accept 
H0 if the likelihood ratio is smaller than B. A and B are chosen to make sure that the 
test has approximately type I error probability α and power 1 −β at θ = θ1. Wald  and  
Wolfowitz (1948) proved that the SPRT under certain assumptions is optimal, in the 
sense that it minimises the expected sample size. One drawback with the SPRT is that 
there is no maximal sample size at which sampling is guaranteed to stop. Truncated 
versions of the test, with a maximal sample size, have been proposed to deal with this 
issue. 
1.2.2 Two-sided group sequential tests with ﬁxed group sizes 
In clinical trial applications, it would often be too logistically challenging to monitor 
data continuously. Continuous monitoring would be particularly inconvenient in large 
scale trials. If thousands of patients are distributed across hundreds of centres around 
the world, it would not be possible to perform a new interim analysis for every patient. 
Pocock (1977) therefore suggested analysing data after certain cumulative sample sizes 
had been accrued. Performing repeated signiﬁcance tests at signiﬁcance level α will 
however lead to an overall type I error probability that is larger than α. Hence, the 
nominal signiﬁcance level at each interim analysis is adjusted downwards in Pocock’s 
test, to account for the multiple looks and get an overall type I error probability of α. 
The test stops to reject H0 : θ = 0  if  
|Zk| ≥ bk, k  = 1, . . . ,K,  
where Zk is usual standardised statistic at analysis k. The critical values bk are in 
Pocock’s test constant on the standardised Z statistic scale, for k = 1, . . . ,K. The  
critical values can be written as 
bk = CP(K,α), 
where CP depends on the total number of analyses K and the type I error probability α. 
The test of Pocock (1977) is an example of a two-sided test of the null hypothesis 
H0 : θ = 0 versus the alternative H1 : θ  0. The critical values are set so that = 
Pθ=0(Reject H0) =  α, while the power requirement is that Pθ=±δ(Reject H0) = 1  − β. 
O’Brien and Fleming (1979) proposed a two-sided group sequential test with much 
wider boundaries at earlier interim analyses and narrower boundaries later. The critical 
values in O’Brien and Fleming’s test can be written as 
K 
bk = COF(K,α) , for k = 1, . . . ,K,  
k 
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where COF is the critical value at the ﬁnal analysis and depends on the total number 
of analyses K and the type I error α. Wang and Tsiatis (1987) deﬁned a very general 
family of tests where the parameter Δ decides the amount of early stopping. This class 
of designs contains the Pocock design the O’Brien and Fleming design as special cases, 
for particular values of Δ. In the tests of Wang and Tsiatis (1987), the critical values 
can be  written as  
( )Δ−1/2k 
bk = CWT(K,α,Δ) , for k = 1, . . . ,K,  
K 
where CWT is the critical value at the ﬁnal analysis and depends on K, α and Δ. We 
see that Δ = 0.5 corresponds to the test of Pocock (1977) and Δ = 0 to the test of 
O’Brien and Fleming (1979). The correct choice of CWT, for a given combination of K, 
α and Δ, is tabulated in Jennison and Turnbull (2000, Chapter 2). This information 
is also available in the software package East-5 (2007). 
1.2.3 Sequential distribution theory 
Suppose that the observations in treatment groups A and B are independent and 
normally distributed with XAi ∼ N(μA, σ2) and  XBi ∼ N(μB , σ2), where the 
common variance σ2 is known. Assume further that the two treatments are compared 
in a group sequential trial where the primary objective is to make inference about the 
parameter θ=μB − μA. At each interim analysis we can calculate θˆk, the  maximum  
likelihood estimate for θ at analysis k, according to 
nk 
θˆk = (XBi − XAi)/nk 
i=1 
where nk is the cumulative per-group sample size. Let Ik denote the Fisher information 
for θ at analysis k, deﬁned as 
nkIk = .2σ2 
The maximum likelihood estimate θˆk then follows a normal distribution according to 
θˆk ∼ N(θ,Ik −1). 
If Zk = θˆk 
√Ik denotes the standardised statistic at analysis k, the sequence of 
statistics Z1, . . . , ZK follow what Jennison and Turnbull (2000, Chapter 3) refer to 
as the canonical joint distribution. The statistics Z1, . . . , ZK have the canonical joint 
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distribution with information levels I1, . . . ,IK for θ if 
(Z1, . . . , ZK ) is multivariate normal, 
E(Zk) =  θ Ik, k = 1, . . . ,K,  and (1.1) 
Cov(Zk1 , Zk2 ) =  Ik1 /Ik2 , 1 ≤ k1 ≤ k2 ≤ K. 
The sequence Z1, . . . , ZK is a Markov sequence, and this is important for the numerical 
integration methods used to calculate properties of group sequential tests. We have so 
far assumed data with normal response and known variance, but note that (1.1) holds 
at least approximately in many other situations, for example survival data or normally 
distributed data adjusted for baseline covariates. We refer to Jennison and Turnbull 
(2000) for a comprehensive acccount of how to construct group sequential tests for a 
wide range of response distributions. 
1.2.4 One-sided group sequential tests with ﬁxed group sizes 
The designs in Section 1.2.2 were proposed for two-sided tests, but in clinical trials we 
are often interested in one-sided testing problems. If θ represents the treatment beneﬁt 
of the experimental drug compared to placebo, it may for example be of interest to 
establish the presence of a positive treatment eﬀect by rejecting H0 : θ ≤ 0. The 
distribution theory in Section 1.2.3 is applicable also for group sequential tests. Hence, 
such tests can be accommodated within a framework similar to that used for the two-
sided tests in Section 1.2.2. In one-sided tests, there is an upper boundary for rejecting 
H0, and there may also be a lower boundary for accepting H0. Stopping early to 
accept H0 is often referred to as stopping for futility, as the trial is deemed futile and 
it is unlikely that the results that were hoped for at the outset can be achieved. One-
sided group sequential tests with futility boundaries are considered in some detail in 
Chapter 4, while one-sided tests without futility boundaries are used in Chapter 3. In 
the context of two-sided tests, Gould and Pecore (1982) proposed including boundaries 
for early stopping to accept the null hypothesis. A variation of this type of design is 
given in Chapter 2, where some of the error probabilities have diﬀerent roles than in 
the designs of Gould and Pecore (1982). 
Let us now consider how one-sided group sequential tests can be set up when there 
is no futility boundary. We consider the clinical trial described in the beginning of 
Section 1.2.3, where the goal is to make inference about θ by testing the null hypothesis 
H0 : θ ≤ 0 against the alternative hypothesis H1 : θ > 0, at signiﬁcance level α = 0.025 
and power 1 − β at θ = δ. At each interim analysis k, we stop to reject H0 if 
Zk = θˆk Ik ≥ bk, 
6
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where the critical values bk are chosen so that the overall type I error probability 
equals α. To ﬁnd critical values b1, . . . , bK that give a test with type I error 
probability α, we can make use of the upper boundary of the two-sided tests of Pocock 
(1977), O’Brien and Fleming (1979) or Wang and Tsiatis (1987), which are described in 
Section 1.2.2. Suppose that one of these tests has two-sided type I error probability 2α. 
The probability of ﬁrst crossing one of the boundaries of the two-sided tests and then 
the other is usually negligible. If this small probability is ignored, a one-sided group 
sequential test, with the upper boundary of any of these two-sided tests but no lower 
boundary, will have type I error probability α. 
When planning the design, it is of interest to know Imax, the amount of information 
needed at the ﬁnal analysis to satisfy the power requirements. Suppose that it has 
been decided to use the group sequential boundary of O’Brien and Fleming (1979). By 
assuming a particular form for the information sequence, for example equally spaced 
analyses, Imax can be found by searching for the maximum information that gives 
power 1 − β at θ = δ. The relationship between Imax and the corresponding ﬁxed 
sample size Iﬁx can be  expressed as  
Imax = R Iﬁx, 
where 
{Φ−1(1 − α) + Φ−1(1 − β)}2 Iﬁx = δ2 
and R is an inﬂation factor. For any group sequential design with early stopping, we 
will have R >  1, and hence, Imax > Iﬁx. The expected information of the group 
sequential test will however typically be lower than for the corresponding ﬁxed sample 
test. 
1.2.5 Error spending designs 
The tests described in Sections 1.2.2 and 1.2.4 all assume ﬁxed information sequences. 
If the observed information sequence diﬀers from the one used to derive the critical 
values, prior to the start of the trial, the type I error probability will no longer be equal 
to α. Lan and DeMets (1983) proposed error spending designs as a way of dealing with 
unpredictable information sequences. In error spending designs, the cumulative type 
I error probability is speciﬁed as a function of the observed information. The critical 
values are derived by using the fact that the sequence of test statistics Z1, . . . , ZK follow 
the joint canonical distribution in (1.1). Let us now consider how to ﬁnd the critical 
value at analysis k, of a one-sided error spending design without futility boundary. 
Deﬁne a non-decreasing type I error spending function f(I), which satisﬁes f(0) = 0 
and f(I) =  α, for  I ≥ Imax. At the ﬁrst interim analysis, the critical value b1 is found 
by solving Pθ=0(Z1 ≥ b1) =  f(I1). The critical value bk at analysis k is calculated as 
7
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the solution to 
Pθ=0(Z1 < b1, . . . , Zk−1 < bk−1, Zk ≥ bk) =  f(Ik) − f(Ik−1). (1.2) 
At the planning stage, the inﬂation factor R and the maximal information level Imax 
needed to meet the power requirement are found in the same way as for group 
sequential designs with ﬁxed information sequences. By construction, the error 
spending method gives type I error probability of exactly α. Furthermore, Jennison and 
Turnbull (2000, Chapter 7) show that for moderate changes to the planned information 
sequences, the attained type II error probability is close to its target β. A  key  
assumption is that the information levels at which future interim analyses take place 
must not be chosen based on the observed treatment eﬀect. Proschan et al. (1992) 
have shown that violations of this assumption can lead to serious inﬂation of the type I 
error rate. The critical values for two-sided error spending tests and one-sided error 
spending tests with futility boundaries can be found using a similar approach. In 
Chapter 2 we shall also introduce error spending designs for group sequential designs 
that simultaneously test superiority and non-inferiority. 
Probabilities like (1.2) can be calculated through numerical integration. The 
calculations in this thesis are based on the methods described by Jennison and Turnbull 
(2000, Chapter 19). Jennison and Turnbull suggest using a grid of m = 189 points to 
integrate a normal density over the real line. Two thirds of the grid points are within 
± three standard deviations of the mean. The method makes use of the thin tails 
of the normal distribution, using a logarithmic spacing for the ﬁnal third of the grid 
points. Chandler and Graham (1988) show that O(m−4) convergence is obtained, when 
integrating a normal density with this type of grid, using Simpson’s rule. 
1.2.6 Inference on termination 
At termination of a group sequential design, it is desirable to make inference about the 
treatment eﬀect θ and present an unbiased point estimate, conﬁdence interval and p-
value. Because of the stopping rule that has been applied, this is not as straightforward 
as for ﬁxed sample trials. If a group sequential design is stopped early for beneﬁt, 
it can for example be shown that the standard maximum likelihood estimate of θ 
at termination is biased. Further details about inference on termination of a group 
sequential test are provided by Proschan et al. (2006, Chapter 7) and Jennison and 
Turnbull (2000, Chapter 8). 
Inference on termination of a group sequential design can be further complicated by 
the issue of overrunning. Overrunning is a concept that has typically been overlooked 
in the literature about group sequential designs. It can occur when there is a delay in 
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time between when a patient is randomised and when the response is observed. When 
a decision is made to stop a trial early after an eﬃcacy boundary has been crossed, 
there are likely to be additional patients who have recently been randomised but were 
not included in the interim analysis. This makes inference on termination even more 
complex, as it would be desirable to include data for these additional patients in the 
ﬁnal analysis. Hampson (2009) gives a very thorough treatment of how to deal with 
these issues, including methods for how to derive conﬁdence intervals and p-values. 
1.2.7 Beneﬁts of group sequential designs 
As the statistical aspects of a group sequential design are clearly more complex than 
for a ﬁxed sample trial, it is reasonable to ask what the beneﬁts with applying group 
sequential methods are. Jennison and Turnbull (2000, Chapter 1) divide the beneﬁts 
of group sequential methods into ethical, administrative and economical. 
•	 Throughout a clinical trial, there is an ethical need to monitor the safety of 
the patients in all treatment arms. This can for example be done through 
group sequential monitoring. If a group sequential trial is stopped early for a 
positive eﬀect, fewer patients are exposed to an inferior treatment than for the 
corresponding ﬁxed sample design. If a group sequential trial is stopped early for 
futility, the patients in the trial do not have to be exposed to potential side eﬀects 
of the drugs under investigation. Moreover, the resources that would have been 
required to complete the trial can instead be used to study another treatment in 
an area of unmet medical need. 
•	 The major administrative beneﬁts can be achieved if an interim analysis is 
performed early in the trial. It is then possible to check that various aspects 
of the experiment are running as planned. Problems that are encountered at an 
early interim analysis might then be dealt with early on, without compromising 
the entire trial.  
•	 Group sequential methods have the potential to reduce the expected sample 
size of a clinical trial to approximately 50 − 70% of the corresponding ﬁxed 
sample design (Jennison and Turnbull, 2000). The possible savings might be 
compromised if there are requirements to collect a minimum amount of safety 
data, in which case early stopping for beneﬁt would not make sense until the 
minimum amount of safety had been collected. The time gained by the early 
stopping may be important in getting the drug approved sooner, giving a longer 
time on the market with a valid patent. Morever, patients will be able to beneﬁt 
from a new eﬀective treatment sooner than if no early stopping would have been 
possible. 
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The ethical reasons for interim monitoring through group sequential methods are 
arguably the most important and persuasive. Most major trials now have a data 
monitoring committee (DMC), whose primary responsibility is to protect the safety 
of the patients. ICH guideline E9 Statistical Principles for Clinical Trials encourages 
the use of interim monitoring through group sequential methods (ICH, 1998). When 
conducting a group sequential design, there are many aspects to consider that may 
diﬀer from ﬁxed sample trials. Additional guidelines, that are more speciﬁc to interim 
monitoring, have therefore also been published by regulatory authorities (FDA, 2006). 
The book by Ellenberg et al. (2003) focuses on practical aspects of interim monitoring, 
in particular the role of DMCs. Other books more focused on the statistical aspects are 
written by Whitehead (1997), Jennison and Turnbull (2000) and Proschan et al. (2006). 
The latter book also covers some of the adaptive methods that will be described next. 
1.3 Adaptive designs 
1.3.1 Motivation 
Over the last decade, the development of new drugs has become increasingly diﬃcult. 
Fewer new medicines are approved and there are increasing demands on proving that 
drugs are both safe and eﬃcacious. Approval of treatments for type 2 diabetes are an 
example of the latter, as the FDA (2008) now requires drug companies to establish both 
glucose control and that there is not an increased risk of cardiovascular events, for drugs 
to be approved. In its Critical Path White Paper, the FDA (2004) expresses concerns 
about the ability of trial sponsors to deal with the increasing problems of getting 
new drugs approved. From a pharmaceutical industry perspective, older drugs with 
expiring patents need to be replaced by more eﬀective medicines. More importantly, 
there are many patients who are waiting for new medicines to treat their conditions. 
These issues highlight the need for novel ideas for how to develop new and eﬀective 
medicines. Adaptive designs is one area that has received a lot of attention, both from 
trial sponsors and regulatory authorities. From the point of view of the trial sponsor, 
the hope is that this new class of designs will improve the drug development process, 
for example with issues such as ﬁnding the right dose and identifying treatments that 
should be discontinued. For regulatory authorities, it is helpful if adaptive designs can 
improve the quality of the clinical trials that they review. Both the EMEA (2007) and 
the FDA (2010) have issued guidelines about how to apply adaptive methods in clinical 
trials. Ultimately, the goal of both sponsors and regulators is that a larger number of 
eﬀective medicines are approved, in particular in areas where there is an unmet medical 
need. 
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1.3.2 The breakthrough of adaptive designs 
The landmark paper by Bauer and Ko¨hne (1994) opened up new possibilities and laid 
the foundation for much of the work that has later been done in the area. Bauer 
and Ko¨hne (1994) consider two sub-samples of patients recruited before and after an 
interim analysis of a clinical trial. Let the two stages of the trial have the same null 
hypotheses H0. The two sub-samples can be used to calculate one-sided p-values p1 
and p2, associated with H0. By using Fisher’s product criterion, H0 is rejected if 
1 
p1p2 ≤ Cα = exp  [− χ42(1 − α)] (1.3)2 
where χ24(1 − α) is the 100 × (1 − α)% quantile of the chi-squared distribution with 
four degrees of freedom (Bauer and Ko¨hne, 1994). Provided that the combination rule 
deﬁned in (1.3) has been speciﬁed in the protocol, many types of design modiﬁcations 
can be performed between the two stages, without aﬀecting the type I error rate. 
Unlike in classical group sequential designs, the design modiﬁcations may be based 
upon the p-value p1 derived from the ﬁrst sub-sample. Care is however needed when 
the adaptation is based on data from patients whose primary endpoint, such as overall 
survival, is only available after the adaptation. Bauer and Posch (2004) point out that 
in the survival setting the type I error can be inﬂated if the adaptation is based on 
biomarkers or covariates that are correlated with the survival endpoint. 
It is also possible to deﬁne diﬀerent hypotheses H0,1 and H0,2 in the two stages, in 
which case the test in (1.3) is for the intersection hypothesis H0,1 ∩ H0,2. The  method  
of Bauer and Ko¨hne can be generalised to more than two stages, and the recursive 
combination tests proposed by Brannath et al. (2002) enable derivation of overall p-
values and conﬁdence intervals. 
A wide range of publications about adaptive designs soon followed, see for example 
Proschan and Hunsberger (1995); Fisher (1998); Cui et al. (1999); Lehmacher and 
Wassmer (1999); Denne (2001); Mu¨ller and Scha¨fer (2001). These methods all ensure 
control of the type I error rate. Adaptations that have been proposed include 
modiﬁcation of sample size, identiﬁcation of sub-populations that might beneﬁt from 
the drug, switching the primary objective and selecting a sub-set of doses that will 
be studied for the remainder of the trial. It goes beyond the scope of this thesis to 
describe all these methods, but we shall now brieﬂy discuss some that are of particular 
relevance for this thesis. 
1.3.3 The methods of Lehmacher and Wassmer and Cui et al. 
Lehmacher and Wassmer (1999) ensure protection of the type I error by using a diﬀerent 
combination rule from (1.3). The method can be illustrated by considering a group 
sequential trial with normal response and K groups of observations collected in K 
11

√ 
Chapter 1. Introduction 
diﬀerent stages. Let Z˜k denote the standardised statistic based on data from stage k 
of the trial and let ∑M ˜
ZM = k=1 
wkZk 
, M  = 1, . . . ,K,  (1.4)
( 
∑M
k=1 wk
2)1/2 
where w1, . . . , wK are weights ﬁxed prior to the start of the trial. Decisions about 
whether to stop or continue at analysis k is then based on the test statistic Zk in (1.4). 
Marginally, each Z˜k follows a N(θ Ik − Ik−1, 1) distribution, where Ik is Fisher’s 
information for θ at analysis k and I0 = 0. In Section 3.3.1 we describe the joint 
distribution of the sequence of statistics Z1, . . . , ZK in (1.4) in further detail. It turns 
out that under the null hypothesis of no treatment eﬀect, the only diﬀerence between 
this joint distribution and the standard joint canonical distribution in (1.1) is that the 
correlation structure is now decided by the pre-speciﬁed weights in (1.4), rather than the 
observed information sequence. Hence, critical values for rejecting the null hypothesis 
that control the type I error rate can be derived in the same way as for non-adaptive 
group sequential designs with ﬁxed information sequences, using the weights that are 
ﬁxed at the outset. This method will be evaluated in Chapter 3, as an alternative to 
error spending designs. 
Cui et al. (1999) consider a classical group sequential design and the issue of how 
to proceed when the eﬀect size turns out to be smaller than what was assumed in 
setting power at the design stage. They propose a method that allows for sample size 
modiﬁcations based on the observed treatment eﬀect, while protecting the overall type I 
error rate. The method essentially turns out to be equivalent to that of Lehmacher 
and Wassmer (1999). Wang et al. (2001) propose an adaptive method for simultaneous 
testing of superiority and non-inferiority, where control of type I error is ensured in a 
way similar to that in the method of Cui et al. (1999). The latter is an example of 
a method for adapting the sample size to obtain adequate power for a new primary 
objective. The method of Wang et al. (2001) will be evaluated in detail in Chapter 2, 
where we present our own method for simultaneous testing of superiority and non-
inferiority. 
1.3.4 Other adaptive designs 
Bretz et al. (2006) give a thorough discussion of so-called seamless phase II / III trials. 
This topic has received a lot of attention, as it has the potential to improve eﬃciency in 
diﬀerent ways. By including data from the phase II subjects in the ﬁnal analysis, a more 
precise estimate of the treatment eﬀect on the phase III endpoint can be achieved. In 
addition, a jointly written protocol for phase II and phase III has the potential to save 
time that is otherwise spent preparing and getting approval for the phase III protocol. 
Seamless phase II / III designs can be thought of as a special case of the more general 
idea of incorporating data from diﬀerent phases in a single trial. These ideas seek to 
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relax the assumption that drug development has to be rigidly divided into the phases 
described in Section 1.1. There is also a connection to the problem of jointly planning 
phase II and phase III, considered in Chapter 5 of this thesis. Koch (2006) and the 
EMEA (2007) express some caution about the use of seamless phase II/III designs, but 
recognise that such designs could be of value if appropriately planned. 
We shall refer to classical group sequential designs as non-adaptive group sequential 
designs, although some authors like Dragalin (2006) consider group sequential testing 
as a form of adaptation. They make it possible to stop a trial early, according to the 
stopping rule that is deﬁned by the group sequential boundary. By using the error 
spending method of Lan and DeMets (1983), the type I error can be controlled when 
future group sizes are unpredictable. Future group sizes in an error spending test 
should however not be chosen based on the observed treatment eﬀect, as this can lead 
to inﬂation of the type I error rate (Proschan et al., 1992). The situation is diﬀerent for 
adaptive methods, where this and other design changes can be accommodated while 
maintaining type I error control. As it is possible to add group sequential boundaries 
to an adaptive design with interim analyses, adaptive designs can be viewed as a 
generalisation of non-adaptive group sequential designs. Several papers have discussed 
the relative eﬃciency of non-adaptive and adaptive group sequential designs, with a 
focus on methods with sample size modiﬁcation based on the observed treatment eﬀect. 
Jennison and Turnbull (2006a) showed that an optimal non-adaptive group sequential 
design can come within a few percentage points of the eﬃciency of an optimal adaptive 
group sequential design. Adaptive designs can on the other hand be substantially 
inferior if a sub-optimal rule for sample size modiﬁcation is applied (Jennison and 
Turnbull, 2003). Burman and Sonesson (2006) criticised adaptive methods from 
another perspective, arguing that some adaptive designs may lack credibility and be 
diﬃcult to interpret. Burman and Lisovskaja (2010) proposed to address this through 
the so-called dual test, where it is required that both the adaptive test and a na¨ıve 
test, ignoring the adaptations, are statistically signiﬁcant. 
Mu¨ller and Scha¨fer (2001, 2004) proposed a new adaptive method referred to as 
the conditional rejection probability (CRP) principle. It is a very general method that 
gives almost complete ﬂexibility for how to re-design a clinical trial. The method is 
very appealing as it tries to combine the beneﬁts of classical group sequential designs 
with novel adaptive approaches. First, a group sequential design is set up to have all 
the beneﬁts of sequential monitoring. Thereafter, an adaptive re-design is applied only 
when considered necessary, based on all available internal and external information. 
The CRP principle is discussed in detail in Chapter 3, where we show that the method 
has some limitations when applied in an error spending design with unpredictable group 
sizes. 
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1.4 Decision Analysis 
In the previous sections we have referred to various group sequential and adaptive 
methods. Some of these methods have optimal properties in the sense that they 
minimise the expected sample size, while satisfying suitably deﬁned frequentist error 
probability constraints. Many of these optimal designs were derived using decision 
analysis. A key feature of decision analysis is to deﬁne a utility function that should 
be maximised, or equivalently, a loss function that should be minimised. Given data, 
one would like to ﬁnd the action or decision rule that is optimal, in the sense that it 
maximises the expected utility. 
Our focus will be on how to apply decision analysis to derive eﬃcient clinical 
trial designs. It is however important to recognise that decision analysis has many 
applications beyond clinical trials. The book by Berger (1985) is a standard reference 
about the subject. It is focused on the underlying theory but also includes a few 
examples from diﬀerent areas. Berger points out that there is a strong link between 
decision analysis and Bayesian statistics. Apart from deﬁning a utility function and a 
cost of sampling, the formulation of a decision problem typically involves choosing a 
prior distribution for the unknown parameter. The link to Bayesian ideas is emphasised 
by Lindley (1997), who argues for choosing the sample size of an experiment based on 
Bayesian decision analysis. The book by Parmigiani and Inoue (2009) is another useful 
reference that provides theoretical background as well as applications in areas such as 
biostatistics and economics. 
There are plenty of examples where decision analysis has been used in work related 
to clinical trials, in diﬀerent phases of drug development. Stallard (1998) uses cost 
and utility functions to derive optimal group sequential phase II designs for binary 
outcomes. Gittins and Pezeshk (2000b) derive the optimal sample size of a phase III 
trial by modeling how the number of patients using the drug depends on the posterior 
distribution of the treatment eﬀect after the trial. Burman et al. (2007, Chapter 14) 
give a good overview about the use of decision analysis in drug development. They 
emphasize how decision analysis can be applied to a wider range of problems than the 
design of a single trial, for example project prioritisation. Julious and Swank (2005) 
provide another interesting example of how decision analysis can be used in a wider 
context. They describe how decision analysis based on elicitation of expert knowledge 
can be used to choose between diﬀerent options for a clinical development plan. We 
refer to the book by O’Hagan et al. (2006) for a good discussion about how elicitation 
can be used to determine an appropriate prior distribution. 
Decision analysis can also be used to solve the problem of ﬁnding an optimal group 
sequential boundary. The possible actions are then typically to stop and make a decision 
about the unknown parameter or to continue sampling. The sequential nature of the 
problem means that the method of dynamic programming can sometimes be applied. 
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When using dynamic programming to derive an optimal sequential decision rule, one 
makes use of the fact the optimal decision rule at the ﬁnal analysis does not depend on 
the decision rules at previous analysis. When searching for an optimal group sequential 
boundary, it is consequently possible to ﬁnd the optimal critical values at the ﬁnal 
analysis and work backwards to the ﬁrst analysis. This works because it is possible to 
consider an unconstrained decision problem, and thereafter search for the costs that 
give the desired frequentist error probability constraints. Dynamic programming has 
been used to derive optimal group sequential boundaries for a variety of problems, see 
for example Lai (1973); Eales and Jennison (1992, 1995); Barber and Jennison (2002); 
Hampson (2009). A good introduction to the method is given in the book by Bather 
(2000). 
In Chapter 4, we solve the problem of ﬁnding optimal group sequential designs 
with non-binding futility boundaries. This is an example of a decision problem where 
dynamic programming cannot be directly applied, as the optimal decision rule at the 
ﬁnal analysis depends on the critical values at previous analyses. We nevertheless show 
that by extending the method of dynamic programming, this more complex problem 
can be solved. 
1.5 Thesis organisation and road map 
In this thesis we are concerned with using sequential and adaptive methods to achieve 
eﬃcient clinical trial designs. In three of the problems we have formulated a utility that 
we seek to maximise, using decision analysis to derive an eﬃcient design. Apart from 
deriving eﬃcient group sequential designs, we are interested in the increased beneﬁts 
that can be achieved through adaptive methods. We also address potential issues with 
adaptive methods, such as control of type I error and the impact of sub-optimal rules 
for sample size modiﬁcation.  
¨ Chapter 2 is mainly based on the publication by Ohrn and Jennison (2010). 
¨ The research for this paper was carried out primarily by Ohrn, but the paper was 
¨ written jointly by Ohrn and Jennison. The problem was motivated by the adaptive 
methods described in Section 1.3 and the idea of adaptively switching primary objective. 
We derive optimal group sequential designs for simultaneous testing of superiority 
and non-inferiority and compare their eﬃciency to designs that have been proposed 
in the literature. To assess the beneﬁts of sample size modiﬁcation based on the 
observed treatment eﬀect, eﬃcient adaptive group sequential designs are derived and 
compared with their non-adaptive counterparts. It is found that both objectives can 
be addressed within a non-adaptive group sequential framework, while the additional 
beneﬁts achieved through sample size modiﬁcation are modest. We also deﬁne error 
spending versions of the non-adaptive group sequential designs that can be used to 
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cope with unpredictable group sizes and information levels. 
In Chapter 3 we focus on the CRP principle, one of the adaptive methods discussed 
in Section 1.3. The method seeks to combine the beneﬁts of error spending designs 
with novel adaptive approaches. It is found that when applying the CRP principle, 
there is an issue related to type I error control that has to be dealt with. There are 
ways to make sure that the type I error rate is controlled, but some of the generality 
of the approach is then lost. It is concluded that rather than enjoying all the beneﬁts 
of error spending design, the CRP principle provides some of these beneﬁts, as well as 
additional advantages related to adaptivity. 
In Chapter 4 we are concerned with one-sided group sequential tests with non­
binding futility boundaries. The need for futility boundaries that are non-binding is an 
issue that has often been overlooked in the literature about group sequential designs. 
In Chapter 4 we assess the implications of this problem, which is caused by practical 
aspects of interim monitoring and how regulatory authorities view the lower boundary. 
A new method for deriving optimal group sequential designs with non-binding futility 
boundaries is presented. Existing designs with non-binding futility boundaries are 
reviewed and compared to designs derived with the new method. 
In Chapter 5 we move beyond the individual trial and try to assess how the design 
of a series of trials can be approached. In a very general framework, we discuss how to 
jointly optimise two phases of a development program. Making use of the knowledge 
gained in Chapter 4, we also assess how the properties of the trial programme change if 
a group sequential design with a non-binding futility boundary is applied in phase III. 
The problem with two studies in Chapter 5 bears similarities with the optimisation 
of a group sequential design with two groups. The development programme can be 
stopped after phase II, which can be thought of as stopping for futility in the group 
sequential design. If the phase III sample size is chosen based on phase II data, 
the problem becomes similar to the so-called optimal sequentially planned decision 
procedures proposed by Schmitz (1993). A version of the Schmitz designs adapted to 
a three-decision problem is studied in Chapter 2. 
All of the chapters in this thesis deal with sequential and adaptive methods for 
the design of clinical trials. We have used computational methods to derive eﬃcient 
designs for a variety of problems, with a special focus on the beneﬁts that can be 
achieved through group sequential and adaptive methods. In Chapter 6 this thesis is 
ﬁnished by discussing general conclusions that can be drawn and outlining possible 
areas for future research. 
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Optimal group sequential designs for simultaneous testing of 
superiority and non-inferiority 
2.1 Introduction 
The primary objective in many clinical trials is to demonstrate superiority of the 
experimental treatment. With an active control treatment, it may also be of interest 
to show the experimental treatment is not worse than the control by more than a 
pre-speciﬁed margin. Proving “non-inferiority” is particularly appropriate if the new 
treatment is safer than the control. 
Let θ denote the treatment diﬀerence between the new treatment and control, 
with positive values of θ indicating superiority of the new treatment. Superiority 
can be established by rejecting the null hypothesis HS,0: θ ≤ 0 in favour  of  the  
alternative θ > 0. Suppose it is agreed that the new treatment may be regarded 
as non-inferior if θ > −δN , where  δN is a positive quantity referred to as the non-
inferiority margin. We shall conclude that the new treatment is non-inferior if the null 
hypothesis HN,0: θ ≤ −δN is rejected in favour of θ > −δN . 
Morikawa and Yoshida (1995) note that tests for superiority and non-inferiority 
involve nested hypotheses and, hence, overall type I error probability will be controlled 
if both tests are conducted simultaneously without any adjustment for multiplicity. 
The same is true if the two hypotheses are tested group sequentially in a closed 
testing procedure (Wang et al., 2001). However, the sample sizes required for tests 
of superiority and non-inferiority may be quite diﬀerent. Suppose the test for non-
inferiority is to have type I error probability α at θ = −δN and power 1 − β at θ = 0,  
while the test for superiority has type I error probability α at θ = 0  and  power  1  − β 
at θ = δS . The  value  of  δN is typically set as a fraction of the estimated treatment 
diﬀerence in an earlier comparison of the active control treatment and placebo, and is 
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liable to be quite small. The value of δS may be chosen to reﬂect expectations of a 
substantial treatment eﬀect and when this is signiﬁcantly larger than δN , the  sample  
size needed for the test of non-inferiority will be considerably higher than that required 
to test for superiority. 
The need for diﬀerent sample sizes to test the two hypotheses has led to quite 
complex proposals for group sequential designs testing both superiority and non-
inferiority. Wang et al. (2001) describe an adaptive group sequential procedure in 
which the sample size is initially set for a test of superiority but, if interest shifts to 
showing non-inferiority, group sizes are increased. When this data-dependent change 
occurs, the type I error rate is preserved by down-weighting later groups of observations 
in the manner of Cui et al. (1999). 
In the two-stage procedures of Shih et al. (2004) and Koyama et al. (2005), ﬁrst 
stage data are used to decide whether to continue and, if so, to select superiority or 
non-inferiority as the primary objective. The second stage sample size is chosen to 
give power for the chosen objective: Shih et al. (2004) set sample size as a function of 
ﬁrst stage data to achieve a given conditional power, while Koyama et al. (2005) use a 
sample size function attaining a speciﬁed unconditional power. 
Lai et al. (2006) describe non-adaptive group sequential designs with ﬁxed group 
sizes and three possible decisions on termination: superiority, non-inferiority (but 
not superiority) and inferiority. Reaching the third decision, inferiority, is sometimes 
referred to as stopping for futility since there is little prospect of reaching either positive 
decision. When δS is greater than δN , the study can terminate at an early stage with a 
decision of superiority or inferiority then, later on, the options switch to non-inferiority 
and inferiority. 
We shall present general classes of group sequential procedures which build on 
existing proposals. We ﬁrst discuss designs with ﬁxed group sizes, extending the options 
considered by Lai et al. (2006) by allowing a choice of all three terminal decisions at 
each analysis. In our formulation of the testing problem in Section 2.2, values for 
δS and δN are stipulated along with a type I and type II error probability for each 
hypothesis test. For a given sequence of group sizes, we derive designs with the lowest 
possible expected sample sizes averaged over a range of values of the treatment eﬀect, θ, 
while meeting the error probability constraints. Although group sizes are ﬁxed, these 
procedures still exhibit a form of adaptation: when δS is signiﬁcantly greater than 
δN , the upper continuation region for testing between superiority and non-inferiority 
comes to an end ﬁrst, while the lower region continues to allow diﬀerentiation between 
non-inferiority and inferiority. 
In Section 2.3 we generalise these designs to let group sizes depend on previously 
observed data. The resulting class includes the adaptive group sequential designs of 
Wang et al. (2001) and the adaptive two-stage procedures of Shih et al. (2004) and 
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Koyama et al. (2005). In the two-decision problem of a one-sided test for superiority, 
Jennison and Turnbull (2006a) found that adaptive choice of group sizes provided only 
a slight eﬃciency gain over non-adaptive designs. In our three-decision problem, when 
diﬀerent ﬁxed sample sizes are appropriate to the two separate hypothesis tests, it 
seems plausible that there could be more substantial gains from using interim data 
both to choose the null hypothesis on which to focus and to adjust sample size 
accordingly. We assess previously proposed designs and new, optimised two-stage 
procedures to investigate the reduction in expected sample size that can be achieved 
by such adaptation. Our conclusion from the examples we have studied is that little is 
gained by choosing the second group size based on the observed treatment eﬀect. 
2.2 Optimal non-adaptive designs 
2.2.1 Framework 
Suppose that the observations XAj and XBj , j = 1, 2, . . . , on  treatments  A and B, 
respectively, are independent and normally distributed with XAj ∼ N(μA, σ2) and  
XBj ∼ N(μB , σ2). We assume for now that σ2 is known but we shall explain in 
Section 2.2.5 how unknown variance can be handled. The parameter of interest is 
the treatment eﬀect θ = μB − μA. We wish to test simultaneously HN,0: θ ≤ −δN 
against θ >  −δN and HS,0: θ ≤ 0 against θ >  0, where the non-inferiority margin δN 
is established prior to the start of the trial. 
Gould (1997) and Koyama et al. (2005) recognise this is a three-decision 
problem with outcomes: superiority, non-inferiority (only) and inferiority. Error rate 
requirements, including power for the two hypothesis tests at θ = 0  and  θ = δS , 
can be expressed through a pair of power curves. The curves displayed in Figure 2-1 
show the probabilities of concluding “Non-inferiority or Superiority” or “Superiority” 
as functions of θ. Formally, we specify type I and type II error rates αN and βN for 
testing HN,0 and error rates αS and βS for testing HS,0 as: 
Pθ=−δN (Declare “Non-inferiority” or “Superiority”) = αN , (2.1) 
Pθ=0(Declare “Superiority”) = αS, (2.2) 
Pθ=0(Conclude “Inferiority”) = βN , (2.3) 
Pθ=δS (Conclude “Inferiority” or “Non-inferiority”) = βS . (2.4) 
In Section 2.6.1 we prove that these conditions imply control of type I error for HN,0 
and HS,0 over all values θ ≤ −δN and θ ≤ 0, respectively, and of type II error over θ ≥ 0 
and θ ≥ δS . This result holds for all non-adaptive designs satisfying certain minimal 
criteria, and it also applies to the adaptive designs we shall introduce in Section 2.3. 
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Power 
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Figure 2-1: Power curves for “non-inferiority or superiority” and superiority. 
For many designs, ﬁxing two points on the power curve results in the whole curve 
being indistinguishable from that of a ﬁxed sample test. Hence, we do not consider 
power under other parameter values when comparing designs. The exceptions are some 
adaptive designs for which power approaches unity rather slowly: see, for example, the 
power curves in Figure 2-11. 
If the tests of the two null hypotheses were carried out in separate ﬁxed sample 
trials, the number of observations required per treatment would be 
nNf  = 2{Φ−1(1 − αN ) + Φ−1(1 − βN )}2σ2/δ2 N 
for testing HN,0 and 
nSf = 2{Φ−1(1 − αS ) + Φ−1(1 − βS )}2σ2/δ2 S 
for testing HS,0, where Φ is the cumulative distribution function of a standard normal 
variate. 
We shall consider group sequential procedures with a maximum of K analyses, 
denoting the cumulative sample size per treatment at analysis k by nk and the 
maximum sample size per treatment by nmax = nK. Let  Zk be the standardised 
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test statistic for testing θ = 0 at analysis k. Allowing early stopping for all possible 
decisions at each analysis leads to a rule at analysis k of the form: 
if Zk ≤ ak, stop and conclude inferiority, 
if ak < Zk < bk, continue sampling, 
if bk ≤ Zk ≤ ck, stop and declare non-inferiority, 
if ck < Zk < dk, continue sampling, 
if Zk ≥ dk, stop and declare superiority. 
Here, ak ≤ bk ≤ ck ≤ dk and termination by analysis K is ensured by setting aK = bK 
and cK = dK . At the ﬁnal analysis, superiority is declared if ZK ≥ dK , while non-
inferiority is declared if bK ≤ ZK < dK . When  nSf < nNf  , we  may  have  ck = dk in 
later stages so the upper continuation region is not present. In such cases, we denote 
the ﬁrst value of k at which ck = dk by KS and the planned group size at this analysis 
by nmax,S . Although the lower boundary ak, is present throughout, it can be helpful 
to think of the design as focusing on the test for superiority up to analysis KS and 
concentrating on the choice between non-inferiority and inferiority thereafter. In order 
to meet the error probability constraints, it will be necessary for nK = nmax to be 
greater than nNf  and nKS = nmax,S to be greater than nSf . We shall refer to the 
ratios 
rS = nmax,S /nSf and rN = nmax/nNf  
as “inﬂation factors” and use these to indicate how much the maximum sample size, 
for the ﬁrst phase or the whole design, has been increased beyond the minimum 
requirement. 
A typical rule is illustrated in Figure 2-2. In this example, bk = ck for k = 1  and  2  
so early stopping for non-inferiority is not possible at the ﬁrst two analyses and the two 
sections of continuation region merge into one. Since ck = dk for k = 4 to 8, there is 
no upper continuation region at these analyses. However, we still allow the possibility 
to stop with a conclusion of superiority if the last group of observations results in a 
suﬃciently high value of Z5, Z6, Z7 or Z8. The boundaries in Figure 2-2 are those of 
an optimal design which we shall describe in Section 2.2.2. They are broadly similar 
to the two-sided tests with an inner wedge described by (Jennison and Turnbull, 2000, 
Chapter 6), however, they lack the symmetry of those designs around θ = 0  and  the  
roles of two of the error probabilities, αN and βN , are reversed. 
The boundary points a1, b1, c1, d1, . . . , aK , bK , cK , dK must be chosen to satisfy the 
error constraints (2.1) to (2.4). A ﬁxed sample size trial can only meet all four 
constraints simultaneously if nNf  = nSf . In contrast, the additional degrees of 
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Figure 2-2: Stopping boundaries for inferiority, non-inferiority and superiority. 
freedom of a group sequential design allow suitable boundaries to be found as long 
as nmax > max(nNf  , nSf ). Moreover, we can exploit the remaining degrees of freedom 
to ﬁnd a trial design with low expected sample size under speciﬁed values of θ. We  
have developed methods to ﬁnd group sequential designs that minimise criteria of the 
mform i=1 wiEθi (N), where N denotes the sample size per treatment on termination. 
We have studied designs for a variety of optimality criteria, but in this thesis we shall 
focus on 
F  = {E−δN (N) +  E−δN /2(N) +  E0(N) +  EδS /2(N) +  EδS (N)}/5 (2.5) 
which combines performance across the range of eﬀect sizes of interest. We shall 
illustrate these procedures with an example for particular design parameters in 
Section 2.2.3 and make an eﬃciency comparison with the design of Lai et al. (2006) in 
Section 2.2.4. 
2.2.2 Derivation of optimal designs 
Our methods enable us to ﬁnd an optimal design with a speciﬁed number of analyses K 
and cumulative sample sizes n1, . . . , nK . Comparing these optimal designs for diﬀerent 
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sequences n1, . . . , nK can inform the choice of suitable group sizes. Increasing K will 
decrease expected sample size but at the cost of more interim analyses, so comparing 
optimal designs for diﬀerent values of K helps assess their costs and beneﬁts. 
Our derivation of optimal designs extends the methods of Eales and Jennison (1992), 
Eales and Jennison (1995) and Barber and Jennison (2002) to the asymmetric three-
decision problem. Given K and n1, . . . , nK , we seek the stopping boundary minimising 
m 
i=1 wiEθi (N) subject to error probability requirements (2.1) to (2.4). We follow a 
Lagrangian approach and introduce the unconstrained problem of minimising 
m 
wiEθi (N) +  λ1 P1 + λ2 P2 + λ3 P3 + λ4 P4, (2.6) 
i=1 
where λ1 to λ4 are positive and P1 to P4 denote the left hand sides of equations (2.1) 
to (2.4). The design minimising (2.6) must have the minimum value of mi=1 wiEθi (N) 
among all designs with the same P1 to P4. Hence, choosing Lagrange multipliers λ1 
to λ4 so that the solution has P1 = αN , P2 = αS, P3 = βN and P4 = βS solves the 
original constrained problem. 
For given λ1 to λ4, the method of dynamic programming can be used to 
minimise (2.6) quickly and accurately. This minimisation problem also has an 
interpretation as a Bayes sequential decision problem with a certain combination of 
prior on θ, costs for incorrect decisions, and sampling costs under the θis appearing 
in mi=1 wiEθi (N). This Bayesian interpretation provides insight into the dynamic 
programming solution where it is seen that decisions at each stage are based on 
expected future costs under the current posterior distribution for θ. Further details 
of the derivation of optimal designs are provided in Section 2.6.2. 
2.2.3 Numerical example 
Suppose a non-inferiority margin of δN = 0.1 has been established, power for the test 
of superiority is set at δS = 0.2, and error probabilities are αN = 0.025, αS = 0.025, 
βN = 0.1, and βS = 0.1. If the response variance is σ2 = 0.5, the ﬁxed sample size per 
treatment for the test of superiority alone is nSf = 263, while the test for non-inferiority 
needs nNf  = 1051. 
We ﬁrst consider a design with K = 8 analyses. The maximum sample size, 
nmax, must be at least a little greater than the larger of nSf and nNf  , so  we  choose  
nmax = 1.2 nNf  = 1261. We set n4 = nmax,S = 1.2 nSf = 316 so a conclusion about 
the superiority objective can be reached in the ﬁrst four analyses, leaving analyses 5 
to 8 to concentrate on testing between non-inferiority and inferiority. Taking equal 
group sizes either side of analysis 4, we have nk = (k/4)n4 for k = 1, . . . , 3, and 
nk = n4 + ((k − 4)/4)(nmax − n4) for  k = 5, . . . , 8. 
Optimising the design for F  yields the boundary values a1, b1, c1, d1, . . . , a8, b8, 
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c8, d8 shown earlier in Figure 2-2. The absence of an inner wedge at the ﬁrst two 
analyses indicates it is not possible to stop early for non-inferiority in this optimal 
design. The form of the upper part of the stopping boundary at later analyses merits 
some comment. Since optimisation has produced ck = dk for k = 4 to 8, there is no 
upper continuation region after analysis 4; this is in line with our intent to deal with 
the issue of superiority by this analysis. The presence of values for d5 to d8 shows it 
is still possible to decide in favour of superiority at a later analysis if the last group 
of observations produces a large increase in the Z-statistic and the study ends with 
Zk > dk. In fact, such a sequence of Zks is unlikely under any value of θ and the 
dramatic change in observed treatment eﬀect in the ﬁnal group needed to achieve this 
might well raise questions about heterogeneity of the treatment eﬀect over time. Let 
KS denote the index of the ﬁrst analysis at which ck = dk in an optimal design. We 
have found that setting ck = dk = ∞ for k > KS , so that only the test between non-
inferiority and inferiority is pursued at analyses k = KS + 1, . . . ,K, has a negligible 
impact on error probabilities and, hence, on eﬃciency. One may, therefore, choose to 
remove the option of a decision in favour of superiority after the analysis at which values 
of ck and dk ﬁrst converge. This will be the case in our deﬁnition of error spending 
designs in Section 2.2.5. However, unless otherwise stated we shall retain the option of 
stopping for superiority, and ﬁnite values for the dk, in the  optimal designs  we  report.  
Hence, we can have a trial that stops for non-inferiority (but not superiority) at 
analysis k, if  bk ≤ Zk ≤ ck, while for another trial we can have Zk < bk but still 
claim superiority later on, if the superiority boundary is crossed at a later analysis. As 
discussed in Section 2.6.1, this property makes the proof of monotonicity of type I and 
type II error probabilities more involved. In principle, it would have been possible to 
follow the approach of Lai et al. (2006) and not allow a superiority decision at later 
analysis. We believe however that it is sensible to declare superiority if the estimated 
treatment eﬀect at the end of the trial is overwhelmingly in favour of such a decision, 
even though results were less impressive at an earlier interim analysis. In practice, it 
is likely to be important to perform sensitivity analyses to understand the reasons for 
the heterogeneity of the treatment eﬀect over time. 
The optimal design’s expected sample size is shown as a function of θ by the solid 
line in Figure 2-3. The two horizontal lines at nNf  and nSf aid comparison with the 
sample sizes of the individual, ﬁxed sample tests for non-inferiority and superiority. 
The sequential design is clearly eﬀective in reducing expected sample size below nNf . 
Since the ﬁxed sample size, nSf , in the individual test for superiority is insuﬃcient 
to provide the desired power for the test of non-inferiority, it is to be expected that 
the sequential design has expected sample size greater than nSf at low values of θ. 
However, at high values of θ, where the main task is to distinguish between superiority 
and non-inferiority, Eθ(N) does  fall below  nSf . Additional curves in Figure 2-3 show the 
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Figure 2-3: Expected sample size functions for optimal designs with 4 and 8 analyses. 
expected sample size function for two more optimal designs, one with K = 4 analyses 
and one with K = 8 analyses. For both these designs, KS = 2,  n2 = 1.1 nSf = 289, 
and the remaining K − 2 analyses are equally spaced up to nK = 1261. With a total 
of 8 analyses, reducing KS from 4 to 2, so that more analyses are devoted to the 
inferiority/non-inferiority comparison, reduces F  by about 1%. However, the design 
with KS = 4 performs better for large values of θ. The eﬃciency gained by increasing 
the total number of analyses from 4 to 8 is close to 10%, a larger improvement than 
is typically seen in one-sided group-sequential tests of θ ≤ 0 against θ > 0. This can 
be attributed to the fact that some analyses are well placed for one testing objective 
but poorly placed for the other, so the “eﬀective” number of analyses for testing each 
individual hypothesis is less than K. We conclude that when the ratio nNf/nSf is as 
high as 4, designs with only a small number of groups may not achieve the full beneﬁts 
of sequential monitoring. 
2.2.4 Comparison with the method of Lai et al. 
Lai et al. (2006) propose a group sequential procedure with K analyses that switches 
objective at a certain analysis. For nNf  > nSf , the procedure allows early stopping 
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Figure 2-4: Critical values for a Lai et al. 5-group design and an optimal 5-group design. 
for superiority at analyses 1, . . . ,KS and for non-inferiority at analyses KS , . . . ,K; 
the test can stop for the negative decision of inferiority at any point. The authors 
present their method in terms of generalized likelihood ratio statistics but we shall 
deﬁne critical values on the Z scale. Figure 2-4 displays a 5-group Lai et al. procedure 
with KS = 3. Note that decisions of non-inferiority (solid line) and superiority (dashed 
line) are both possible at analysis 3. The authors deﬁne a parameter  governing the 
amount of early stopping and recommend using  = 1/3. The outer boundaries have 
constant critical values on the Z scale so, in our notation, d1 = . . .  = dKS −1 = d˜ and 
a1 = . . .  = aK−1 = a˜. For the non-inferiority boundary, bk = b˜ − δN 
√{nk/(2 σ2)}
for k = KS , . . . ,K  − 1. The values of a˜, aK , b˜, d˜ and dKS are chosen so that: the 
probability under θ = 0 of stopping to declare superiority by analysis KS − 1 is   αS 
and by analysis KS is αS ; the probability under θ = −δN of stopping to declare 
non-inferiority or superiority by analysis K − 1 is   αN and by analysis K is αN ; the  
probability under θ = 0 of stopping to conclude inferiority by analysis K − 1 is   βN . 
This construction does not produce speciﬁc type II error probabilities, instead these 
are determined by nK , nKS and . There is a demarcation at analysis KS , with stopping 
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for superiority only possible at analyses 1 to KS , and stopping for non-inferiority only 
at analyses KS to K. The framework of Section 2.2 imposes no such constraints and we 
allow an inner wedge for non-inferiority before KS and a continuing superiority/non­
inferiority boundary thereafter. 
We have applied the method of Lai et al. to the numerical example of Section 2.2.3, 
in which δN = 0.1, δS = 0.2, σ2 = 0.5 and  αN = αS = 0.025. We set K = 5,  KS = 3  
and  = 1/3, with nmax,S = 263 and nmax = 1051, the values that would give 90% 
power if the two testing objectives were addressed in ﬁxed sample trials. This implies 
n1 = 88, n2 = 175, n3 = nmax,S = 263, n4 = 657, and n5 = nmax = 1051. It is the 
resulting boundaries that are shown in the upper panel of Figure 2-4. This design has 
type II error probabilities βN = 0.125 and βS = 0.11. Using these numbers to deﬁne 
ﬁxed sample sizes nSf and nNf  , we ﬁnd the inﬂation factors for the Lai et al. design 
are rS = 1.035 and rN = 1.086. 
We compared the Lai et al. (2006) design with a 5-group sequential design with the 
same group sizes and attained error probabilities, optimised for F  . This optimised 
design with KS = 3,  rS = 1.035 and rN = 1.086 is depicted in the lower panel of 
Figure 2-4 and its expected sample size function is shown in Figure 2-5: the value of 
F  is about 4% lower than that of the Lai et al. design. However, the inﬂation factor 
rS = 1.035 is rather low and there is no obvious need to restrict nmax,S , given  that  
higher sample sizes are allowed if the study continues to later analyses. Keeping KS = 3  
and increasing rS from 1.035 to 1.2 while maintaining the same overall maximum 
sample size gives cumulative group sizes n1 = 102, n2 = 204, n3 = 306, n4 = 678, and 
nmax = 1051. The boundary optimising F  for these group sizes has an inner wedge 
at the second interim analysis. It is evident from Figure 2-5 that this increase in rS 
reduces the expected sample size function a little. In the example of Section 2.2.3, 
we found some advantage in scheduling fewer analyses for the superiority objective, 
leaving more to test between non-inferiority and inferiority. Here, we have considered 
KS = 2  and  rS = 1.2, so n1 = 153, n2 = 306, n3 = 554, n4 = 803 and n5 = 1051. The 
lowest curve in Figure 2-5 is for the test minimising F  with these group sizes and we 
see this design has the smallest expected sample size at all but the highest eﬀect sizes. 
Overall, we recognise that Lai et al’s proposal gives designs with quite good 
eﬃciency, but our wider class allows a design to be tailored to particular objectives 
and the “inner wedge”, not considered by Lai et al, can be instrumental in reducing 
expected sample size. 
2.2.5 Error spending designs 
To be of real practical value, a group sequential method should be able to deal 
with variation in group sizes about their planned values. Error spending designs 
oﬀer this ﬂexibility and, we shall show, can do so with high eﬃciency in terms of 
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Figure 2-5: Expected sample size functions for the Lai et al. design and three optimal 5-group 
designs. 
expected sample size. In introducing these designs we broaden consideration to general 
response distributions, still with the parameter θ representing the treatment eﬀect 
under investigation. Jennison and Turnbull (1997) show that for normal linear models, 
and asymptotically for general parametric models, the sequence of estimates θˆ1, . . . ,  θˆK 
based on accumulating data at K analyses is multivariate normal with 
θˆk ∼ N(θ, Ik −1), k = 1, . . . ,K,  
and 
Cov(θˆk1 , θˆk2 ) = Var(θˆk2 ) =  Ik−2 1 for k1 < k2, 
where Ik represents the Fisher information for θ at analysis k. 
In error spending designs, the cumulative type I and type II error probabilities 
are speciﬁed as functions of the observed information at each analysis; boundaries for 
standardised statistics Zk = θˆk 
√Ik are found that satisfy these conditions using the 
distribution theory stated above. This approach relaxes the requirement of achieving 
pre-planned information levels at each analysis implicit in the tests of Section 2.2. Lan 
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and DeMets (1983) introduced error spending to handle unpredictable group sizes in 
two-sided tests of a null hypothesis. We now extend this approach to our three-decision 
problem with its four type I and type II error probabilities. 
The information levels required by individual tests of superiority and non-inferiority 
are 
ISf = {Φ−1(1 − αS ) + Φ−1(1 − βS )}2/δ2 S 
and 
I = {Φ−1(1 − αN ) + Φ−1(1 − βN )}2/δ2 Nf  N . 
Multiplying these expressions by inﬂation factors rS and rN gives target information 
levels for an error spending design. Assuming INf  > ISf , the overall maximum 
information level which an error spending design may require is Imax = rN INf  . We  
also specify a target information level by which testing for superiority should terminate, 
Imax,S = rS ISf . 
Type I and II error probabilities αS and βS for the test of superiority are spent 
according to functions fS(I) and  gS (I) as  I increases from zero to Imax,S . Similarly, 
spending of error probabilities αN and βN for the test of non-inferiority follows functions 
fN (I) and  gN (I) as  I increases from zero to Imax. At the design stage, we make a 
working assumption that a speciﬁc sequence of information levels will be observed and 
specify a combination of fS, gS , fN , gN , Imax,S and Imax for which boundaries converge 
to spend all four error probabilities exactly by the end of the study. We plan for K 
interim analyses at information levels 
Ik = k Imax,S /KS for k = 1, . . . ,KS (2.7) 
and 
Ik = Imax,S + (k −KS )(Imax − Imax,S )/(K −KS ) for  k = KS + 1, . . . ,K.  (2.8) 
In practice, the test will adapt to observed information levels, maintaining type I error 
probabilities precisely but with small perturbations to the type II error rates. 
Our choice of error spending functions is motivated by the cumulative error rates 
seen in optimal designs. Since these designs do not allow very early decisions of non-
inferiority, we also delay spending αN and βS until information reaches a minimum 
threshold γ Imax,S , where  0  ≤ γ ≤ 1. This is a sensible feature since, with only a small 
amount of data, one cannot be conﬁdent that θ is both above −δN and below δS . We  
propose a family of designs with spending functions indexed by the parameter ρ >  0, 
similar in form to those for the two-decision problem used by Jennison and Turnbull 
(2003). The four error spending functions are: 
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⎧
⎪
⎪0  if  I < γ I⎪ max,S ⎨ 
fN (I) =  αN (I/Imax)ρ if γ Imax,S ≤ I < Imax ⎪ ⎪ ⎪ ⎩αN if I ≥ Imax 
⎧ ⎨αS (I/Imax,S )ρ if I < Imax,S 
fS(I) = 
 ⎩αS if I ≥ Imax,S

⎧ ⎨βN (I/Imax)ρ if I < Imax 
gN (I) =  ⎩βN if I ≥ Imax 
⎧
⎪
⎪0  if  I < γ I⎪ max,S ⎨ 
gS (I) =  βS (I/Imax,S )ρ if γ Imax,S ≤ I < Imax,S ⎪ ⎪ ⎪ ⎩βS if I ≥ Imax,S , 
where γ > 0. Figure 2-6 shows these functions for the case ρ = 1  and  γ = 0.5. When 
ISf < INf  , Brannath et al. (2003) comment on the desirability of spending the type 
I error probability αS for the superiority objective more rapidly than that for the test 
of non-inferiority, αN . This feature is built into our deﬁnitions of spending functions 
but there would be no diﬃculty in taking such considerations further and varying the 
values of ρ in the four spending functions. 
Application of this error spending design with an observed sequence of information 
levels, I1, I2, . . . , follows the general framework described by (Jennison and Turnbull, 
2000, Chapter 7) for other types of error spending test. At the ﬁrst few analyses 
with Ik < γ Imax,S only the outer boundary values dk and ak are required. These are 
calculated to satisfy 
Pθ=0(Declare “Superiority” by analysis k) =  fS(Ik) (2.9) 
and 
Pθ=0(Declare “Inferiority” by analysis k) =  gN (Ik). (2.10) 
We do allow stopping to declare superiority when fN (Ik) = 0, even though this 
represents a type I error for the test of non-inferiority under θ = −δN . Similarly, 
we permit a decision of inferiority when gS (Ik) = 0, even though this is a type II 
error for the test of superiority under θ = δS . The probabilities of these outcomes 
are computed so they can be accounted for at later analyses when fN (Ik) and  gS (Ik) 
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Figure 2-6: Error spending functions with ρ = 1  and  γ = 0.5. 
become positive. 
For γ Imax,S ≤ Ik ≤ Imax,S , we compute dk and ak to satisfy (2.9) and (2.10) and 
perform a two-dimensional search to ﬁnd values bk and ck satisfying 
Pθ=−δN (Declare “Non-inferiority” or “Superiority” by analysis k) =  fN (Ik) (2.11) 
and 
Pθ=δS (Declare “Inferiority” or “Non-inferiority” by analysis k) =  gS (Ik). (2.12) 
Further details of how bk and ck can be found are given in Section 2.6.3. 
At the ﬁrst analysis K˜S where IK˜S ≥ Imax,S we calculate dK˜S so that 
Pθ=0(Declare “Superiority” by analysis K˜S ) =  αS 
and set cK˜S = dK˜S . We ﬁnd aK˜S and bK˜S satisfying (2.10) and (2.11) with k = K˜S and 
Ik = IK˜S . At subsequent analyses with Ik < Imax we set ck = dk = ∞ and calculate 
ak and bk to satisfy (2.10) and (2.11). Finally, at the ﬁrst analysis K˜ with IK˜ ≥ Imax 
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we ﬁnd bK˜ satisfying 
Pθ=−δN (Declare “Non-inferiority” or “Superiority” by analysis K˜) =  αN 
and set aK˜ = bK˜ . 
By construction, this error spending procedure attains the type I error probabilities 
αN and αS exactly. The type II error probabilities may diﬀer slightly from βN and βS 
but they will be close to these targets if the observed information levels are similar to 
the sequence deﬁned by (2.7) and (2.8) which was assumed for planning purposes. 
Suppose that αS , αN , βN and βS are speciﬁed, so ISf and INf  are ﬁxed multiples 
of δ−2 and δ−2, respectively. For given δN /δS , ρ, γ, KS and K, and assuming analyses S N 
are scheduled according to (2.7) and (2.8), a two-dimensional search can be conducted 
to ﬁnd the inﬂation factors rS and rN which give power 1 − βN at θ = 0  and  1  − βS 
at θ = δS . Within the ρ family, increasing ρ reduces the rate at which error is spent, 
leading to smaller inﬂation factors. Thus, for given αS , αN , βN , βS , γ, KS , K and 
δN /δS < 1, say, there is a one-to-one correspondence between ρ and rN . While inﬂation 
factors do increase gradually with K, broadly speaking, setting ρ = 3 gives an inﬂation 
factor around rN = 1.05 and wide outer boundaries similar to an O’Brien and Fleming 
(1979) test, whereas ρ = 1 yields an inﬂation factor around 1.2 or 1.25 and narrower 
boundaries, as in a Pocock (1977) test. 
Comparing the ρ family error spending tests with designs optimised for F , we  have  
found the ρ family tests to be highly eﬃcient and achieve values of F  within a few 
percent of the minimum possible for a given inﬂation factor rN . We conclude that error 
spending designs in the ρ family are both eﬃcient and suﬃciently ﬂexible to handle 
unpredictable group sizes or information levels. These ﬁndings are in keeping with 
those of Barber and Jennison (2002) for one-sided error spending tests with similar 
spending functions. 
As an illustration of the preceding remarks, Figure 2-7 shows the expected sample 
size function for the design with αN = αS = 0.025, βN = βS = 0.1, δN = 0.1, δS = 0.2, 
ρ = 1,  γ = 0.5, KS = 3  and  K = 6, as well as that for the optimal design minimising 
F  for the same problem and group sizes. It is evident that the error spending design 
is highly eﬃcient across the range of θ values and, overall, it achieves a value of F  
within 2% of the optimum. 
If we consider the same example, but vary ρ from 0.5 to 3, we obtain designs with 
inﬂation factors rN ranging from around 1.5 to 1.05. Figure 2-8 shows values of F  for 
these error spending designs plotted against the inﬂation factor rN for each design. The 
slightly lower curve gives the value of F  achieved by optimal designs for this criterion 
with the same group sizes, which is around 2 to 4 per cent smaller than that of the 
error spending design. The levelling oﬀ of F  as ρ decreases and rN increases indicates 
there is no advantage in taking rN greater than around 1.2, which is attained by ρ of 
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Figure 2-7: E(N)/nNf  for a 6-group error spending design with ρ=1 and γ = 0.5 and for the 
optimal 6-group design with analyses performed at the same information levels. 
about 0.8. 
We recommend 0.5 as a simple default value for γ. In a detailed assessment of a 
particular case one can go further and compare values of γ with respect to expected 
sample size functions under diﬀerent sequences of information levels, paying particular 
attention to the eﬀect of I1. 
Another advantage of error spending tests is that they support use of the method 
of information monitoring, as proposed by Mehta and Tsiatis (2001). This approach 
can be used to manage a trial when the sample size needed for speciﬁc power depends 
on nuisance parameters which are only estimated once the trial is under way. One 
example of such a parameter is the variance of a normal response: thus, error spending 
and information monitoring provide a way to deal with unknown variance in the normal 
response problem introduced in Section 2.2.1. 
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Figure 2-8: F /nNf  for ρ family error spending designs with ρ in the range 0.5 to 3 and for 
optimal designs minimising F  with the same sequences of information levels. 
2.3 Optimal adaptive designs 
2.3.1 Framework 
The need for diﬀerent sample sizes to test superiority and non-inferiority has prompted 
proposals for designs in which future group sizes are based on previously observed 
data. Such procedures are examples of adaptive group sequential designs, as proposed 
for one-sided tests by Schmitz (1993). These methods extend those of Section 2.2 by 
allowing each new group size to depend on previous data. Since this wider class includes 
non-adaptive group sequential designs as special cases, optimising over it yields a lower 
value of an objective function, such as F , than that of the best non-adaptive design. 
We shall now explore the beneﬁts of adaptation in reducing expected sample size in 
the three-decision problem and consider whether they justify the extra complexity of 
this approach. The deﬁnition of adaptive group sequential designs applies for general 
K but we shall focus on K = 2 for computational simplicity. 
In the three-decision problem, adaptive designs may terminate at each analysis with 
a decision of inferiority, non-inferiority or superiority. However, if sampling continues 
at analysis k, the next group size is allowed to depend on Zk. We seek the sequential 
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decision rule that minimises F  subject to the error constraints (2.1) to (2.4). The 
optimal K-group adaptive design can be derived by the Lagrangian approach used in 
Section 2.2 for the non-adaptive case. The unconstrained problem is a Bayes decision 
problem, solvable by dynamic programming. 
In solving the unconstrained problem for the case K = 2, suppose the ﬁrst analyses 
takes place after n1 observations. We approximate the continuous range of values for 
n2 by giving M possible cumulative group sizes, n2,1, . . . , n2,M , for the ﬁnal analysis. 
We ﬁnd the optimal critical values b2,1, . . . , b2,M and d2,1, . . . , d2,M to decide between 
inferiority, non-inferiority and superiority in each case. The task at the ﬁrst analysis 
is to determine which of the following actions is optimal: stop for inferiority, stop for 
non-inferiority, stop for superiority, or continue to the ﬁnal analysis with cumulative 
group size n2,m for a value of m ∈ {1, . . . ,M}. This gives the optimal design for a 
given value of n1 and a further search over n1 gives the two-stage adaptive design with 
the overall minimum of F  . 
In numerical calculations we have used M = 100 and n2,1, . . . , n2,M equally spaced 
between n1 and an upper limit RnNf  where R > 1. We performed sensitivity analyses 
to check there is no signiﬁcant change to the design if M or R is increased. For most 
examples, we have found that when using R = 1.35, the optimal choice of n2 is lower 
than RnNf  for all values of Z1. We give further details of implementing the dynamic 
programming algorithm in Section 2.6.2. 
2.3.2 Eﬃciency gains through adaptation 
We illustrate with an example the possible eﬃciency gains from adaptation in two-stage 
designs. The results in Table 2.1 are for non-adaptive and adaptive two-stage designs 
which minimise F  subject to error probabilities αN = αS = 0.025 and βN = βS = 0.1 √ 
for values of δSf/δNf  = (nNf/nSf )1/2 ranging from 1 to 3. In the adaptive design the 
initial group size, n1, is chosen optimally and the second group size, n2 −n1, is selected 
to be optimal for the observed Z1. For the non-adaptive designs, n1 and n2 are ﬁxed at 
optimal values for the objective function F . The maximum value of n2 in the adaptive 
designs ranges from 1.20 nNf  to 1.26 nNf  in the six cases of Table 2.1 whereas, in the 
non-adaptive designs, n2 takes lower values between 1.12 nNf  and 1.17 nNf  . In  fact,  for  
the case nNf/nSf = 3,  values  of  n1 greater than nSf help to minimise F  in both the 
non-adaptive and adaptive designs, but lead to power for the test of superiority greater 
than the stipulated 1 −βS = 0.9. Reformulating this requirement as an inequality that 
power should be at least 0.9, leads to the designs reported here which have both higher 
power for the test of superiority (around 0.93) and lower F  . 
The results in Table 2.1 show only minor beneﬁts from adaptation. These beneﬁts 
are greatest for intermediate values of the ratio nNf/nSf and in these cases there are 
areas of the adaptive design’s continuation region at the ﬁrst analysis where each of 
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nNf/nSf = 1.0 1.25 1.5 1.75 2.0 3.0 
Optimal non-adaptive designs 81.8 75.3 71.7 69.1 67.0 64.6

Optimal adaptive designs 81.7 74.3 70.1 67.7 66.1 64.2

Table 2.1: Values of 100 F /nNf  for optimal two-stage designs with error probabilities at 
most αN = αS = 0.025 and βN = βS = 0.1 for selected values of nNf/nSf = (δS/δN)2 . 
the three ﬁnal decisions is plausible. This leads to substantial variation of the optimal 
values for n2 with Z1, as displayed in Figure 2-9 for the case nNf/nSf = 1.5. In view of 
the variation in the optimal n2, it is not surprising that the best non-adaptive design, 
with only a single value of n2, is less eﬃcient. On the other hand, Figure 2-9 suggests 
it might be suﬃcient to choose between just two sample sizes, nN,2 and nS,2 say, in 
the lower and upper continuation regions, either side of the “inner wedge”. We refer 
to such a procedure as a restricted adaptive design. 
We computed a two-stage restricted design minimising F  for the case 
nNf/nSf = 1.5, with n1 set at the value chosen for the unrestricted adaptive design. 
The dashed lines in Figure 2-9 show the continuation intervals, which diﬀer slightly 
from the unrestricted design, and values of nN,2 and nS,2. In Figure 2-10, the expected 
sample size function for the restricted adaptive design lies very close to that of the 
optimal unrestricted adaptive design, demonstrating that the key improvement in the 
adaptive design comes from choosing a sample size appropriate to the most relevant 
decision choice, superiority vs non-inferiority or non-inferiority vs inferiority, and not 
from any further ﬁne-tuning. Values of 100F /nNf  are 71.7 for the two-group non­
adaptive test, 70.4 for the restricted adaptive test, and 70.1 for the two-group adaptive 
test. 
Figure 2-10 also shows the expected sample size function for the optimal non­
adaptive three-group design with nNf/nSf = 1.5 and cumulative sample sizes equal to 
the values of n1, nS,2 and nN,2 in the restricted adaptive design. Since the third analysis 
is only used to distinguish between inferiority and non-inferiority, this is an example 
from our class of non-adaptive designs with K = 3  and  KS = 2  (and  c3 = d3 = ∞). 
This three-group non-adaptive design has lower expected sample size than the optimal 
adaptive two-stage design across the range of θ values and it is signiﬁcantly more 
eﬃcient at low values of θ; its value of 100F /nNf  is 66.8, compared to 70.1 for the 
optimal adaptive two-stage design. Our conclusions here concur with those of Jennison 
and Turnbull (2006a) about the two-decision problem: while adaptivity can lead to a 
small increase in eﬃciency, similar or larger improvements can be achieved with one 
additional interim analyses in a non-adaptive group sequential design. In view of the 
minor beneﬁts accruing from adaptive choice of group size in the case K = 2,  we  have  
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Figure 2-9: Final sample size, n2, as a function of Z1 for the optimal adaptive design for 
nNf  /nSf = 1.5 (solid lines) and sample sizes nN,2 and nS,2 for the optimal restricted adaptive 
design (dashed lines). 
not carried out computation of optimal adaptive designs for higher values of K. 
2.3.3 Competing adaptive methods 
The sample size function for the optimal adaptive design in Figure 2-9 is qualitatively 
diﬀerent from that arising from a conditional power rule, where sample size rises as Z1 
decreases, at least within each continuation interval. While optimal adaptive designs 
oﬀer modest gains over their non-adaptive counterparts, the following comparisons 
show published adaptive methods with sub-optimal sampling rules can be less eﬃcient 
than simpler non-adaptive designs. 
Koyama et al. (2005) propose an adaptive two-stage procedure for simultaneous 
testing of superiority and non-inferiority. After the ﬁrst stage, stopping is possible for 
inferiority, non-inferiority or superiority. If the trial continues, the second stage sample 
size is set as a function of the ﬁrst stage test statistic, Z1. The sample size function and 
terminal decision rules are chosen to achieve speciﬁed overall error probabilities αN , 
αS , βN , and βS . Koyama et al. (2005) provide an example with δN = 1.0, δS = 0.5, 
σ = 4,  αN =αS = 0.025, βN = 0.1 and  βS = 0.2. While we have focused on designs 
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Figure 2-10: Expected sample size functions for optimal non-adaptive, restricted adaptive 
and adaptive 2-group designs and the optimal non-adaptive 3-group design. 
with δS > δN , our framework also applies to the case δS < δN studied by Koyama 
et al. (2005), Lai et al. (2006) and Brannath et al. (2003). We have compared the 
adaptive procedure of Koyama et al. with a two-stage non-adaptive design with the 
same error probabilities optimised for F  . In this design, the ﬁrst analysis is scheduled 
after 337 observations per treatment and the ﬁnal analysis after 1200 observations. 
Expected sample sizes per treatment are shown in Table 2.2. Not only is the non­
adaptive procedure more eﬃcient, but its maximal sample size per treatment is only 
1200, compared to more than 1500 for the adaptive design. 
The method proposed by Shih et al. (2004) falls within the framework for 2-stage 
adaptive procedures deﬁned in Section 2.3.1. Early stopping for futility, non-inferiority 
or superiority is possible at the ﬁrst analysis and critical values at both analyses are 
chosen to control the overall type I error probabilities at speciﬁed values αN and αS . 
The procedure does not aim to achieve a particular overall power, rather the second 
stage sample size is chosen with reference to conditional power given the ﬁrst stage data. 
We have simulated the design presented for the survival data example in Section 3 of 
Shih et al. (2004) and found the overall power curves and expected sample size function 
of this design: with a survival endpoint, “sample size” should be interpreted as the 
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Eθ(N) for  Koyama  Eθ(N) for  a  2-group  
θ et al’s design non-adaptive design 
−δN 337 337 
0 643 625 
δS 996 937 
Table 2.2: Comparison between the adaptive design of Koyama et al. and an optimal non­
adaptive design. 
number of events observed at termination. We constructed a non-adaptive 2-group 
sequential design with the same type I error probability and overall power curves at 
least as high as those of the procedure of Shih et al. (2004), over the range of eﬀect sizes. 
This non-adaptive group sequential design had lower expected sample size by between 
3% and 11% at values of θ in the range −δN to 2 δN . We attribute the lower eﬃciency of 
the adaptive procedure to the choice of sample size function: for the optimal adaptive 
rule, values of n2 are highest in the middle of each arm of the continuation region and 
lower nearer the boundary points, whereas the conditional power construction implies 
n2 increases monotonically as θˆ decreases. 
Wang et al. (2001) propose an adaptive group sequential closed (AGSC) procedure 
which starts out as a group sequential design for testing superiority, but can shift 
adaptively between superiority and non-inferiority objectives. When δN < δS and 
nNf  > nSf , the initial design has nSf observations and K analyses. At each 
interim analysis, conditional power calculations determine whether to shift to the non-
inferiority objective. If so, group sizes are increased to lead to a ﬁnal sample size of nNf  
at analysis K with down-weighting as in the method of Cui et al. (1999) to maintain 
the type I error rate. Type II error rates are not controlled directly but are governed 
by nNf , nSf , the group sequential stopping boundary and the adaptive decision rule. 
We evaluated the AGSC method by simulation with one million replicates. We 
assumed normal responses with σ2 = 9,  αN = αS = 0.025, δN = 0.4 and  δS = 0.8. The 
initial design had ﬁve equally spaced analyses and a total of nSf = 221 observations per 
treatment arm, increasing to nNf  = 883 under adaptation. Figure 2-11 compares the 
AGSC method and a non-adaptive 5-group sequential design with KS = 2,  nKS = 221, 
K = 5,  and  n5 = 883. The non-adaptive design has higher power and a substantially 
lower expected sample size function. Since the AGSC method has no lower boundary 
to allow stopping for inferiority, its high expected sample size under low values of θ is 
to be expected. At higher eﬀect sizes, using non-suﬃcient statistics as a result of down-
weighting later observations is a source of ineﬃciency. More important, we believe, is 
the reliance on uncertain estimates of θˆ at the interim analyses in making the decision 
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Figure 2-11: Expected sample size functions and power for non-inferiority and superiority, 
for the AGSC design of Wang et al. (solid line) and an optimal non-adaptive 5-group sequential 
design (dashed line). 
to increase sample size four-fold. While we have found the addition of a lower futility 
boundary to the AGSC method improves performance for low values of θ, the  method  
still fails to match the performance of the non-adaptive group sequential test at higher 
eﬀect sizes. 
2.4 An example in type 2 diabetes 
We shall illustrate how the method can be applied, to a clinical trial in type 2 diabetes. 
EMEA (2002) recommends decrease from baseline HbA1c, a measure of blood glucose 
control, as the primary endpoint for studies of type 2 diabetes. In the trial reported 
by Home et al. (2007), the response was the percentage decrease in HbA1c, the non-
inferiority margin was δN = 0.4 and a standard deviation of 1.4 was used in the sample 
size calculation. Go¨ke et al. (2007) report a clinical trial with power to detect an 
improvement of δS = 0.5 under the new treatment and, again, a standard deviation of 
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Figure 2-12: Expected sample size functions for designs in the type 2 diabetes example. 
1.4 was used to determine sample size. 
Consider designing a trial to compare a new treatment for type 2 diabetes against 
a standard, testing for both superiority and non-inferiority. Suppose responses are 
normally distributed with XAi ∼ N(μA, σ2) on the new treatment and XBi ∼ 
N(μB , σ2) on the standard. Denoting the treatment eﬀect by θ=μA − μB, we  wish  
to test simultaneously the null hypothesis HN,0: θ ≤ −0.4 against θ > −0.4 with  power  
speciﬁed at θ = 0 and the null hypothesis HS,0 : θ ≤ 0 against θ >  0 with power  at  
θ = 0.5. Thus, we set δN = 0.4, δS = 0.5, αN = 0.025, αS = 0.025, βN = 0.1, and 
βS = 0.1 in our general framework. With σ = 1.4, ﬁxed sample sizes per treatment are 
nSf = 165 and nNf  = 258 for the two individual hypothesis tests. 
For nNf/nSf around 1.5, the results of Section 2.3.2 indicate adaptation may be 
helpful if only two analyses are possible. We computed an adaptive two-group design 
optimised for F  with n1 = 99 and no upper limit for the second group size. We also 
derived a “restricted adaptive” design, as introduced in Section 2.3.2, where n1 = 99  
and, if sampling continues, the choice of the ﬁnal sample size is either 198 or 309. 
The two upper curves in Figure 2-12 are the expected sample size functions for these 
restricted adaptive and adaptive designs. We see that restricting the second group size 
to just two values has a negligible eﬀect on eﬃciency. 
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Comparison of expected sample size functions allows an informed choice of a suitable 
design. In making this choice, investigators may also consider the logistical challenges 
of setting up a trial with data-driven choice of the second group size. Information 
leakage should be considered since, in both the adaptive and restricted adaptive designs, 
knowledge of the second stage sample size provides an indication of the ﬁrst stage 
results. In this joint testing problem, leakage can also be an issue for a non-adaptive 
group sequential design: in a 3-group procedure with KS = 2, continuation past the 
second analysis implies the new treatment has not been found to be superior and the 
decision will be either “non-inferior” or “inferior”. 
The error spending method of Section 2.2.5 can be used to give a design with close 
to optimal eﬃciency as well as the ﬂexibility to deal with unpredictable group sizes. 
If we use ρ family error spending functions with ρ =  1  and design for  K = 3 analyses 
with KS = 2  and  γ = 0.4, the inﬂation factors are rS = 1.167 and rN = 1.195, so 
nmax,S = 1.167nSf = 193 and the maximum sample size is nmax = 1.195 nNf  = 308. 
If observed sample sizes follow the design pattern of n1 = 97, n2 = 193 and n3 = 308, 
power of 0.9 is attained exactly in both hypothesis tests. The expected sample size 
function for this design shown in Figure 2-12 is almost identical to that obtained by a 
3-group sequential design with rS = rN = 1.2 optimised for F  . 
Suppose patient accrual is lower than expected and only n˜1 = 71 responses are 
observed at the ﬁrst analysis. Since n˜1 < γnmax,S , there is no inner wedge at the 
ﬁrst analysis. If accrual remains slow throughout the trial, a fourth analysis will 
be needed to reach nmax but the error spending design adjusts easily to the new 
sequence of sample sizes. Suppose we observe n˜2 = 144, n˜3 = 220 and n˜4 = 308. The 
critical values for what is now a 4-group design are computed following the prescription 
in Section 2.2.5: the resulting boundaries are shown in Figure 2-13. The type I 
error probabilities are automatically controlled at αN = 0.025 and αS = 0.025 and 
the attained type II error probabilities are Pθ=0(Conclude “Inferiority”) = 0.102 and 
Pθ=δS (Conclude “Inferiority or Non-inferiority”) = 0.088, both close to their intended 
values of βN = βS = 0.1. The inner wedge plays an important role, allowing stopping 
for any of the three possible outcomes, superiority, non-inferiority and inferiority, at 
analyses two and three. The expected sample size function in this case is the lowest 
curve in Figure 2-12. So, not only does the error spending design deal well with the 
observed pattern of group sizes, but results for this four group design show it gains 
eﬃciency by adapting to a higher number of smaller group sizes when these arise in 
practice. 
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Figure 2-13: Critical values for 4-group error spending design. 
2.5 Discussion 
We have introduced a framework to deﬁne group sequential designs which test 
simultaneously for superiority and non-inferiority and allow early stopping for any one 
of the three conclusions of superiority, non-inferiority and inferiority. We can compute 
the design of this type which minimises a weighted combination of expected sample sizes 
at several eﬀect sizes. We have also deﬁned error spending versions of these designs 
which can handle unpredictable group sizes while retaining almost optimal eﬃciency. 
Expressing these error spending designs in terms of information for the eﬀect size 
parameter shows they are applicable to a wide variety of response types and can deal 
with nuisance parameters governing the sample size needed for a speciﬁc power through 
the information monitoring approach of Mehta and Tsiatis (2001). 
We have followed other authors in addressing the situation where the non-inferiority 
margin δN is smaller than the eﬀect size δS at which power is set in the test for 
superiority. Here, much larger sample sizes are required when the study focuses on 
distinguishing between non-inferiority and inferiority. If such large sample sizes are 
known to be available if needed, one might expect investigators to consider increasing 
the power of the test for superiority to detect smaller eﬀect sizes than δS . If  this  
occurs, nSf will increase and the ratio nNf/nSf will be closer to one. Our framework 
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will still be appropriate and the inner wedge, which allows early stopping to declare 
non-inferiority, will play an important role in such cases. 
In the two-decision problem, Barber and Jennison (2002) found the greatest beneﬁt 
of an additional interim analyses to arise when moving from a ﬁxed sample test to a 
two-group test. For the three-decision problem, two analyses are required simply to 
meet the diﬀerent error constraints for the pair of hypothesis tests. When sample sizes 
for the two testing objectives are very diﬀerent, a total of four analyses is needed to 
allow two suitably placed analyses for each hypothesis test. Thus, it is a feature of 
the group sequential designs for the three decision problem that a larger number of 
interim analyses is likely to be worthwhile than for group sequential designs for the 
two-decision problem. 
In the “adaptive” designs considered in Section 2.3, future group sizes are based on 
current data, in particular the observed eﬀect θˆ. Remember, though, that our “non­
adaptive” group sequential designs also respond to the observed data: the stopping 
rule provides a very deﬁnite response and, when nNf  > nSf , the absence of an upper 
continuation region at the last few analyses shows a shift of focus to the test between 
non-inferiority and inferiority. 
In exploring the adaptive choice of group sizes, we have found only minor beneﬁts 
of adaptation in two-stage designs, the case most often considered in the literature. 
In fact, we saw in Section 2.3.3 that non-adaptive group sequential designs can out­
perform some proposed adaptive methods with the same number of analyses. The 
greatest advantage we have found of an adaptive over an optimal non-adaptive 2-group 
design is around 3% of the ﬁxed sample size. This may be a signiﬁcant beneﬁt in a 
clinical trial with thousands of patients — but then there is reason to pursue the even 
greater beneﬁts of a non-adaptive 3-group sequential design. We have not invested 
eﬀort in deriving optimal adaptive designs with three or more analyses as we do not 
anticipate substantively diﬀerent results from the two-group case. 
2.6 Proofs and derivations 
2.6.1 Proof of monotonicity of type I and type II error probabilities 
It seems intuitive that the probability of rejecting a null hypothesis such as HS,0: θ ≤ 0 
should increase with θ in any sensible experimental design. A coupling argument can 
provide a proof for some group sequential designs (see, for example, Jennison and 
Turnbull (2000, Page 183)), but this approach does not extend to group sequential 
designs with an inner wedge. Adaptive designs pose further problems, indeed Jennison 
and Turnbull (2003, Section 4.2) present an adaptive design with a non-monotone 
power function. However, Shih et al. (2004) are able to prove monotonicity of the 
type I error probability within the null hypothesis for two-stage adaptive designs. We 
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now generalise their result to K-group designs. 
Consider ﬁrst the non-adaptive case and a K-group design, as deﬁned in 
Section 2.2.1. Let fk(zk; θ) denote the density of Zk at analysis k under treatment 
eﬀect θ in the absence of any prior early stopping. Deﬁne pkc(zk) to be the conditional 
probability that Z1, . . . , Zk−1 lie in the continuation regions 
(a1, b1) ∪ (c1, d1), . . . , (ak−1, bk−1) ∪ (ck−1, dk−1), 
given that Zk = zk. Since  Zk is suﬃcient for θ, this probability does not depend on θ. 
We can write 
K ∫ ∞ 
Pθ(Declare “Superiority”) = fk(zk; θ) pkc(zk) dzk. (2.13) 
k=1 dk 
√
Now, marginally, Zk ∼ N(θ Ik, 1). Thus, if dk ≥ 0, fk(zk; θ) is an increasing function 
of θ for all θ ≤ 0 and  zk > dk. It follows that all the integrands in the right hand side 
of (2.13) are increasing in θ for θ ≤ 0. Hence, as long as dk ≥ 0 for  each  k = 1, . . . ,K, 
Pθ(Declare “Superiority”) increases monotonely with θ for θ ≤ 0 and the maximum 
type I error probability over θ ≤ 0 occurs at θ = 0. The condition dk ≥ 0 implies that 
stopping to reject HS,0: θ ≤ 0 is only possible when θˆk ≥ 0, which is to be expected in 
any sensible design. 
A similar argument shows Pθ(Declare “Non-inferiority or Superiority”) is monotone 
over θ ≤ −δN . In this case, the integrals in (2.13) have range (bk, ck) ∪ (dk,∞) and  the  √
condition for integrands to be increasing for θ ≤ −δN becomes bk ≥ −δN Ik, so  HN,0: 
θ ≤ −δN is only rejected when θˆk ≥ −δN . The same approach can be used to establish 
monotonicity results for type II error probabilities: 
Pθ(Conclude “Inferiority”) 
decreases with θ for θ ≥ 0 as long as this decision only occurs when θˆk ≤ 0, and 
Pθ(Conclude “Inferiority” or “Non-inferiority”) 
decreases with θ for θ ≥ δS as long as this decision requires θˆk ≤ δS . 
We can obtain results for adaptive group sequential designs by essentially the same 
argument. Since the sample size at each analysis now depends on previous responses, 
the sum over k in (2.13) becomes a double sum over k and the set of possible sequences 
{I1, . . . ,Ik}. In some designs the critical value dk may depend on the whole sequence 
{I1, . . . ,Ik}. It is useful, conceptually, to deﬁne the sequence of Z-statistics at all 
information levels that might arise, noting the joint distribution theory stated at the 
start of Section 2.2.5 applies to this whole sequence. We let fk(zk,Ik; θ) denote  the  
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√ 
N(θ Ik, 1) density of Zk for treatment eﬀect θ and information level Ik in the absence 
of any prior early stopping. We deﬁne 
pkc(zk,I1, . . . ,Ik) 
to be the conditional probability of following the sequence of information levels 
I1, . . . ,Ik to reach analysis k with information Ik and Zk = zk, given  that  Zk takes 
this value when information is equal to Ik. Again, this conditional probability does 
not depend on θ. In place of (2.13) we now have 
K ∑ ∫ ∞ 
Pθ(“Superiority”) = fk(zk,Ik; θ) pkc(zk,I1, . . . ,Ik) dzk. 
k=1 {I1,...,Ik} dk (I1,...,Ik) 
As before, all the integrands in this equation are monotone increasing in θ, as  long  as  
each critical value dk(I1, . . . ,Ik) is positive and, hence, the maximum type I error rate 
over θ ≤ 0 occurs at θ = 0. Results for other error probabilities follow as before with 
the same conditions on critical values when these are expressed in terms of the ﬁnal θˆk. 
2.6.2	 Derivation of optimal group sequential designs by solving Bayes 
decision problem 
We illustrate our methods in the derivation of a design minimising F  subject to error 
constraints (2.1) to (2.4). In this case, we place a ﬁve point prior distribution on θ with 
probability 1/5 at  −δN , −δN /2, 0, δS /2 and  δS . We deﬁne a loss function associated 
with decisions on termination DI : declare inferiority, DN : declare-inferiority, and DS : 
declare superiority, 
⎧ ⎪ ⎪ ⎪ k1 for D = DN or DS and θ = −δN ⎪ ⎪ ⎪ ⎪⎪ for D and θ = 0  ⎪ k2 = DS ⎨ 
L(D, θ) =  k3 for D = DI and θ = 0 	 (2.14) ⎪ ⎪ ⎪ ⎪ ⎪k4 for D = DI or DN and θ = δS⎪ ⎪ ⎪ ⎪ ⎩0  otherwise.  
With a cost c(θ) = 1 per observation at each value of θ, the total expected cost is 
F  + {k1 Pθ=−δN (DN ∪ DS ) +  k2 Pθ=0(DS ) +  k3 Pθ=0(DI ) +  k4 Pθ=δS (DI ∪ DN )}/5. 
We use dynamic programming, as described below, to solve this unconstrained Bayes 
decision problem for either non-adaptive or adaptive designs. It then remains to 
perform a numerical search for values of k1, k2, k3 and k4 which give a solution 
satisfying the error probability constraints (2.1) to (2.4). The standard Lagrangian 
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argument implies that this Bayes sequential decision rule minimises F  among all 
designs satisfying (2.1) to (2.4). 
Consider ﬁrst the non-adaptive case where nk, k = 1, . . . ,K, are pre-speciﬁed. Let 
π(k)(θ|zk) denote the posterior distribution of θ given Zk = zk. If sampling continues 
until the ﬁnal analysis K, a decision DI , DN , or  DS must be chosen. The critical values 
at this analysis are obtained by solving k3 π(K)(0|zK ) =  k1 π(K)(−δN |zK ) to ﬁnd bK , 
and k4 π(K)(δS |zK ) =  k2 π(K)(0|zK ) to ﬁnd dK ; the monotone likelihood ratio property 
of the normal distribution implies each of these equations has a unique solution. The 
dynamic programming algorithm works backwards from this point to ﬁnd the optimal 
decision rule at earlier analyses. 
If Zk = zk, the expected loss when stopping to make the Bayes optimal decision at 
stage k is 
γ(k)(zk) =  min{k3 π(k)(0|zk) +  k4 π(k)(δS |zk), k1 π(k)(−δN |zk) +  k4 π(k)(δS |zk), 
k1 π
(k)(−δN |zk) +  k2 π(k)(0|zk)}, 
the minimum of the expected costs of stopping for inferiority, non-inferiority or 
superiority. 
We denote by F k+1(zk+1|zk) the conditional cumulative distribution function of 
Zk+1 given Zk = zk. For  k = 1, . . . ,K − 2, the additional expected cost for proceeding 
from stage k to stage k + 1 and acting optimally thereafter is 
5 
β(k)(zk) = (nk+1 − nk) c(θi)π(k)(θi|zk)

i=1

+ min{β(k+1)(zk+1), γ(k+1)(zk+1)}dF (k+1)(zk+1|zk) (2.15) 
while at stage K − 1, we have 
5 
β(K−1)(zK−1) = (nK − nK−1) c(θi) π(K−1)(θi|zK−1) 
i=1 
+ γK (zK )dF (K)(zK |zK−1). (2.16) 
The functions β(k)(zk) can be calculated recursively, working backwards from analysis 
K − 1: using the stage k + 1 stopping boundary and values of β(k+1) and γ(k+1) 
previously calculated on a grid of zk+1 values, the integral in (2.15) can be found 
by numerical integration using, say, Simpson’s rule. At each analysis k, the  roots  of  
β(k)(zk) =  γ(k)(zk) are found by a numerical search and these roots deﬁne the stopping 
boundaries. 
The above method can be extended to ﬁnd optimal adaptive designs using the 
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approach followed by Jennison and Turnbull (2006a) for the two-decision problem. 
Consider the case K = 2,  with  n1 ﬁxed and n2 allowed to take values in the set 
{n2,1, . . . , n2,M }. We ﬁrst ﬁnd the M pairs of critical values b2,m and d2,m deﬁning 
the optimal decisions when the second analysis takes place at cumulative sample size 
n2,m, m = 1, . . . ,M . We then divide the range of values of Z1 into intervals over 
which each of the following actions is found to be optimal: stop and declare inferiority, 
stop and declare non-inferiority, stop and declare superiority, continue to analysis 2 
with cumulative group size n2,m, m = 1, . . . ,M . As before, a numerical search is 
performed to ﬁnd the set of costs k1, k2, k3, and  k4 for which the solution satisﬁes the 
error probability constraints (2.1) to (2.4) and this gives the solution to the original 
constrained problem. This process is then nested within a search over n1 to optimise 
both group sizes. 
2.6.3 Calculation of critical values for error spending designs 
Consider an analysis k with γ Imax,S ≤ Ik ≤ Imax,S , the case where all four critical 
values, ak, bk, ck and dk, are required. We assume boundary values for analyses 1 to 
k − 1 have already been calculated. Deﬁne the increments in error probabilities under 
θ = 0  for  analysis  k 
kΔfS
k = fS(Ik) − fS(Ik−1) and  ΔgN = gN (Ik) − gN (Ik−1). 
For the other two error probabilities, under θ = −δN and δS , we set increments 
ΔfN
k = fN (Ik) − fN (Ik−1) and  ΔgSk = gS (Ik) − gS (Ik−1) 
unless this is the ﬁrst analysis with Ik ≥ γ Imax,S , in  which  case  we  take  
ΔfN
k = fN (Ik) − Pθ=−δN (Stop to declare superiority by analysis k − 1) 
and 
ΔgS
k = gS (Ik) − Pθ=δS (Stop to declare inferiority by analysis k − 1) 
to account for the error probability incurred at analyses where fN (I) and  gS (I) are  
zero. 
We denote the continuation region at analysis i by Ci = (ai, bi) ∪ (ci, di). Two 
one-dimensional searches can be used to ﬁnd ak and dk satisfying 
kPθ=0(Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ≤ ak) = ΔgN 
and 
Pθ=0(Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ≥ dk) = ΔfSk . 
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Let

Δfk1 = Pθ=−δN (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ≥ dk)N 
and 
ΔgS
k1 = Pθ=δS (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ≤ ak). 
We now want to ﬁnd bk and ck satisfying 
Pθ=−δN (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ∈ [bk, ck]) = ΔfNk −ΔfNk1 (2.17) 
and 
Pθ=δS (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ∈ [bk, ck]) = ΔgSk −ΔgSk1 . (2.18) 
uSince bk and ck must lie in the interval [ak, dk], an upper bound bk for bk is found by 
solving 
uPθ=−δN (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ∈ [bk , dk]) = ΔfNk −ΔfNk1 (2.19) 
and a lower bound ck
l for ck by solving 
Pθ=δS (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ∈ [ak, ckl ]) = ΔgSk −ΔgSk1 . (2.20) 
Using these values of bk
u and ck
l , we can now ﬁnd a lower bound blk for bk as the solution 
to 
Pθ=−δN (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ∈ [bkl , ckl ]) = ΔfNk −ΔfNk1 
uand an upper bound ck for ck as the solution to 
Pθ=δS (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ∈ [bku , cku]) = ΔgSk −ΔgSk1 . 
uWe have now reduced the original interval [ak, dk] to  [blk, ck ] and can repeat the same 
usteps with ck in place of dk in (2.19) and bk
l in place of ak in  (2.20).  We have found  
repeated iterations of these steps to give an eﬃcient method for ﬁnding bk and ck 
satisfying (2.17) and (2.18). 
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CHAPTER 3 
Control of type I error when applying the CRP principle in an 
error spending design 
3.1 Introduction 
3.1.1 The CRP principle for known future information sequences 
In the previous chapter we considered non-adaptive and adaptive group sequential 
methods for simultaneous testing of superiority and non-inferiority. We shall now 
consider another adaptive method that can be used within a group sequential 
framework. There has recently been an increased interest in adaptive methods that 
allow for changes to the design of an on-going clinical trial. While sample size 
modiﬁcation based on the observed treatment eﬀect has attracted a lot of attention, 
other types of design changes may also be of importance. It may for example be of 
interest to adapt the design to external information that was not available prior to 
the start of the trial. Withdrawal of a competing drug from the market may result in 
interest in detecting a smaller eﬀect size than when the original design was planned. 
Since both classical group sequential designs and adaptive designs have many useful 
properties, it would be very appealing to be able to combine the advantages of these 
approaches. In particular, an approach that enjoys all the beneﬁts of error spending 
designs and in addition has the ﬂexibility of adaptive methods would be of great value. 
One interesting proposal is due to the conditional rejection probability (CRP) principle 
proposed by Mu¨ller and Scha¨fer (2001) and later generalised by Mu¨ller and Scha¨fer 
(2004). In the CRP principle it is possible to re-design the remainder of the trial by 
calculating the conditional rejection probability under H0, that is, the probability under 
H0 of rejecting the null hypothesis given the data observed so far. This conditional 
rejection probability can then be used to design a new trial, with type I error equal to 
the conditional rejection probability. We shall now introduce how the method can be 
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applied through an example. 
Suppose that the observations in treatment groups A and B are independent and 
normally distributed with XAj ∼ N(μA, σ2) and  XBj ∼ N(μB , σ2) j = 1, 2, . . . , 
where the common variance σ2 is known. The two treatment groups are compared 
in a clinical trial that is monitored through the error spending method, following the 
general framework described in Section 1.2.5. The objective of the trial is to make 
inference about the parameter θ=μB − μA. A one-sided group sequential design, of 
the type without futility boundary described in Section 1.2.4, is used to test the null 
hypothesis H0 : θ ≤ 0 against the alternative hypothesis H1 : θ >  0, with type I error 
probability α = 0.025 and power 1 − β at θ = δ. Interim analyses are performed at 
ﬁxed information levels I1, . . . ,Imax, and the trial is stopped to reject H0 if 
Zk = θˆk Ik ≥ bk k = 1, . . . ,K.  
Once the trial has started, the probability of falsely rejecting the null hypothesis 
H0 : θ ≤ 0 can at any point be calculated, conditional on the data that has been 
observed so far. It is clear that for θ ≤ 0, this probability is maximised for θ = 0.  
This conditional type I error probability will be referred to as CRPθ=0 and plays a 
fundamental role for the CRP principle. Suppose that Z1 = z1 is observed at the ﬁrst 
interim analysis. The conditional type I error can then be deﬁned as 
⎧ ⋃K ⋂k−1 ⎪ ⎪⎪ Pθ=0 j=2 Zj < bj and Zk ≥ bk |Z1 = z1 if Z1 < b1k=2 ⎨ 
CRPθ=0 = (3.1) ⎪ ⎪ ⎪ ⎩ 1 if  Z1 ≥ b1. 
The probability in (3.1) can now be calculated through a repeated evaluation of 
univariate integrals. Suitable methods for numerical integration are described in 
Jennison and Turnbull (2000, Chapter 19). The methods for numerical integration are 
based on the distribution theory for a sequence of estimates in a group sequential design, 
deﬁned in equation (1.1) in Section 1.2.3. We also note that the calculation of (3.1) 
relies on the assumption that there is no uncertainty about which future information 
sequence will be observed. 
The investigator is free to choose whether to continue with the original design, or re­
design the remainder of the study as if it were a new trial with type I error probability 
equal to CRPθ=0. We shall denote by α˜ this type I error probability available for 
the re-design. Since the conditional type I error rate will be the same regardless of the 
investigator’s choice, the overall type I error rate is also protected. This is in agreement 
with Jennison and Turnbull (2003), who show that any design which controls the overall 
type I probability and gives ﬂexibility to choose whether to adapt or not, must also 
preserve the conditional type I error. A key feature of the CRP principle is that there 
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is almost complete ﬂexibility for how to re-design the remainder of the trial. The only 
requirement is that the observations in the remainder of the trial must be independent 
from the observations that were used to calculate (3.1) and that the type I error of the 
new trial is at most α˜. Denne (2001) also uses a conditional error function approach 
but requires that the adaptation takes place at the ﬁnal interim analysis. The CRP 
principle is however more general. Although it was assumed in (3.1) that the re-design 
took place at one of the pre-planned interim analysis, Scha¨fer and Mu¨ller (2001) have 
shown that the re-design may occur at any point during a clinical trial. As described in 
Mu¨ller and Scha¨fer (2001), the principle can also be applied for two-sided tests. In this 
case, CRPθ=0 is calculated separately for the upper and lower boundaries, giving one 
value α˜u for the upper boundary and another value α˜l for the lower. Unless α˜l = α˜u, 
the two-sided test of the re-designed trial will thus be asymmetric, in the sense that a 
higher type I error can be spent for one of the boundaries than the other. 
The CRP principle has gained popularity. It is implemented in the software 
package East-5 (2007) and has been applied in diﬀerent areas. The method is used 
in the protocol of Martinez-Torres et al. (2008), while Scherag et al. (2009) report an 
application in genome-wide association studies. Rinke et al. (2009) provide results from 
a clinical trial in oncology, where re-design using the CRP principle was possible but 
not applied. 
3.1.2 The CRP principle for unknown future information sequences 
The CRP principle ﬁts very naturally in a group sequential framework with ﬁxed group 
sizes, but it would be very beneﬁcial to be able to apply the method also when group 
sizes are unpredictable. Mu¨ller and Scha¨fer (2001) did not discuss how to calculate 
CRPθ=0 for unpredictable information sequences. Mu¨ller and Scha¨fer (2004) use an 
alpha spending function to derive the critical values for the original design, where it is 
planned that the interim analyses will be carried at certain information levels. When 
applying the CRP principle, the future group sizes are assumed to follow this original 
plan, but Mu¨ller and Scha¨fer (2004) do not discuss how to proceed if the observed group 
sizes would turn out to diﬀer from this plan. In the user manual of the software package 
(East-5, 2007, p. 960), it is pointed out that the future course of the trial must be fully 
speciﬁed. No suggestions for how to handle deviations from this pre-speciﬁcation are 
however given. Scha¨fer et al. (2006) point out that for a safe use of the CRP principle, 
the protocol must specify how to calculate CRPθ=0 at any time during the trial. As 
will be shown in this chapter, it may be challenging to construct such a rule in practice. 
Several authors have discussed how to apply the CRP principle in situations where 
there is uncertainty about how to calculate CRPθ=0. In the context of a survival trial 
with uncertainty about the number of events at future interim analyses, Scha¨fer and 
Mu¨ller (2001) suggest specifying a rule for how to calculate CRPθ=0 in the protocol. 
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Posch et al. (2004) describe some issues when conditional rejection probabilities depend 
on nuisance parameters such as the unknown variance in a t-test, while Timmesfeld 
et al. (2006) give a very detailed account of the t-test situation. We consider the simple 
case of an error spending design with normally distributed data and known variance, as 
we are not aware of any publication that fully addresses how to calculate the conditional 
type I error probability in this situation. 
Consider an error spending design with type I error spent in the usual way described 
in Section 1.2.5. Suppose that that at the ﬁrst interim analysis, Z1 < b1, where  b1 is 
given by the error spending rule. To be able to apply the CRP principle, we need 
to calculate the conditional type I error. It is clear from (3.1) that to calculate the 
conditional type I error in a group sequential design, we need to know the information 
sequence that will actually be observed at future interim analyses. This sequence will in 
general not be known and may diﬀer from the information sequence that was assumed 
when setting power, prior to the start of the trial. This does not cause problems in an 
error spending design without re-design, where Ik can be observed before deriving the 
critical value bk for rejecting H0. 
In Section 3.2.2 we give an example of how substantially CRPθ=0 can depend on 
which future information sequence is used in the calculation. Thereafter, the impact 
on the overall type I error probability, when there is no pre-speciﬁcation of how to 
calculate CRPθ=0, is assessed In Section 3.2.3. In Section 3.2.4, we investigate if the 
type I error can be controlled by using a pre-speciﬁed rule for calculation of CRPθ=0. 
In Section 3.3, adaptive designs with a pre-speciﬁed combination rule that controls the 
type I error are considered. We present eﬃciency comparisons between these adaptive 
designs and error spending designs, for the case when the future information sequence 
is unpredictable. Finally, conclusions about the possibilities for eﬃcient and ﬂexible 
designs with type I error control are presented in Section 3.4. 
3.2 A numerical example 
3.2.1 Framework 
We consider the framework described in Section 3.1, where two treatments with 
normally distributed response and known variance are being compared in a clinical trial. 
Assume that the trial is monitored through the error spending method as described in 
Section 1.2.5, with interim analyses scheduled every six months until Imax has been 
reached. The type I error probability is spent according to 
⎧ ⎨0.0001 for k = 1  
f(Ik) =  (3.2) ⎩α min ((Ik/Imax)ρ , 1) for k = 2, . . . ,K.  
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The wide boundary at the ﬁrst interim analysis is plausible if results based on only a 
small amount of data may be unconvincing, unless they are overwhelmingly in favour 
of the alternative. On the other hand, a more reasonable chance of stopping for beneﬁt 
at subsequent analyses, when more information has been accrued, can be achieved by 
setting ρ = 1.  
Suppose that α = 0.025 and that 90% power is required at θ = δ = 0.1. Based on 
these assumptions, we can calculate the information needed in a ﬁxed sample trial as 
{Φ−1(1 − α) + Φ−1(1 − β)}2 Iﬁx = δ2 = 1051. 
For an error spending design with three equally spaced analyses and type I error spent 
according to (3.2) with ρ = 1, an inﬂation factor of R = 1.08 is required. For normally 
distributed data and two treatment groups of equal size with common known variance 
σ2, the maximum information is converted to maximum sample size per treatment 
group according to 
nmax = 2σ2Imax. 
We thus obtain that the maximum information Imax = 1135 and that for σ2 = 1,  
nmax = 2270 patients per treatment group are required. 
3.2.2 Conditional type I error for the re-designed trial 
Suppose that it turns out that at the time of the ﬁrst interim analysis, the investigators 
ﬁnd it desirable to perform a re-design, by applying the CRP principle. To calculate 
α˜ = CRPθ=0, assumptions about the future information sequence are however needed. 
Suppose that recruitment has been slower than expected and that the information 
observed is I1 = Imax/5, rather than the planned Imax/3. With equally spaced 
analyses in time, it seems very natural to assume that the observed accrual rate will 
continue until Imax has been reached and use 
Ip1 = Imax × (0.4, 0.6, 0.8, 1.0). 
Another reasonable choice would be to suppose that future information sequences will 
follow the plan speciﬁed prior to the start of the trial, i.e. to use 
Ip2 = Imax × (0.67, 1.0). 
Using Ip2 bears similarities with the rule used by Scha¨fer and Mu¨ller (2001), who 
stipulate that CRPθ=0 in a survival trial will be calculated according to the planned 
number of events at future interim analyses. As a third possibility, we consider 
Ip3 = Imax × (1.0), 
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Information sequence α˜ = CRPθ=0 
Ip1 = Imax × (0.40, 0.60, 0.80, 1.0) 0.64 
Ip2 = Imax × (0.67, 1.0) 0.43 
Ip3 = Imax × (1.0) 0.32 
Table 3.1: Conditional type I error for diﬀerent future information sequences, when 
I1 = 0.2Imax and Z1 = 3.47. 
as it has been used by other authors like Cui et al. (1999) as a simple default rule for 
calculating conditional power. 
There could be diﬀerent reasons for wishing to apply the CRP principle in this 
situation. Suppose that the treatment eﬀect is estimated to be θˆ = 0.23, i.e. more than 
double what was assumed in setting power at the design stage. As 
Z1 = θˆ (n1/2σ2) = 3.47, 
the boundary of b1 = 3.719 is almost crossed. The investigators may wish to design 
a new trial with more frequent interim analyses. Indeed, Mu¨ller and Scha¨fer (2001) 
point to the possibility of changing the number and timing of interim analyses as one 
of the major beneﬁts of their method. Another reason for re-design could be the wish 
to rescue an under-powered study, if the treatment eﬀect turns out to be worse than 
expected. External information that has emerged about a competitor drug could be 
yet another reason to re-design, even though the treatment eﬀect is largely as expected. 
Table 3.1 lists CRPθ=0, calculated for Ip1 , Ip2 and Ip3 , when  I1 = 0.2Imax and 
Z1 = 3.47. The results in Table 3.1 vary substantially depending on which future 
information sequence is used. The conditional type I error for information sequence 
Ip1 is, for example, about two times that calculated for Ip3 . Investigators have to 
make a choice about which future information sequence to use. Choosing an option 
which gives higher power is attractive, so one possibility is to choose the information 
sequence that gives the highest CRPθ=0, i.e. Ip1 in this case. Hence, there seems to be 
scope for increasing power by choosing a “suitable” future information sequence when 
calculating CRPθ=0. This possibility of increasing power also raises the question of 
whether the overall type I error probability can be inﬂated. 
3.2.3 Impact on overall type I error 
Suppose it is decided to re-design a trial at the ﬁrst interim analysis by applying the 
CRP principle, but there is uncertainty about which future information sequence will 
be observed if the study continues as originally planned. Consider future information 
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sequences Ip1 , . . . ,IpN that seem plausible; here each Ipj is a sequence of values for 
I2 to IK˜, where  K˜ is the number of analysis needed to reach Imax. It  may  well  be  
tempting to increase the probability of a positive study, by choosing the information 
sequence, referred to as Ipmax (z1), that among diﬀerent future information sequences 
Ipj maximises 
CRPθ=0 (Ipj , Z1 = z1) , (3.3) 
the conditional type I error calculated for Z1 = z1. If  φ(z) is the standard normal 
probability density function, the overall type I error for the procedure is given by 
∫ ∞ 
αi (Ipmax (z1)) = dz1φ(z1)CRPθ=0 (Ipmax (z1), z1) . (3.4) 
−∞ 
The integral in (3.4), as well as the other integrals below, can be calculated through 
numeric integration using the methodology described by Jennison and Turnbull 
(2000, Chapter 19). We note that 
∫ ∞ 
dz1φ(z1)CRPθ=0 (Ipj , z1) =  α, (3.5) 
−∞ 
for j = 1, . . . , N , while 
∫ ∞ 
αi (Ipmax (z1)) = dz1φ(z1) max CRPθ=0 (Ipj , z1) ≥ α. (3.6) 
−∞ j=1,...,N 
Since the integrand in (3.6) is continuous, the integral will equal α only if 
CRPθ=0(Ipmax (z1), z1) =  CRPθ=0(Ipj , z1) j = 1, . . . , N  (3.7) 
for all z1. The condition requires that CRPθ=0(Ipj , z1) are equal for all j at every z1. 
If Ipmax (z1) is consistently used to calculate the type I error probability α˜, to be  used  
for the re-design of the remainder of the trial according to the CRP principle, then 
clearly the overall type I error will no longer be protected. 
The conditional type I error probabilities for our three future information sequences 
Ip1 , Ip2 and Ip3 , calculated after having observed Z1 = z1 and I1 = 0.2Imax, are  
displayed in Figure 3-1. Figure 3-1 illustrates that the maximum of the three curves 
is noticeably higher than each individual curve, by a small amount over a region with 
high φ(z1) or a large amount over a region with low φ(z1). If the results at the ﬁrst 
interim analysis are positive, like in Table 3.1, a higher conditional type I error is 
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Figure 3-1: Conditional type I error for diﬀerent future information sequences, after having 
observed Z1 = z1 at I1 = 0.2Imax. 
achieved for Ip1 than for Ip2 and Ip3 . If results go in the other direction, it is Ip3 that 
gives the highest conditional type I error probability. 
By considering the information sequences Ip1 , Ip2 , and Ip3 , we can now calculate 
the overall type I error according to (3.6), where CRPθ=0 is always calculated using 
the information sequence that maximises the conditional type I error. The calculation 
can be performed for diﬀerent α spending functions and for maximisation over diﬀerent 
sets of information sequences. If for example Ip2 is thought to be hard to justify, the 
type I error can still be inﬂated by considering Ip1 and Ip3 . As we would expect, the 
type I error turns out to be smaller if only two of the three information sequences 
are considered. The type I error is however larger than 0.025 provided that the 
maximisation is carried out over more than one information sequence. These results 
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Information sequences f(I1) = 0.0001 f(I1) =  α min((I1/Imax)ρ , 1) 
maximised over ρ = 1  ρ = 2  ρ = 3  ρ = 1  ρ = 2  ρ = 3  
Ip1 , Ip2 , Ip3 0.0289 0.0270 0.0261 0.0273 0.0267 0.0261 
Ip1 , Ip2 0.0271 0.0259 0.0254 0.0261 0.0257 0.0254 
Ip1 , Ip3 0.0288 0.0269 0.0261 0.0273 0.0267 0.0261 
Ip2 , Ip3 0.0268 0.0261 0.0257 0.0262 0.0260 0.0256 
Ip1 0.0250 0.0250 0.0250 0.0250 0.0250 0.0250 
Ip2 0.0250 0.0250 0.0250 0.0250 0.0250 0.0250 
Ip3 0.0250 0.0250 0.0250 0.0250 0.0250 0.0250 
Table 3.2: Type I error depending on ρ family alpha spending function, type I error spent at 
ﬁrst interim analysis and the information sequences considered to calculate CRPθ=0. 
are summarised in Table 3.2, for ρ family error spending functions with ρ = 1,  2  and  3.  
Table 3.2 shows that when the type I error is spent according to (3.2) with ρ = 1,  
the type I error is in the range of 0.027 − 0.029, depending on the future information 
sequences that are considered. We also present results for a slightly modiﬁed spending 
function, when type I error spent at the ﬁrst interim analysis is α min((I1/Imax)ρ , 1), 
rather than 0.0001. The columns to the right in Table 3.2 show results for this case. 
Further results are displayed in Figures 3-2 and 3-3. In Figure 3-2, we see that the 
type I error inﬂation is monotonically decreasing in ρ. This can be understood by noting 
that if ρ is high, a large proportion of the type I error is spent at the ﬁnal analysis. 
The information sequences that we have considered all assume that the planned Imax 
is reached at the ﬁnal analysis, so for high ρ most of the type I error is spent there. 
Hence, the conditional type I error for the diﬀerent information sequences will be more 
similar, than if ρ is low and a larger proportion of the type I error is spent before the 
ﬁnal analysis. This in turn limits the potential impact on the overall type I error that 
can be achieved by calculating CRPθ=0 for Ipmax (z1), the information sequence that 
maximises the conditional type I error. 
The situation is diﬀerent in Figure 3-3, where the type I error spent at the ﬁrst 
interim analysis depends on ρ, and increases with decreasing ρ. The type I error 
spent at the ﬁrst interim analysis cannot contribute to diﬀerences in CRPθ=0, which  
makes the potential impact on the type I error by using Ipmax (z1) to calculate  CRPθ=0 
smaller. So when α min((I1/Imax)ρ , 1) is spent at the ﬁrst interim analysis, low values 
of ρ contribute to decreasing the overall type I error a little compared to the results in 
Figure 3-2, where the type I error spent at the ﬁrst interim analysis equals 0.0001. 
As would be expected from (3.5), the type I error is controlled at α = 0.025 in both 
Figure 3-2 and Figure 3-3, provided that CRPθ=0 is always calculated for the same 
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Figure 3-2: Overall type I error depending on ρ family alpha spending function and the 
information sequences considered to calculate CRPθ=0. The type I error spent at the ﬁrst 
interim analysis equals 0.0001. 
future information sequence. This suggests that always using the same sequence for 
the calculation might be a way of avoiding type I error inﬂation. We shall investigate 
this approach in the next section. 
3.2.4	 Calculating the conditional type I error according to a pre-
speciﬁed rule 
Suppose that it is pre-speciﬁed that the conditional type I error will always be calculated 
according to the plan in the protocol. Such an approach could be applied for our 
example with three equally spaced analyses. For a re-design at analysis 1 it may for 
example be speciﬁed that CRPθ=0 will be calculated assuming that the second interim 
analysis will occur at 2Imax/3, with a ﬁnal analysis at Imax. A similar approach is 
suggested by Scha¨fer and Mu¨ller (2001). Consider the possibility that more information 
than expected, Imax/2 instead of Imax/3, is observed at the ﬁrst interim analysis. As 
before, the investigator needs to decide whether to use the CRP principle and re-design 
the remainder of the trial with type I error α˜. The possible decisions are 
D1 : Continue without re-design, or 
D2 : Re-design. 
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interim analysis equals α min((I1/Imax)ρ , 1). 
If the study continues without re-design, a very reasonable assumption is that Imax 
will be reached after another six months, i.e. at the next interim analysis. It is clear 
that choosing D1 will give a diﬀerent CRPθ=0 than D2. Suppose that it is decided to 
make the decision that gives the highest conditional type I error probability. Basing 
the decision D on the conditional type I error probabilities for D1 and D2 leads to the 
decision rule 
⎧ ⎨D1 if CRPθ=0(D1) ≥ CRPθ=0(D2)
D = (3.8) ⎩D2 if CRPθ=0(D2) > CRPθ=0(D1). 
We ﬁnd that if the decision rule in (3.8) is used to decide whether to re-design, the 
type I error can be inﬂated from 0.025 to 0.0288, i.e. an inﬂation of similar size as 
the results in Table 3.2.3. An even more extreme situation occurs if I1 = 0.6Imax, 
in which case application of (3.8) can inﬂate the type I error from 0.025 to 0.0302. It 
may be argued that it is impossible for the investigator to know exactly which future 
information sequence will be observed if D1 is chosen. In many situations, including 
the present example, it should however be fairly obvious that the future information 
sequence, in the case of no re-design, will diﬀer substantially from what was speciﬁed 
in the protocol. Furthermore, the CRP principle may be applied repeatedly, at any 
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time during the trial. Moreover, we have seen cases with even higher inﬂation, if we 
do not require that Imax is reached exactly at the ﬁnal analysis for all the information 
sequences that are considered. Hence, type I error inﬂation is possible even when a 
rule in the protocol stipulates how to calculate CRPθ=0. The increase in type I error is 
obtained by choosing between the decisions D1 and D2, using the decision rule deﬁned 
in (3.8). In summary, we would envisage that most of the inﬂation in type I error 
probability seen in this example could be obtained in practice. 
3.3 A method that controls type I error exactly 
3.3.1 Weighted inverse normal method 
It is clear that type I error control is an issue whenever there is a possibility to apply 
the CRP principle, and CRPθ=0 is not uniquely deﬁned. One solution is to use a pre-
speciﬁed combination rule of the type proposed by Bauer and Ko¨hne (1994), which 
is described in Section 1.3.2. We shall illustrate how to apply the CRP principle 
with another pre-speciﬁed combination rule, the weighted inverse normal method of 
Lehmacher and Wassmer (1999), which was brieﬂy introduced in Section 1.3.3. 
The method of Lehmacher and Wassmer (1999) can be illustrated by considering a 
group sequential trial with K groups of observations. Suppose that data are normally 
distributed and let Z˜k denote the standardised statistic based on data from stage k of 
the trial. The sequence of test statistics 
∑M 
k=1 wkZ˜kZM = , M  = 1, . . . ,K,  (3.9)∑M 2( k=1 wk)1/2 
can then be deﬁned. The decision whether to stop or continue is based on these 
test statistics, and Lehmacher and Wassmer (1999) show that data-dependent sample 
size modiﬁcation is possible without inﬂating the type I error rate. The weights wk 
in (3.9) may be chosen to reﬂect the pre-planned groups and need not be equal, but 
Lehmacher and Wassmer (1999) require ﬁxing the weights prior to the start of the trial. 
Equally informative observations may thus be given diﬀerent weights, if the observed 
group sizes diﬀer from what was planned at the outset. Marginally, each Z˜k follows 
a N(θ Ik − Ik−1, 1) distribution, where Ik is Fisher’s information for θ at analysis k 
and I0 = 0. The sequence of test statistics Z1, . . . , ZK in (3.9) then has the following 
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properites: 
(Z1, . . . , ZK ) is multivariate normal, 
M ∑ Ik − Ik−1wk
E(ZM ) =  θ ∑M , k = 1, . . . ,K,  and (3.10) 
k=1 
( k=1 wk
2)1/2 
√∑M1 2 
Cov(ZM1 , ZM2 ) =  √ k=1 wk , 1 ≤M1 ≤M2 ≤ K.∑M2 2 
k=1 wk 
There are similarities with the standard joint canonical distribution in (1.1), but the 
correlation structure is now decided by the pre-speciﬁed weights in (3.9) rather than by 
the observed group sizes. In order to preserve the type I error rate, critical values for 
rejecting the null hypothesis can be derived in the same way as for non-adaptive group 
sequential designs with ﬁxed information sequences, using the fact that the correlation 
structure is known from (3.10) and the pre-speciﬁed weights. This correlation structure 
can also be used to calculate the conditional type I error probability. In addition, the 
critical values do not change because of the observed group sizes. Hence, the conditional 
type I error is well deﬁned and we can apply the CRP principle, without facing the 
problems with how to calculate CRPθ=0 encountered in the previous sections. 
Let us now return to the 3-group error spending design described in Section 3.2.2, 
where we test the null hypothesis θ ≤ 0, with type I error α = 0.025 and 90% power is 
required at θ = δ = 0.1. The type I error is spent according to (3.2) and three equally 
spaced analyses are planned, at 
k Ik = × Imax, k  = 1, . . . ,K  
K 
for Imax = 1135. Suppose that prior to the start of the trial, the weights in (3.9) 
have been speciﬁed as w1 = w2 = w3 = 13 , to reﬂect the pre-planned group sizes. The 
conditional type I error is then unambiguously deﬁned and equals 0.71, when calculated 
according to (3.1) for I1 = 0.2Imax and Z1 = 3.47. The higher conditional type I error 
compared to the numbers in Table 3.2.2 is to be expected, as more weight is given 
to the ﬁrst stage data than for an error spending design that adapts to the observed 
information of I1 = 0.2Imax. 
3.3.2 Eﬃciency comparison with error spending design 
Lehmacher and Wassmer (1999) present eﬃciency comparisons between their method, 
applied with 5 groups of observations, and 5-group Pocock (1977) tests. The 
comparisons focus on the situation when there is no design adaptation and the initially 
planned group sizes have been perturbed. In this situation Lehmacher and Wassmer 
(1999) ﬁnd that there is some eﬃciency loss associated with their method, compared 
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to the Pocock test. The critical values of the Pocock tests are in these comparisons 
derived assuming that the observed group sizes that will later be observed are known 
at the outset. This is necessary to obtain Pocock tests with exact control of the type I 
error rate, as the Pocock test cannot really deal with perturbations of the group sizes 
that are unknown when planning the design. The comparison may thus be regarded 
as unfair to the method of Lehmacher and Wassmer (1999), as in practice the group 
sizes that will later be observed would not be known when planning the Pocock test. 
We shall instead make a comparison with error spending designs, as these just 
like the method of Lehmacher and Wassmer (1999) control type I error exactly also 
for unpredictable information sequences. Unpredictable information sequences can 
however be an issue also for error spending designs, as perturbation of the initially 
planned group sizes does have a small impact on power and expected sample size. 
Hence, it is of interest to assess how the eﬃciencies of the method of Lehmacher and 
Wassmer (1999) and the error spending approach as described by Jennison and Turnbull 
(2000, Chapter 7) compare, when having to deal with unpredictable group sizes. 
Let us again consider the numerical example in Section 3.2, with Iﬁx = 1051. We 
now consider an error spending design from the ρ family, planned for K = 5 equally 
spaced analyses. For the method of Lehmacher and Wassmer (1999), the pre-speciﬁed 
weights are set to 1/5 for all ﬁve stages. This choice reﬂects the initial plan of ﬁve 
equally spaced analyses. For ρ = 1.5, we obtain R = 1.086 and Imax = R×Iﬁx = 1141. 
The boundary b1, . . . , b5 can be derived from the error spending function and the 
planned information sequence, and is the same for both the error spending design 
and the Lehmacher and Wassmer design. Our eﬃciency comparison will focus on 
the situation where no design changes take place, but there is some perturbation of the 
initially planned information sequence. The observed information sequences considered 
are of the form ( )
k s Ik = × Imax, k  = 1, . . . ,K,  
K 
where s >  0. We note that for s = 1, the observed group sizes coincide with the pre-
planned weights and the multivariate normal distribution of the sequence of statistics 
in (3.10) coincides with that in (1.1) obtained for classical group sequential tests. For 
s = 0.6, we obtain the information sequence 
Imax × (0.38, 0.58, 0.74, 0.87, 1.0), 
while for s = 1.6, we obtain 
Imax × (0.08, 0.23, 0.44, 0.70, 1.0). 
Whenever the parameter s = 1, the boundary of the error spending design will be
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adjusted, while the boundary of the Lehmacher and Wassmer design will remain the 
same. The statistics Z˜ in the Lehmacher and Wassmer design are weighted according to 
the pre-speciﬁed weights when calculating the pooled statistic ZM in (3.9), even though 
the group sizes are not the same for all k. The two methods will have changes in both 
expected sample size and power, so focusing on just one of these two properties will not 
give the complete picture. To enable a fair assessment of the methods, the eﬃciency 
index proposed by Jennison and Turnbull (2006a) is used. Suppose that at treatment 
eﬀect θ, an error spending design with type I error rate α has power 1 − bES (θ) and  
expected information EES,θ(I). In a similar way, a Lehmacher and Wassmer design is 
assumed to have power 1 − bLW (θ) and expected information ELW,θ(I) at  θ. We  can  
then deﬁne eﬃciency indexes EIES (θ) and  EILW (θ) according to 
(z1−α + zbES (θ) )
2 1
EIES (θ) =  (3.11)
θ2 EES,θ(I) 
(z1−α + zbLW (θ) )
2 1
EILW (θ) =  (3.12)
θ2 ELW,θ(I) 
and an eﬃciency ratio according to 
EILW (θ) (z1−α + zbLW (θ) )
2 EES,θ(I)ERLW/ES (θ) = 100 × = 100 × . (3.13)EIES (θ) (z1−α + zbES (θ) )2 ELW,θ(I)
Figure 3-4 shows the power and expected sample size at θ = δ, as well as the eﬃciency 
ratio, deﬁned in (3.13) and also calculated at θ = δ. As a benchmark, we also include 
horizontal lines for the power, expected sample size and eﬃciency ratio, for the case 
when there is no perturbation to the initially planned information sequence. The 
power of the error spending design is close to the target of 0.9, which is in agreement 
with the ﬁndings of Jennison and Turnbull (2000, Chapter 7). For 0.3 ≤ s ≤ 1.3, 
the power of the method of Lehmacher and Wassmer (1999) is also close to its target 
value, while the power loss is more pronounced for extreme values of s. The expected 
sample size is lower for the error spending design for some values of s and for the 
method of Lehmacher and Wassmer (1999) for others. Hence, considering the eﬃciency 
ratio should provide a better assessment of the relative eﬃciency of the methods than 
considering power or expected sample size in isolation. The right panel of Figure 3-4 
shows that 95 ≤ ERLW/ES (θ = δ) ≤ 100, for 0.6 ≤ s ≤ 1.6. If the eﬃciency of the 
designs is judged by ERLW/ES (θ = δ), there is thus some eﬃciency loss associated with 
the method of Lehmacher and Wassmer. On the other hand, if re-design is desired, 
the pre-speciﬁed combination rule gives the increased ﬂexibility of being able to apply 
the CRP principle, with a well-deﬁned rule for how to calculate CRPθ=0 . The  size  
of the eﬃciency loss depends on to what degree the parameter s diﬀers from one. In 
practice, the observed group sizes will not necessarily follow a neat pattern like the 
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Figure 3-4: Power, 100E(N)/nfix  and eﬃciency ratio at θ = δ, for a 5-group, Lehmacher and 
Wassmer (dashed line) design and a 5-group, ρ = 1.5 error spending design (solid line). Also 
shown are horizontal dot-dashed lines with eﬃciency ratio, expected sample size and power at 
θ = δ, for the case of no perturbations (i.e. s=1). 
ones considered here. If the perturbations are of roughly the same size as for s = 0.9 
or s = 1.1, the eﬃciency loss of the method of the method of Lehmacher and Wassmer 
(1999) compared to the error spending design is quite small. When choosing between 
using an error spending design and the method of Lehmacher and Wassmer (1999), 
there appears to be a trade-oﬀ between eﬃciency and ﬂexibility. For values of s close 
to one, it may well be that the higher ﬂexibility of the method of Lehmacher and 
Wassmer (1999) compensates for the small eﬃciency loss that is incurred. 
3.4 Discussion 
In many situations it can be diﬃcult to predict the amount of information that will 
be available at future interim analyses. Maximum information error spending designs 
provide a very ﬂexible method for coping with unpredictable information sequences 
without inﬂation of the overall type I error probability. Furthermore, error spending 
designs have been shown to provide eﬃcient designs in many situations, see for example 
65

Chapter 3. Control of type I error when applying the CRP principle in an error spending design 
Barber and Jennison (2002) for comparisons against optimal non-adaptive group-
sequential designs and Jennison and Turnbull (2006b) for comparisons against optimal 
adaptive group sequential designs. 
According to Mu¨ller and Scha¨fer (2001, p. 890), “any group sequential design can 
be given the full ﬂexibility of an adaptive design”. We have however shown that 
error spending designs cannot be given the full ﬂexibility of adaptive designs, without 
losing some of their most important properties. This is a concern, as error spending 
designs are widely used, and it would be very appealing to be able to combine the 
two approaches. The numerical examples in Section 3.2 clearly show that the overall 
type I error probability is not protected, unless the conditional type I error probability 
is uniquely deﬁned in all situations when a re-design can occur. In particular, the 
example in Section 3.2.4 shows that there are even situations where the approach of 
pre-specifying how to calculate CRPθ=0 does not guarantee type I error control. 
In the numerical examples, it was shown that the type I error can be inﬂated from 
0.025 to about 0.029, while an admittedly rather extreme example produced an inﬂation 
from 0.025 to just over 0.03. It should also be mentioned that while only one re-design 
point has been considered in our examples, recursive use of the CRP principle may lead 
to additional inﬂation. It is well known that error spending tests protect the type I 
error rate exactly, provided that the future information sequence is independent of the 
observed treatment eﬀect. This important property is however lost if the CRP principle 
is applied in situations when CRPθ=0 is ambiguously deﬁned. 
In Section 3.3 it is shown that the type I error is controlled when a pre-speciﬁed 
combination rule for multi-stage deﬁnes how to calculate CRPθ=0. In contrast to the 
methods that require pre-speciﬁed weights, the error spending tests adjusts to the 
observed group sizes and all observations are weighted equally, which in Figure 3-4 is 
shown to be more eﬃcient. Applying the CRP principle in a design with a pre-speciﬁed 
combination rule, like the weighted inverse normal method of Lehmacher and Wassmer 
(1999), must be seen as an alternative to error spending tests, rather than as a method 
that enjoys all the beneﬁts of error spending tests plus additional advantages. 
As discussed in Section 3.2.4, inﬂation of the type I error rate is possible if the 
investigators may choose between two conditional type I error probabilities that are 
not equal at all times during the trial. Suppose that an independent body, with full 
access to all trial data but without access to individuals involved in running the trial, 
is given the task of estimating the future information sequence that is most likely to 
occur. This independent body could for example be a regulatory authority. If the 
investigator were interested in designing a new trial according to the CRP principle, 
CRPθ=0 would simply be calculated by the independent body. Such an approach would 
limit the possibility of inﬂating the overall type I error probability by using the decision 
rule deﬁned in (3.8). A more conservative procedure would be to consider a class of 
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future information sequences that are plausible and use the information sequence that 
gives the lowest CRPθ=0. A drawback with such an approach is that some conservatism 
in type I error probability would be inevitable as a result. 
If a decision is made to use the CRP principle in a clinical trial, a simple approach 
that protects the type I error rate is given by pre-speciﬁed combination rules like that 
of Lehmacher and Wassmer (1999). Such an approach can lead to some eﬃciency loss 
for unpredictable information sequences, while the type I control is controlled exactly. 
When information sequences are unpredictable, the type I error inﬂation that can 
occur when there is no pre-speciﬁed combination rule that uniquely deﬁnes CRPθ=0, is  
potentially more serious than the eﬃciency loss of the weighted inverse normal method. 
The recursive combination tests of Brannath et al. (2002) provide another alternative 
that ensures control of the type I error, even though repeated use of the method may 
be logistically challenging. The possibility of giving an independent body the task 
of estimating future information sequences also deserves further consideration. Most 
importantly, the pros and cons should be compared to standard error spending designs 
before a decision is made to use the CRP principle in a clinical trial. 
In summary, the CRP principle provides a very interesting and ﬂexible tool for 
clinical trial design. It is however crucial that the potential issues highlighted in this 
chapter are taken into account at the design stage and dealt with in the study protocol. 
The increased ﬂexibility that the method provides comes at a price. This price is paid 
either in terms of credibility of results when there may have been inﬂation of the type I 
error rate, or in terms of some eﬃciency loss. 
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CHAPTER 4

Group sequential designs with non-binding futility boundaries 
4.1 Introduction 
In the previous chapter we saw that type I error control can be a concern when applying 
novel adaptive methods. We will now consider a situation where type I error control 
can be an issue also for classical group sequential designs. The problem that we will 
consider arises for one-sided group sequential tests with futility stopping, so it is not 
applicable for the group sequential designs without futility boundary in Chapter 3. 
We will start by giving a brief introduction to one-sided group sequential designs with 
futility boundaries, and then move on to discuss issues about type I error control if there 
is a concern that the futility boundary will not always be applied. As a solution, we 
will consider making the futility boundaries non-binding. With a non-binding futility 
boundary, the upper boundary is set to protect the type I error rate, even if the 
study continues after the futility boundary has been crossed and the null hypothesis is 
subsequently rejected. Later in the chapter we will present a new method for deriving 
optimal group sequential designs with non-binding futility boundaries, and compare 
these optimal designs to other designs in the same class. 
Consider a clinical trial, comparing an experimental drug to placebo or an active 
control, that is monitored using group sequential methodology. It is then typically 
possible to stop early for beneﬁt, when at an interim stage the estimated treatment 
diﬀerence is over-whelmingly in favour of the experimental drug. It may however also 
be preferable to stop early if, based on interim data, the trial is unlikely to deliver the 
beneﬁts hoped for at the outset. Early stopping in the latter situation is often referred 
to as stopping for futility and it is clear that many beneﬁts can be achieved by such a 
decision. As discussed in Chapter 1, there are both ethical and economical reasons to 
stop. Patients do not have to be exposed to a drug that is unlikely to be eﬀective, and 
may have unexpected side eﬀects. Moreover, the trial sponsor can usually save some 
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of the resources that would have been needed to complete the trial. Focus can instead 
be shifted to study another promising treatment that in light of the interim trial data 
is more likely to bring beneﬁt to patients. 
When the primary outcome of a clinical trial is monitored within a group sequential 
framework, it is generally accepted that certain adjustments have to be made to 
account for the multiple tests that are performed. In particular, trials that form the 
basis for a new drug application for regulatory approval must meet a certain overall 
type I error probability, typically α = 0.025 for a one-sided test. While it is generally 
straightforward to use numerical integration techniques to calculate the probability of 
falsely rejecting the null hypothesis given a certain stopping rule, the actual conduct 
of clinical trials makes things more complicated. We shall ﬁrst describe the general 
framework of a one-sided group sequential test in the clinical trial setting, and thereafter 
point to some issues regarding how to calculate the overall type I error probability of 
such trials. 
Suppose that in a clinical trial comparing two treatments, the observations XAj 
and XBj , j = 1, 2, . . . , on  treatments  A and B respectively, are independent and 
normally distributed with XAj ∼ N(μA, σ2) and  XBj ∼ N(μB , σ2), where the 
common variance σ2 is known. We wish to make inference about the diﬀerence in 
means θ = μB − μA, by performing a one-sided K - group sequential test of H0 : θ ≤ 0 
versus H1 : θ >  0. Denote by nk the cumulative per-group sample size at interim 
analysis k, for  k = 1, . . . ,K.  Given information levels I1, . . . ,IK , where  Ik = nk/(2σ2), 
we can ﬁnd a stopping boundary so that the test has type I error probability α and 
power 1 − β at θ = δ. 
Let θˆk be the maximum likelihood estimate of θ at analysis k. At  each  interim  
analysis, we calculate the usual standardised statistic 
Zk = θˆk Ik 
and stop early to reject H0 if Zk ≥ bk and to accept H0 if Zk ≤ ak. Termination  is  
ensured by setting aK = bK at analysis K. The type I error and the power at θ = δ, 
respectively, are deﬁned according to 
Pθ=0(Reject H0) =  Pθ=0(Cross upper boundary before lower boundary)

Pθ=δ(Reject H0) =  Pθ=δ(Cross upper boundary before lower boundary).

There are many diﬀerent ways to construct a group sequential boundary so that the 
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error probability constraints are satisﬁed according to 
Pθ=0(Cross upper boundary before lower boundary) = α (4.1) 
Pθ=δ(Cross lower boundary before upper boundary) = β. (4.2) 
Pampallona and Tsiatis (1994) introduced a family of one-sided tests, indexed by a 
parameter Δ, where the degree of early stopping can be tailored to the investigator’s 
needs by choosing an appropriate value for Δ. Pampallona et al. (2001) introduced 
further ﬂexibility by deﬁning spending functions for the type I and type II error 
probabilities. This contribution made it possible to deal with unpredictable group 
sizes and information levels without increasing the type I error probability. Jennison 
and Turnbull (2000, Chapter 7) found that the power remains close to its target value 
for such error spending designs, provided that deviations from the planned information 
sequence are moderate. 
Let us now return to the example in the previous paragraph, and let us for a 
moment consider what can happen if a trial is not stopped according to the critical 
values. As for any θ ∈ R, there is under θ = 0 a probability larger than zero to cross 
the lower boundary and then the upper boundary. We see in (4.1) that such sample 
paths are not included when calculating the overall type I error probability. When the 
type I error is calculated in this way, the presence of a futility boundary can thus pull 
down the upper boundary at later analyses. The critical value bk required to stop is 
then smaller than what would have been the case without a futility boundary. Making 
use of the lost type I error probability associated with sample paths that cross the 
lower boundary before the upper boundary is sometimes referred to as re-claiming or 
buying back type I error. 
The decision to stop a clinical trial is typically made after recommendation from a 
data monitoring committee (DMC). As discussed by Lan et al. (2003), it is however far 
from certain that a trial will be stopped, even though a boundary has been crossed. The 
experience of Proschan et al. (2006, Chapter 5) is that in practice, DMCs typically treat 
futility boundaries as more advisory than upper boundaries. There may be various 
reasons for a trial not being stopped, even though the futility boundary is crossed. 
There may for example be secondary variables that show promising results. Another 
reason could be that the decision about whether to stop for futility is inﬂuenced by 
other trials that are being run to investigate the same drug. 
If type I error is re-claimed and the study may sometimes continue despite crossing 
the lower boundary, the overall type I error probability will be inﬂated. Chang and 
Chuang-Stein (2004) state that it should be possible to re-claim type I error. Snapinn 
(2006) takes a more cautious view and argues that while it is statistically valid to re­
claim type I error, this should only be done if it is certain that the futility stopping rule 
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is always applied. Proschan et al. (2006, Chapter 5) go a step further and recommend 
making futility boundaries non-binding, so that the type I error is controlled even if 
the futility boundary is always overruled. 
We are not aware of regulatory guidance that explicitly rules out re-claiming 
type I error, but there are documents that point in this direction. In regulatory 
guidance from the FDA (2006), it is assumed that the upper boundary is derived 
independently of the lower boundary, in a similar fashion to Proschan et al. 
(2006, Chapter 5). It can be argued that if there is no guarantee that the futility 
boundary will always be applied, it is preferable not to re-claim type I error. Another 
concern with binding futility boundaries is that it actually is possible to construct 
an arbitrarily small critical value bK , by using a very aggressive futility boundary at 
previous analyses. Hence, it is possible to construct group sequential designs with 
binding futility boundaries that make it possible to reject the null hypothesis even 
though Zk < z1−α. Burman and Sonesson (2006) have pointed to similar problems for 
adaptive designs. 
In Section 4.2 we discuss existing group sequential designs with non-binding futility 
boundaries. As it is of interest to assess the eﬃciency of the designs in Section 4.2, 
we have developed a new method to derive optimal designs in the same class. The 
designs obtained from our optimisation procedure are a little conservative with respect 
to attained type I error, which is typical for group sequential designs with non-binding 
futility boundaries. Our optimal designs still maintain most of the beneﬁts of early 
stopping found in group sequential designs with binding futility boundaries. The 
optimisation method is outlined in Section 4.3, which also contains an illustrative 
example. Further details of the optimisation method are provided in Section 4.6. Our 
approach builds on the method of dynamic programming, that was used in Chapter 2. 
It is however not simply an application of dynamic programming, since the non-binding 
futility boundary makes the optimisation problem more complex and diﬃcult to solve. 
The next step is to use our optimal designs to assess the eﬃciency of the designs in 
Section 4.2. In Section 4.4 we present eﬃciency comparisons between error spending 
designs, stochastic curtailment designs, and the optimal group sequential designs 
discussed in Section 4.3. Finally, we summarise our conclusions in Section 4.5. 
4.2 Existing designs with non-binding futility boundaries 
4.2.1 Formulation 
The issues described in Section 4.1 raise the question of whether it is possible to enjoy 
the beneﬁts of futility stopping, while making sure that the type I error is controlled. 
Setting ak = −∞, for  k = 1, . . . ,K  − 1, makes sure that the type I error is controlled, 
but the beneﬁts of futility stopping are then lost. A more interesting suggestion is 
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given by Proschan et al. (2006, Chapter 5), who advise against re-claiming type I error 
and propose making futility boundaries non-binding. They strongly prefer to give the 
DMC increased ﬂexibility by deriving the upper boundary independently of the lower 
boundary. The type I error probability is then controlled even if the futility boundary is 
overruled, but slightly below its intended value if the study is in fact stopped for futility 
whenever the lower boundary is crossed. This proposal is thus a little conservative. It 
makes use of the fact that even though we would like the type I error probability to be 
exactly α, the most important thing is to make sure that it does not exceed α. Hence, 
we shall consider procedures with type I error probability at most α, with equality 
when the futility boundary is always overruled. We also require power of 1 − β under 
θ = δ, assuming that the futility boundary is always applied. Instead of the constraints 
deﬁned in (4.1) and (4.2), we now require 
Pθ=0(Cross upper boundary ignoring lower boundary) = α (4.3) 
Pθ=δ(Cross lower boundary before upper boundary) = β. (4.4) 
We shall be referring to designs that satisfy (4.3) and (4.4) as non-binding designs, 
while designs that satisfy (4.1) and (4.2) will be referred to as binding designs. 
The software package East-5 (2007) provides various ways to construct group 
sequential tests that satisfy (4.3) and (4.4). One possibility is to modify the power 
family tests of Pampallona and Tsiatis (1994) a little, making the boundary to reject 
H0 slightly more conservative. We will however focus on error spending designs, as 
these have the additional beneﬁt of being able to cope with unpredictable group sizes 
and information levels. Another possibility that we shall consider in Section 4.2.3 is to 
use methods for stochastic curtailment to derive a lower boundary. 
4.2.2 Error spending designs 
The construction of error spending designs that satisfy (4.3) and (4.4) bears similarities 
with the error spending designs with binding futility boundaries of Pampallona et al. 
(2001). We ﬁrst calculate the information 
(Φ−1(1 − α) + Φ−1(1 − β))2 Iﬁx = δ2 
needed for power of 1 − β at θ = δ in a ﬁxed sample trial. The next step is to deﬁne 
functions f and g that are used to spend the type I and type II error probabilities, 
respectively. These functions must be non-decreasing and satisfy f(0) = g(0) = 0, 
f(I) =  α and g(I) =  β, for  I ≥ Imax. One popular choice is the so-called ρ family, 
with f and g deﬁned according to 
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f(I) =  αmin{(I/Imax)ρ , 1} (4.5) 
g(I) =  βmin{(I/Imax)ρ , 1}, (4.6) 
where the parameter ρ > 0 and governs the amount of early stopping. For given ρ and 
Imax, we have (4.5) and (4.6). The next step is to search for the correct Imax so that, 
for equally spaced analyses say, aK = bK at the ﬁnal analysis. When Imax has been 
calculated, the inﬂation factor can be calculated as R = Imax/Iﬁx. 
Suppose that interim analyses are performed at information levels I1, . . . ,IK . We  
can then deﬁne π1,1 = f(I1), π2,1 = g(I1) and, for k = 2, . . . ,K,  
π1,k = f(Ik) − f(Ik−1) 
and 
π2,k = g(Ik) − g(Ik−1). 
The critical values ak and bk at analysis k can be calculated in turn, starting with k = 1  
and working upwards, as the solutions to 
π1,k = Pθ=0(Z1 < b1, . . . , Zk−1 < bk−1, Zk ≥ bk) 
and 
π2,k = Pθ=δ(a1 < Z1 < b1, . . . , ak−1 < Zk−1 < bk−1, Zk ≤ ak). 
The upper boundary is thus calculated without taking the lower boundary into account. 
The upper boundary is however taken into account when constructing the lower 
boundary, so that the power is at least 1 − β at θ = δ, with equality if the study 
is always stopped when crossing the lower boundary. For given K, α, β, ρ and 
planned information sequence I1, . . . ,Imax, we can thus calculate the critical values 
a1, b1, . . . , aK , bK that deﬁne a one-sided group sequential test satisfying the error 
probability constraints deﬁned in (4.3) and (4.4). Several iterations, where Imax is 
adjusted, may be necessary to obtain aK = bK at the ﬁnal analysis K. 
4.2.3 Designs based on stochastic curtailment 
Suppose that in a K-group sequential design to test H0 : θ ≤ 0 versus the alternative 
H1 : θ >  0, an upper boundary b1, . . . , bK that satisﬁes (4.3) has been chosen. This 
upper boundary may have been derived from an alpha spending function or some other 
approach. Without a lower boundary, this upper boundary in itself deﬁnes a one-
sided group sequential test, with no possibility of early stopping for futility. Given 
the upper boundary, we can, assuming equally spaced analyses or some other pattern 
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for the interim analyses, derive the maximum information level Imax = R × Iﬁx that 
gives power 1 − β at θ = δ. In the context of methods for stochastic curtailment, 
Jennison and Turnbull (2000, Chapter 10) refer to this test without a lower boundary 
as a reference test. 
Suppose that we are happy with the upper boundary of the reference test, but 
would also like to enjoy the beneﬁts of early stopping for futility. Instead of deriving the 
lower boundary through a beta spending function, we shall focus on another approach, 
called stochastic curtailment. In stochastic curtailment methods, the trial is stopped 
for futility when the probability of rejecting H0 : θ ≤ 0 later on in the trial falls below 
a certain threshold. 
It is important to note that there are diﬀerent ways to deﬁne the probability that 
the reference test rejects H0 later on in the trial. The reason is that it is not obvious 
which value of the treatment eﬀect θ to use in the calculation. In this section we will 
give a precise deﬁnition for three possibilities, which in turn give three diﬀerent criteria 
for futility stopping: 
•	 predictive power calculated given the current posterior distribution for θ, where  
the posterior distribution given Zk = zk is calculated for the prior distribution 
π(θ), 
•	 conditional power calculated for θ = θˆ, where  θˆ is the maximum likelihood 
estimate of θ, 
•	 conditional power calculated for θ = δ. 
Various authors have described methods for stochastic curtailment, including the 
three methods that we shall focus on. Lachin (2005) gives an overview of methods 
for futility stopping based on conditional power. Jennison and Turnbull (2000, 
Chapter 10) describe diﬀerent methods for stochastic curtailment, including conditional 
power, predictive power and a parameter-free approach. From a Bayesian point 
of view, Spiegelhalter et al. (1986) argue that the use of predictive power may be 
more appropriate than conditional power. Proschan et al. (2006, Chapter 3) discuss 
further possibilities, for example using updated estimates of nuisance parameters in the 
conditional power calculation. 
Let us now return to the reference test with an upper boundary that satisﬁes (4.3). 
Given the upper boundary of the reference test we can, after having observed Zk = zk 
at interim analysis k, calculate  
PP(zk) =  dθπ(k)(θ|zk)CPθ(zk) (4.7) 
CPδ(zk) =  Pδ(Cross upper boundary at analyses k + 1, . . . ,K|Zk = zk). (4.8) 
CPθˆ(zk) =  Pθˆ(Cross upper boundary at analyses k + 1, . . . ,K|Zk = zk) (4.9) 
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For (4.7), π(k)(θ|zk) will be calculated for the improper prior π(θ) = 1. This prior 
takes the value 1 over the whole real line and is called improper because the integral 
of the pdf is not ﬁnite. If the treatment eﬀect is estimated to be θˆk at analysis k, with  
information level Ik, the posterior distribution for θ is N(θˆk,Ik −1). Another possibility 
would be to assume that the prior distribution for θ follows a normal distribution. We 
refer to Proschan et al. (2006, Chapter 3) for a discussion of how to choose the mean 
and variance of the prior distribution in this case. 
It is noteworthy that since (4.8) is calculated under the alternative θ = δ, it  can  
be viewed as a special case of (4.7), with a one-point prior at θ = δ. It is on the other 
hand not possible to choose a prior so that (4.9) becomes a special case of (4.7). In 
Section 4.4.2 we will see that futility stopping based on (4.9) is not very eﬃcient. The 
fact that there is no prior distribution that leads to a one-point posterior distribution 
at θ = θˆ, may be a reason for the ineﬃciency. 
If either (4.8), (4.9) or (4.7) is below a certain threshold, this may indicate that 
a trial is unlikely to achieve a statistically signiﬁcant result. We shall be focusing on 
stopping rules of the type 
Stop for futility at analysis k if PP(zk) ≤ η1 (4.10) 
Stop for futility at analysis k if CPδ(zk) ≤ η2 (4.11) 
Stop for futility at analysis k if CPθˆ(zk) ≤ η3. (4.12) 
If a criterion of this type is used at each interim analysis of a clinical trial, it is 
straightforward to derive an equivalent rule, where Zk = zk is compared to a lower 
boundary a1, . . . , aK−1. Combined with an upper boundary b1, . . . , bK that satisﬁes 
(4.3) and information levels I1, . . . ,Imax, we can calculate the power at a certain eﬀect 
size δ. The presence of the futility boundary will imply some loss of power compared 
to the reference test. If it is important to satisfy the power requirement, a reference 
test with power higher than 1 − β must be chosen. 
4.3	 Optimal group sequential designs with non-binding 
futility boundaries 
4.3.1	 Motivation 
Barber and Jennison (2002) found that for group sequential designs with binding futility 
boundaries, ρ family error spending designs are close to optimal in a wide range of 
situations. Moreover, error spending designs have other advantages, for example the 
ability to cope with unpredictable information sequences without inﬂating the type I 
error probability. It is thus of interest to assess whether ρ family error spending 
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designs with non-binding futility boundaries are also close to optimal in their class. If 
the eﬃciency loss compared to optimal designs is small, error spending des´ıgns would 
provide an eﬃcient class of designs that are convenient for use in practice. 
The methods for stochastic curtailment described in Section 4.2.3 also have 
appealing features. The focus of these methods is primarily on the lower boundary 
and stopping for futility, but it is also of interest to assess the overall eﬃciency of 
these designs compared to optimal designs. It may well be that we can ﬁnd stochastic 
curtailment designs that are close to optimal, providing an eﬃcient alternative to error 
spending designs. An additional beneﬁt of these methods is that they are easy to 
communicate. We believe that the probability of rejecting H0, given current data, 
might be easier to interpret than a critical value on the Z scale. 
4.3.2 Formulating the optimality criteria 
While the designs in Section 4.2 satisfy the error probability constraints (4.3) and 
(4.4), we have not yet assessed their eﬃciency. Eﬃciency will be expressed in terms of 
expected information, which can easily be converted to sample size. For normally 
distributed data with known variance we have Ik = nk/(2σ2), where nk is the 
cumulative per-treatment sample size at analysis k. For  a  K-group sequential design 
with critical values a1, b1, . . . , aK , bK , we deﬁne the expected information, at a given 
value of the eﬀect size θ, as  
K 
Eθ(I) =  Pθ{Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ≤ ak or Zk ≥ bk}Ik, (4.13) 
k=1 
where Ck = (ak, bk). The expected information is thus calculated assuming that the 
futility boundary will be strictly adhered to, reﬂecting how the investigator expects 
the trial to be monitored. This would appear to be the most logical deﬁnition, as 
the constraint on how to calculate the type I error probability can be viewed as an 
additional requirement imposed by regulatory authorities. Rather than focusing on 
one value of θ, a more appropriate way to assess the performance of the designs in 
Section 4.2 may be to calculate (4.13) across a range of values of θ. We shall present 
a method to derive group sequential designs that are optimal, in the sense that they 
minimise 
F˜ = 
E0(I) +  Eδ/2(I) +  Eδ(I) (4.14)
3 
subject to the constraints in (4.3) and (4.4). Thereafter, we will assess the performance 
of designs in Section 4.2 that satisfy the same error probability constraints, by 
calculating F˜ and comparing this number to that obtained for the optimal design. 
The expected information in (4.14) is calculated according to (4.13), i.e. assuming that 
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the futility boundary will always be applied. We note that if desirable, it would be 
straightforward to use our method to optimise another weighted average than (4.14). 
4.3.3 Derivation of optimal designs 
The ﬁrst step necessary to enable an eﬃciency comparison with the designs in 
Section 4.2 is to develop a method to derive optimal designs. For binding futility 
boundaries, Barber and Jennison (2002) describe how dynamic programming can be 
used to derive one-sided group sequential tests that are optimal, in the sense that they 
minimise the expected sample size while satisfying (4.1) and (4.2). This is done by 
deﬁning a prior for θ, a cost of sampling and a loss function that deﬁnes costs for 
making the wrong decision about θ. Each interim analysis can be thought of as a 
decision node. At each decision node, the decisions are based on expected future costs 
under the current posterior distribution for θ. 
Suppose that instead we wish to minimise F˜ as deﬁned in (4.14), subject to the 
error probability constraints in (4.3) and (4.4). We can follow an approach that 
bears similarities with the method of Barber and Jennison (2002), but which also 
has important diﬀerences. Consider the unconstrained optimisation problem of ﬁnding 
the critical values that minimise 
F˜ + λ1P1 + λ2P2, (4.15) 
where λ1 and λ2 are positive and P1 and P2 are the probabilities, deﬁned in (4.3) 
and (4.4), of rejecting and accepting H0. Provided that we can ﬁnd the solution 
a1, b1, . . . , aK , bK that minimises (4.15), it remains to choose the Lagrange multipliers 
λ1 and λ2 so that the solution gives P1 = α and P2 = β. The design that minimises 
(4.15) for these values of λ1 and λ2 must then also minimise F˜ among all designs 
satisfying the same constraints. 
P1 and P2 are however probabilities under two diﬀerent stopping rules, so this is 
not a standard Bayes sequential decision problem. Hence, it is not straightforward 
to solve (4.15) through the method dynamic programming used in Section 2.2.2. The 
key ingredient that makes this problem diﬀerent is that the optimal critical values at 
analysis k depend on the critical values at both previous and future analyses. A slightly 
diﬀerent approach is thus warranted, details of which are provided in Section 4.6. 
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Figure 4-1: Critical values for optimal group sequential designs with non-binding (black solid 
line) and binding (blue solid line) futility boundaries 
4.3.4 An illustrative example 
Consider a 5-group sequential design with type I error probability α = 0.025 and 90% 
power at δ = 0.2. The information required for a ﬁxed sample test is 
(Φ−1(1 − 0.025) +Φ−1(1 − 0.1))2 Iﬁx = = 263.0.22 
For normally distributed data with known variance, this can be converted to patients 
per treatment group by using the identity nﬁx = 2σ
2Iﬁx. Assuming equally spaced 
analyses and an inﬂation factor R = 1.2, we schedule interim analyses at 
k 
, k  = 1, . . . ,K,  Ik = Imax 
K
where Imax = R×Iﬁx = 315. Optimising the design for F˜ , subject to the constraints in 
(4.3) and (4.4), gives the boundaries displayed with a black solid line in Figure 4-1. For 
comparison we also include the boundaries (blue solid line) for the design with binding 
futility boundaries, which has also been optimised for F˜ . The boundaries of the two 
designs are very similar, but we can observe that the critical values are slightly more 
conservative for the design with non-binding futility boundaries. The binding design 
can stop for eﬃcacy for lower Z values since, as discussed in Section 4.1, treating the 
futility boundary as binding makes it possible to re-claim type I error. 
Figure 4-2 shows four power curves that merit some comment. Two of the curves are 
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Figure 4-2: Power for optimal design with non-binding futility boundaries, if futility boundary 
is always applied (black solid line) and never applied (black dashed line). Also shown are the 
power curve (red line) for a design with no futility boundary and optimal upper boundary and 
the power curve (blue solid line) for an optimal binding design for which the futility boundary 
is never applied. 
the result of two diﬀerent ways of applying the optimal non-binding boundary displayed 
with solid line in Figure 4-1. The solid line displays the probability of rejecting H0 if 
the futility boundary is strictly adhered to. Hence, the probability of rejecting H0 
at θ = 0  is  0.023, while the probability of rejecting H0 at θ = 0.2 equals  0.90. From the 
point of view of the trial sponsor, this shows that the power requirement is satisﬁed if, 
as intended, the futility bound is always applied. The dashed line shows what happens 
to the power curve of the design with a non-binding futility boundary, if the futility 
boundary is never applied. The type I error is controlled at α = 0.025 also in this case, 
which should be reassuring to regulators. The power is also slightly higher, 0.93 rather 
than 0.90, since sample paths that ﬁrst cross the lower boundary and later the upper 
boundary are now allowed to continue. 
We have seen that non-binding futility boundaries make designs a little conservative 
with respect to type I error. Using designs without a futility boundary is an obvious 
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Figure 4-3: 100 ˜F/Iﬁx for optimal non-binding design if futility boundary is always applied 
(black solid line) and never applied (black dashed line). Also shown is 100 ˜F/Iﬁx for a design 
with no futility boundary and optimal upper boundary (red solid line). 
way to get around the problem of how to treat the lower boundary. Such designs 
have type I error α and power 1 − β at θ = δ, but do not enjoy the beneﬁts of futility 
stopping. The power curve for such a design, with optimised upper boundary b1, . . . , b5, 
but no futility boundary, is shown with a solid red line in Figure 4-2. The power curve 
is very close to the solid line, i.e. the design with a futility boundary that is always 
applied. Finally, we also show a curve (solid blue line) for the optimal binding design 
in Figure 4-1, for the case when the futility boundary is never applied. This design has 
type I error 0.029 and power 0.94 at θ = 0.2, giving an indication of what can happen 
if a binding futility boundary is incorrectly ignored. 
Figure 4-3 shows the ratio 100 F˜ /Iﬁx for the three diﬀerent ways of applying the 
futility boundary. The black solid line shows 100 F˜ /Iﬁx calculated according to (4.13), 
i.e. by assuming that the futility boundary will be strictly adhered to. As we would 
expect, the presence of a futility boundary is crucial for achieving good eﬃciency for 
small values of θ. It is however worth remembering that applying the futility boundary 
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Figure 4-4: 100 ˜F/Iﬁx for optimal K-group sequential designs with equally spaced analyses 
and non-binding futility boundaries. The designs have inﬂation factor R, type I error α = 0.025 
and power 1 − β at θ = δ. 
also implies a loss of power, as illustrated in Figure 4-2. Also shown in Figure 4-3, 
with red solid line, is 100 F˜ /Iﬁx for a design with optimised upper boundary b1, . . . , b5, 
but without a futility boundary. The design without futility boundary shows good 
eﬃciency for high values of θ. It is on the other hand very ineﬃcient for small values 
of θ. The results are similar for the design, displayed with dashed line, with a futility 
boundary that is not applied, with slightly higher F˜ and slightly higher power. We 
conclude that if values of θ close to the null hypothesis are of interest, designs with 
futility boundaries are to be preferred. These can be non-binding if that is what is 
required. Non-binding designs are a little conservative with respect to type I error, but 
show good eﬃciency across a range of values of θ. If the futility boundary is always 
applied, this class of designs can deliver substantial eﬃciency gains, compared to the 
corresponding ﬁxed sample trial. 
Figure 4-4 shows the eﬃciency gains of optimal K-group sequential designs with 
non-binding futility boundaries and inﬂation factor R, compared to the corresponding 
ﬁxed sample designs. As will be the case for the remainder of this chapter, 100 F˜ /Ifix  
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Figure 4-5: Eﬃciency comparison between three 5-group sequential designs, with equally 
spaced analyses, that are optimal with respect to F˜ within their respective class. 
is calculated assuming that the futility boundary is always applied. For each K, the  
ratio 100 F˜ /Iﬁx initially decreases in R, but as R increases there comes a point where 
F˜ /Iﬁx starts to increase. 
We also show the eﬃciency of K-group binding designs with varying inﬂation factor, 
that have been optimised with respect to F˜ . A similar pattern, with an initial decrease 
of 100 F˜ /Iﬁx with increasing R, followed by an increase, is seen for the binding designs. 
For given K, the optimal eﬃciency is however achieved for a slightly smaller R than for 
non-binding designs. For ﬁxed R and K, the eﬃciency loss of the non-binding designs 
compared to the binding is about 2%, which can be interpreted as the cost incurred 
for the additonal constraint that is imposed on the type I error. 
Figure 4-5 shows, with solid line, 100 F˜ /Ifix  for optimal 5-group designs with non­
binding futility boundaries. As a benchmark, two other designs have also been included 
in the ﬁgures. We consider optimal group sequential designs with binding futility 
boundaries, with adjusted and unadjusted α levels. In summary, the following three 
classes of designs are displayed in Figures 4-5: 
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1.	 Optimal group sequential designs with non-binding futility boundaries, displayed 
with a solid line. 
2.	 Optimal group sequential designs with binding futility boundaries and adjusted 
type I error, displayed with a dashed line. Here, the type I error has been adjusted 
downwards, so that for the ﬁxed K and R, it equals the type I error attained for 
the optimal design with non-binding futility boundary. 
3.	 Optimal group sequential designs with binding futility boundaries and unadjusted 
type I error, displayed with dot-dashed line. These designs have type I error 
probability α, calculated according to (4.1). 
The designs with unadjusted type I error ought to give lower expected sample size 
than the other designs, as their attained type I error probabilities are higher. This is 
conﬁrmed in Figure 4-4 and Figure 4-5. The designs with binding futility boundaries 
and adjusted type I error perform slightly better than the design with non-binding 
futility boundary satisfying the same error probability constraints. This should be the 
case, as we are comparing the optimal design within a certain class to a design that 
happens to be in this class, but is not necessarily optimal. The diﬀerence is however 
very small. Hence, most of the eﬃciency loss associated with the design with non­
binding futility boundary is due to the diﬀerences in attained type I error, as a result 
of the futility boundary being treated diﬀerently. 
4.4 Eﬃciency comparisons with existing designs 
4.4.1 Assessment of error spending designs 
We now consider error spending designs with type I error according to (4.3) and 
type II error according to (4.4). Hence, the type I error is calculated without taking 
the futility boundary into account, while the power is calculated assuming that the 
futility boundary is always applied. To enable a fair comparison between ρ family error 
spending designs and optimal group sequential designs, we consider optimal group 
sequential designs with the same type I and type II errors and cumulative group sizes 
as the corresponding error spending designs. The eﬃciency of the designs is evaluated 
by calculating F˜ , i.e. by assuming that the study is stopped for futility whenever the 
lower boundary is crossed. 
For K equally spaced analyses there is, for α and β held ﬁxed, a one-to-one 
correspondence between the choice of ρ and the inﬂation factor R necessary for 
power 1 − β at θ = δ. When  K = 5,  we  obtain  R = 1.07 for ρ = 3  and  R = 1.31 for 
ρ = 1.  For  each  value  of  ρ we obtain a maximum information level Imax, and  given  
our assumption about equally spaced analyses, an information sequence I1, . . . ,Imax. 
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Figure 4-6: Eﬃciency comparison between K = 5,  ρ family error spending designs and 
corresponding optimal 5-group sequential designs. All designs have non-binding futility 
boundaries, equally spaced analyses, type I error α and power 1 − β at θ = δ. 
Given this information sequence, we can ﬁnd the design that is optimal with respect 
to F˜ and compare its eﬃciency to that of the error spending design. Figure 4-6 shows 
an eﬃciency comparison between ρ family, K = 5 group, error spending designs and 
optimal designs, where we have drawn R instead of ρ on the horizontal axis. The 
eﬃciency loss of the error spending designs is small, typically between 0.5% − 2%. 
Hence, we can be conﬁdent about using non-binding error spending designs in clinical 
trials, without losing much eﬃciency compared to optimal non-binding designs. This is 
an important conclusion, and was in Section 4.3.1 part of our motivation for developing 
a method to derive optimal designs. 
Figure 4-7 displays comparisons of non-binding, ρ = 1 error spending designs, with 
the corresponding optimal non-binding designs, for diﬀerent values of K. Also  shown  
are the optimal binding designs with adjusted and unadjusted type I error, of the type 
displayed in Figure 4-5. We see a similar pattern for K = 3 and  K = 10  as shown  
for K = 5, in Figures 4-5 and 4-6. 
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Figure 4-7: Eﬃciency comparison between K-group, ρ = 1 error spending designs and 
corresponding optimal K-group sequential designs. All designs have non-binding futility 
boundaries, equally spaced analyses, type I error α and power 1 − β at θ = δ. 
4.4.2 Assessment of methods for stochastic curtailment 
We shall now assess the eﬃciency of methods based on stochastic curtailment, by 
comparing the eﬃciency of such designs to that of optimal designs derived using our 
optimisation method described in Section 4.3. We will ﬁrst consider an example of how 
a stochastic curtailment design can be constructed in practice. Thereafter, eﬃciency 
comparisons, of the type presented for error spending designs in Section 4.4.1, will be 
made. We will describe a design with futility stopping based on predictive power, but 
our description of how to derive the lower boundary is applicable also for the other 
methods described in Section 4.2.3. 
Consider a group sequential test of H0 : θ ≤ 0 against the alternative H1 : θ >  0, 
with type I error α and power 1 − β at θ = δ. Suppose that it has been decided to 
have K = 5 equally spaced analyses with an upper boundary b1, . . . , bK that satisﬁes 
(4.1). This upper boundary can play the role of a reference test, and we can search 
for the maximum information Imax = R × Iﬁx that is required to satisfy the power 
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requirements, without a futility boundary present. The reference test thus has interim 
analyses at 
k 
, k  = 1, . . . ,K,  Ik = Imax × 
K
with early stopping to reject H0 if θˆk 
√Ik ≥ bk. 
Let us now consider how to add a lower boundary to this design by using stochastic 
curtailment based on predictive power. The lower boundary is constructed by using 
a rule of the type deﬁned in (4.10). At each interim analysis, we can calculate the 
predictive power to reject the the null hypothesis of the reference test. Suppose that 
the trial is stopped for futility if the predictive power falls below η1. At  each  interim  
analysis, we can search for the critical value ak where the predictive power to reject the 
null hypothesis of the reference test equals η1. For the new group sequential design, 
with lower boundary a1, . . . , aK and the upper boundary of the reference test, we can 
calculate properties such as power and expected sample size. 
We shall now consider the eﬃciency of stochastic curtailment designs compared 
to optimal group sequential designs. To this end, the stochastic curtailment designs 
will be given the same upper boundary as the optimal designs, while we will assess 
the eﬃciency of the lower boundaries derived from stochastic curtailment methods. 
To enable a fair comparison between two designs, it is desirable that they satisfy the 
same error probability constraints and have interim analyses at the same cumulative 
sample sizes. It follows from (4.3) that two designs with the same upper boundary 
have the same type I error, as this is assessed without taking the futility boundary into 
account. The power curve will however be aﬀected by the lower boundary. It is clear 
that for the stochastic curtailment design, the power is monotonically decreasing in 
η1, the threshold that is used to decide whether to stop for too low predictive power. 
To make sure that both designs have power 1 − β at θ = δ, we can for the stochastic 
curtailment design perform a one-dimensional search for the threshold η1 that gives 
the same power as the optimal design. For K = 2, any stochastic curtailment design 
derived in this way is equivalent to the optimal design, as the boundary point a1 must 
be set to satisfy the requirement of power 1 − β at θ = δ. For  K >  2, an additional 
degree of freedom is added for each interim analysis. 
Consider two of the optimal designs that were used in Figure 4-6, for comparisons 
against ρ = 1  and  ρ = 3 error spending designs. These designs have inﬂation factors of 
about 1.31 and 1.07, respectively. The design with an inﬂation factor of 1.31 might be 
considered aggressive and has an upper boundary that is broadly similar to the designs 
of Pocock (1977), with a substantial probability of early stopping. The design with 
inﬂation factor of 1.07 is more conservative with wider boundaries early on, similar 
to the O’Brien and Fleming (1979) designs. We consider group sequential designs 
with optimised lower and upper boundary. We now wish to investigate the merits of 
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Figure 4-8: Critical values for optimal non-binding design and for non-binding designs with 
optimised upper boundary and lower boundary based on stochastic curtailment. All designs 
have K = 5 equally spaced analyses, inﬂation factor R = 1.31, type I error α = 0.025 and 
power 1 − β at θ = 0.2. 
stochastic curtailment methods through an eﬃciency comparison with these optimised 
designs. We assess if it can still be highly eﬃcient to use the same upper boundary as 
the optimal design, but construct a new lower boundary through stochastic curtailment. 
Figures 4-8 and 4-9 show the critical values for the two optimal designs with 
R = 1.07 and R = 1.31, as well as for the diﬀerent methods for stochastic curtailment 
deﬁned in Section 4.2.3. We note that the rule based on predictive power is rather 
close to the optimal boundary. Compared to the optimal design, the rule based on 
conditional power at θ = δ is a little more conservative early on, while the rule based 
on conditional power at θ = θˆ gives a more aggressive boundary at earlier interim 
analyses. In Figures 4-8 and 4-9 we use constant thresholds η1, η2 and η3, to deﬁne 
the lower boundaries that are based on stochastic curtailment. Another possibility, not 
considered here, would be to vary the threshold in some systematic way over the interim 
analyses. The values of the thresholds are driven by our requirement that the designs 
should have 90% power at θ = δ. For  R = 1.31, we have η1 = 0.10, η2 = 0.61 and 
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Figure 4-9: Critical values for optimal non-binding design and for non-binding designs with 
optimised upper boundary and lower boundary based on stochastic curtailment. All designs 
have K = 5 equally spaced analyses, inﬂation factor R = 1.07, type I error α = 0.025 and 
power 1 − β at θ = 0.2. 
η3 = 0.0078, while for R = 1.07, η1 = 0.029, η2 = 0.35 and η3 = 0.00008. A diﬀerent 
threshold can be obtained by ﬁnding the optimal design for a diﬀerent inﬂation factor 
R, where a higher inﬂation factor will give a higher threshold. It may well be the case 
that it is found desirable to have a higher or lower threshold than the ones we report 
here. Proschan et al. (2006, Chapter 3) comment that a typical rule may be to stop if 
CPδ(zk) is  below  0.10 − 0.15, i.e a little more conservative than the rules that we have 
considered. In our framework, we can obtain a rule with a value of η2 in this range by 
setting R ≈ 1.01. Because of their higher eﬃciency, we believe that the designs that 
we have considered, with a higher inﬂation factor, are to be preferred. 
Figures 4-10 and 4-11 show the expected sample size functions for the optimal 
designs and for the rules based on stochastic curtailment for R = 1.31 and R = 1.07, 
respectively. The design with futility stopping based on predictive power is close to 
optimal across a range of values of θ. Conditional power based on θ = δ also does 
rather well, but shows some ineﬃciency as we move away from θ = δ. We  note  that  
the method assumes θ = δ also when the data observed so far do not support this 
88

Chapter 4. Group sequential designs with non-binding futility boundaries 
50
 
60
 
70
 
80
 
10
0F~
 
I fi
x 
Conditional on θ=θ ^ 
Conditional on θ=δ 
Predictive power 
Optimal non−binding 
0.00 0.05 0.10 0.15 0.20 0.25 0.30 
Effect Size 
Figure 4-10: 100 ˜F/Iﬁx for optimal non-binding design and for non-binding designs with 
optimised upper boundary and lower boundary based on stochastic curtailment. All designs 
have K = 5 equally spaced analyses, inﬂation factor R = 1.31, type I error α = 0.025 and 
power 1 − β at θ = 0.2. 
assumption. To stop for futility at the ﬁrst interim analysis, data have to be more 
extreme in the negative direction, than for the other methods. Conditional power 
based on θˆ on the other hand seems to be a rather ineﬃcient stopping rule. This rule 
relies on estimates of θˆ, without taking into account the variability of the estimates. 
This might be a source of ineﬃciency, in particular early on in the trial when estimates 
are uncertain. The boundaries based on predictive power are somewhere in between 
those based on θ = θˆ and θ = δ, and are the closest to the optimal boundary. Hence, we 
would recommend futility stopping based on predictive power for a constant threshold 
η1 as an eﬃcient stopping rule, that should be easy to implement in practice. The 
value of η1 can be chosen by considering the power curve and the probability of early 
stopping that is achieved for a given threshold. 
4.5 Discussion 
We have described issues with how to calculate the type I error in one-sided group 
sequential designs with futility stopping. These issues are related to the conduct of 
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Figure 4-11: 100 ˜F/Iﬁx for optimal non-binding design and for non-binding designs with 
optimised upper boundary and lower boundary based on stochastic curtailment. All designs 
have K = 5 equally spaced analyses, inﬂation factor R = 1.07, type I error α = 0.025 and 
power 1 − β at θ = 0.2. 
group sequential designs and the fact that it is challenging to prove that a futility 
boundary will always be applied. Several authors have pointed out that in clinical 
trial practice, it may be diﬃcult to justify the use of binding futility boundaries and 
some of them strongly advice against re-claiming type I error. The simplest solution 
is to remove the futility boundary from the design, but retain the possibility of early 
stopping for beneﬁt. This possibility was considered in Section 4.3.4, and can still give 
good eﬃcacy for high values of θ. The drawback is that such a method is very ineﬃcient 
if the treatment eﬀect is close to the null hypothesis. It can also be argued that there 
are ethical reasons to stop, if it is unlikely that the trial will give a positive result. 
A better solution is to require that the probability of crossing the upper boundary 
equals the desired type I error probability when the lower boundary is not taken into 
account. This points to group sequential designs with non-binding futility boundaries of 
the type recommended by Proschan et al. (2006, Chapter 5). Using non-binding designs 
results in a small loss of power, but makes sure that the type I error probability is at 
most α. This should be reassuring to regulatory authorities, who might question that 
a binding futility boundary will always be applied. This chapter has dealt with the 
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eﬃciency of such designs, with a focus on error spending designs and designs based on 
stochastic curtailment. We have found error spending designs to give eﬃcient designs. 
Good eﬃciency was also obtained for designs with optimised upper boundary and a 
lower boundary deﬁned by the predictive power being equal to a certain threshold. It 
turned out to be surprisingly eﬃcient to let this threshold be constant across the interim 
analyses. The other methods for stochastic curtailment were evaluated in a similar way, 
but were not as eﬃcient. The most ineﬃcient method was futility stopping based on 
θˆ, which calculates the conditional power assuming θ = θˆ and ignores the variability of 
the estimate. 
Most of the work in this chapter went into deriving optimal group sequential designs 
with non-binding futility boundaries. The aim of this exercise was to enable eﬃciency 
comparisons with error spending designs and stochastic curtailment designs that satisfy 
the same error probability constraints. The optimisation method was outlined in 
Section 4.3.3, while further details are provided in Section 4.6. Deriving the optimal 
designs was an interesting challenge, as it was not straightforward to use dynamic 
programming in the way it was used in Chapter 2. We have nevertheless showed that 
it is possible to use some of these ideas and extend the dynamic programming method, 
to solve a more complex problem than is normally possible. 
The most important application of the optimal designs is perhaps not to use them 
in clinical trials, but rather to benchmark other designs such as error spending designs 
and stochastic curtailment designs. Error spending designs are convenient to use, as 
they can handle unpredictable group sizes and information levels. We have found that 
non-binding error spending designs are close to optimal, and therefore recommend their 
use if non-binding futility boundaries are required. These ﬁndings concur with those of 
Barber and Jennison (2002), for group sequential tests with binding futility boundaries. 
Stopping for futility if the predictive power is below a certain threshold seems to be 
another eﬃcient alternative. In order to protect the type I error for unpredictable 
information sequences, we would recommend to derive the upper boundary from an α 
spending function. The lower boundary could then be based on either predictive power 
or a β spending function. 
4.6	 Derivation of optimal group sequential designs with 
non-binding futility boundaries 
4.6.1	 Introduction 
We consider a one-sided group sequential test with cumulative information levels 
I1, . . . ,IK . We will show how to derive a group sequential design with a non-binding 
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futility boundary, that minimises F˜ subject to the desired error probability constraints 
Pθ=0(Cross upper boundary ignoring lower boundary) = α (4.16) 
Pθ=δ(Cross lower boundary before upper boundary) = β. (4.17) 
To this end, we ﬁrst consider a Bayes decision problem where we place a three point 
prior distribution on θ, with probability 1/3 at  θ1 = 0,  θ2 = δ/2 and  θ3 = δ. In  
our model, θ is generated from this prior distribution, while the sequence of statistics 
Z1, . . . , ZK follows the usual joint canonical distribution for θ given I1, . . . ,IK , deﬁned 
in equation (1.1). For Zk = zk, costs  kθ1 and kθ3 are charged as described below, where 
we assume that ak < bk, for  k = 1, . . . ,K  − 1. 
•	 If ak and bk are set so that zk ≤ ak, we  say  that  zk is in the futility zone. The 
cost charged is then kθ3 if θ = θ3 and neither boundary has been crossed before 
analysis k, and zero otherwise. 
•	 If ak and bk are set so that ak < zk < bk, we  say  that  zk is in the continuation 
zone. 
•	 If ak and bk are set so that zk ≥ bk, we  say  that  zk is in the eﬃcacy zone. The 
cost charged is then kθ1 if θ = θ1 and the upper boundary has not been crossed 
before analysis k, and zero otherwise. 
We deﬁne Ck = (ak, bk) and  Bk = (−∞, bk), for k = 1, . . . ,K  − 1. With a cost of 
sampling cθ = 1 per unit information at each value of θ, the total expected cost can be 
written as 
3	 K 
πθi c Pθi {Z1 ∈ C1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj or Zj ≥ bj }Ijθi 
i=1 j=1 
+ πθ1 kθ1 Pθ1 {Zj ≥ bj for some j = 1, . . . ,K} 
+ πθ3 kθ3 Pθ3 {Z1 ∈ C1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj for some j = 1, . . . ,K} 
= F˜ + πθ1 kθ1 Pθ1 {Zj ≥ bj for some j = 1, . . . ,K} 
+ πθ3 kθ3 Pθ3 {Z1 ∈ C1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj for some j = 1, . . . ,K} .(4.18) 
We will solve the problem of ﬁnding the critical values a1, b1, . . . , aK , bK that minimise 
(4.18) through the following steps: 
1.	 Finding ak and bk, the critical values at analysis k that minimise (4.18), given 
critical values a1, b1, . . . , ak−1, bk−1, ak+1, bk+1, . . . , aK , bK and ﬁxed costs kθ1 and 
kθ3 . 
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2. Using the method in the previous step, combined with an iterative approach, to 
ﬁnd the critical values a1, b1, . . . , aK , bK that minimise (4.18), given ﬁxed costs 
kθ1 and kθ3 . 
3. Performing further sensitivity analyses to make sure that the solution that we 
have found is optimal. 
Suppose that we are able to solve the unconstrained decision problem, by ﬁnding 
the critical values a1, b1, . . . , bK that minimise (4.18), for ﬁxed costs kθ1 and kθ3 . It  
then remains to perform a numerical search for the costs that give a solution that 
satisﬁes the error probability constraints in (4.16) and (4.17). The standard Lagrangian 
argument implies that this decision rule minimises F˜ among all rules satisfying the same 
constraints. 
4.6.2 Optimising ak and bk given critical values at all other analyses 
We ﬁrst consider the problem of ﬁnding the critical values ak, bk, that  solve  the  
unconstrained decision problem deﬁned in the previous section, given boundary points 
a1, b1, . . . , ak−1, bk−1, ak+1, bk+1, . . . , aK , bK and ﬁxed costs kθ1 and kθ3 . Equation (4.18) 
can be  written as  
{ k−1 
πθ1 k Pθ1 {Z1 < b1, . . . , Zj−1 < bj−1, Zj ≥ bj}θ1 
j=1 
+	 Pθ1 {Z1 < b1, . . . , Zk−1 < bk−1, Zk ≥ bk}

K }

+ Pθ1 {Z1 < b1, . . . , Zj−1 < bj−1, Zj ≥ bj }
j=k+1
{ k−1

+	 πθ3 k Pθ3 {Z1 ∈ C1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj}θ3 
j=1 
+	 Pθ3 {Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1, Zk ≤ ak}

K }

+ Pθ3 {Z1 ∈ C1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj}
j=k+1

3 k−1

+ πθi cθi Pθi {Z1 ∈ C1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj or Zj ≥ bj }Ij 
i=1 j=1

3

+ πθi cθi Pθi {Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1}Ik 
i=1

3 K

+	 πθi cθi Pθi {Z1 ∈ C1, . . . , Zj ∈ Cj , Zj+1 ≤ aj+1 or Zj+1 ≥ bj+1}(Ij+1 − Ik). 
i=1 j=k 
(4.19) 
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We have divided the terms in (4.19) into three diﬀerent categories: 
1. Terms that do not depend on the critical values at analysis k. 
2. Terms that depend on critical values at analysis k, as well as on  critical  values at  
previous interim analyses. 
3. Terms that are aﬀected by the critical values at analysis k, but are also aﬀected 
by critical values at previous and later interim analysis. 
We shall be making use of the fact that terms in the ﬁrst category, which later in the 
derivation will be denoted T1, T2 and T3, do not have to be taken into account when 
searching for the optimal critical values at analysis k. 
Let 
fZ1,...,Zk|θi (z1, . . . , zk|θi) 
denote the joint pdf of Z1, . . . , Zk given θi and let 
fZ1,...,Zk−1|Zk,θi (z1, . . . , zk−1|zk, θi) 
denote the joint conditional pdf given Zk = zk and θi. We also deﬁne the product sets 
Bk = B1 × B2 × . . .× Bk 
and 
Ck = C1 × C2 × . . .× Ck. 
We now introduce the notation ∫ ∫ ∫ 
Bk 
dzkhθi,k(zk) =  
B1 
. . .  
Bk 
dz1, . . . , dzkfZ1,...,Zk|θi (z1, . . . , zk|θi) (4.20) 
fθi,k(zk) =  fZk|θi (zk|θi) 
3 
(4.21) 
∑ 
fk(zk) =  πθi fθi,k(zk) (4.22) 
i=1 
hk−1|k(zk−1|zk) =  hθi,k−1|k(zk−1|zk) 
= fZ1,...,Zk−1|Zk,θi (z1, . . . , zk−1|zk, θi). (4.23) 
In (4.23) we have used that since we condition on Zk = zk, which is a suﬃcient statistic 
for θ, the expression must be independent of θ. By using a similar convention as in 
previous expressions, as well as the fact that we know from (1.1) that the sequence of 
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test statistics Z1, . . . , ZK has the Markov property, we can write 
hθi,k|k−1(zk|zk−1) =  fZk|Zk−1,θi (zk|zk−1, θi) 
=	 fZk|Zk−1,θi (zk|zk−1, θi) 
=	 hθi,k|k−1(zk|zk−1). (4.24) 
We can now use the notation that has been introduced to write (4.19) as 
∫	 ∫ ∞ 
T1 + kθ1 πθ1 dzk−1hθ1,k−1(zk−1) dzkhθ1,k|k−1(zk|zk−1) 
Bk−1	 −∞ 
× I(zk ≥ bk) + (I(zk < ak) +  I(ak < zk < bk)) 
×	 Pθ1 (Zj ≥ bj for some j = k + 1, . . . ,K|Zk = zk) ∫	 ∫ ∞ 
+	 T2 + k πθ3 dzk−1hθ3,k−1(zk−1) dzkhθ3,k|k−1(zk|zk−1)θ3 
Ck−1	 −∞ 
× I(zk ≤ ak) +  I(ak < Zk < bk) 
×	 Pθ3 (Zk+1 ∈ Ck+1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj , for some j = k + 1, . . . ,K|Zk = zk) 
3 ∫	 ∫ ∞ 
+	 T3 + πθi dzk−1hθi,k−1(zk−1) dzkhθi,k|k−1(zk|zk−1) 
i=1 Ck−1	 −∞ 
×	 I(ak < Zk < bk)Eθi (Iﬁnal − Ik|Zk = zk), (4.25) 
where Iﬁnal is the information on termination of the group sequential test, assuming 
that the futility boundary is always applied, and the terms 
k−1 
T1 = kθ1 πθ1 Pθ1 {Z1 < b1, . . . , Zj−1 < bj−1, Zj ≥ bj}

j=1

k−1

T2 = k πθ3 Pθ3 {a1 < Z1 < b1, . . . , aj−1 < Zj−1 < bj−1, Zj ≤ aj }θ3 
j=1

3 k−1

T3 = πθi cθi Pθi {Z1 ∈ C1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj or Zj ≥ bj}Ij 
i=1 j=1 
3 
+	 πθi cθi Pθi {Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1}Ik

i=1

do not depend on the critical values at analysis k. 
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We shall now derive some properties that can be used to further simplify (4.25). 
We can combine (4.23) and (4.24) to obtain 
hθ,k|k−1(zk|zk−1)hθ,k−1(zk−1) =  hθ,k|k−1(zk|zk−1)hθ,k−1(zk−1) 
= fθ,k(zk)hθ,k−1|k(zk−1|zk) 
= fθ,k(zk)hk−1|k(zk−1|zk). (4.26) 
We will now use the conditional probabilities 
pkc(zk) =  P (Z1 ∈ C1, . . . , Zk−1 ∈ Ck−1|Zk = zk) (4.27) 
pkb(zk) =  P (Z1 ∈ B1, . . . , Zk−1 ∈ Bk−1|Zk = zk), (4.28) 
which for the same reason as hk−1|k(zk−1|zk) in (4.23) are independent of θ. Finally 
we will use that 
πθi fθi,k(zk)fk(zk)πθi fθi,k(zk) =  fk(zk)
= π(k)(θi|zk)fk(zk), (4.29) 
where π(k)(θi|zk) denotes the density of the posterior distribution of θi given Zk = zk 
and consequently, the last equality follows from Bayes theorem. By combining (4.26), 
(4.27) and (4.29), it follows that for any function g(zk), ∫ ∫ ∞ 
πθ1 dzk−1hθ1,k−1(zk−1) dzkhθ1,k|k−1(zk|zk−1)g(zk) 
Bk−1 −∞ ∫ ∞ ∫ 
= πθ1 dzkfθ1,k(zk)g(zk) dzk−1hk−1|k(zk−1|zk) 
−∞ Bk−1 ∫ ∞ ∫ 
= dzkfk(zk)π(k)(θ1|zk)g(zk) dzk−1hk−1|k(zk−1|zk) 
−∞ Bk−1 ∫ ∞ 
= dzkfk(zk)π(k)(θ1|zk)g(zk)P (Z1 ∈ B1, . . . , Zk−1 ∈ Bk−1|Zk = zk) 
−∞ ∫ ∞ 
= dzkfk(zk)π(k)(θ1|zk)pkb(zk)g(zk) (4.30) −∞ 
and in the same way, for any function g(zk), that ∫ ∫ ∞ 
πθ3 dzk−1hθ3,k−1(zk−1) dzkfθ3,k(zk|zk−1)g(zk) 
Ck−1 −∞ ∫ ∞ 
= dzkfk(zk)π(k)(θ3|zk)pkc(zk)g(zk). (4.31) −∞ 
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Finally, we can now insert (4.30) and (4.31) into equation (4.25) to obtain

∫ ∞ 
T1 + T2 + T3 + dzkfk(zk) pkb(zk)kθ1 π
(k)(θ1|zk) I(zk ≥ bk 
−∞ 
+ (I(zk ≤ ak) +  I(ak < zk < bk))Pθ1 (Zj ≥ bj for some j = k + 1, . . . ,K|Zk = zk) 
+ pkc(zk)kθ3 π
(k)(θ3|zk) I(zk ≤ ak) +  I(ak < zk < bk) 
× Pθ3 (Zk+1 ∈ Ck+1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj , for some j = k + 1, . . . ,K|Zk = zk) 
3	 }} 
+	 I(ak < Zk < bk)pkc(zk) π
(k)(θi)|zk)Eθi (Iﬁnal − Ik)|Zk = zk) . (4.32) 
i=1 
We now consider Zk = zk and in which zone zk should be put, in order for (4.32) 
to be minimised. It follows from the deﬁnition of T1, T2 and T3 that these terms 
are not aﬀected by the critical values at analysis k, so they can be disregarded. By 
comparing the terms multiplying the indicator functions I(zk ≤ ak), I(zk ≥ bk) and  
I(ak < zk < bk), we ﬁnd the following: 
If we put zk in the futility zone, the expected additional cost incurred is proportional 
to 
pkb(zk)kθ1 π
(k)(θ1|zk)Pθ1 (Zj ≥ bj for some j = k + 1, . . . ,K|Zk = zk) 
+ pkc(zk)kθ3 π
(k)(θ3|zk).	 (4.33) 
If we put zk in the continuation zone, the expected additional cost incurred is 
proportional to 
pkc(zk)kθ3 π
(k)(θ3|zk) 
× Pθ3 (Zk+1 ∈ Ck+1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj , for some j = k + 1, . . . ,K|Zk = zk) 
+ pkb(zk)kθ1 π
(k)(θ1|zk)Pθ1 (Zj ≥ bj for some j = k + 1, . . . ,K|Zk = zk) 
3 
+	 pkc(zk) π
(k)(θi|zk)Eθi (Iﬁnal − Ik)|Zk = zk). (4.34) 
i=1 
If we put zk in the eﬃcacy zone, the expected additional cost incurred is proportional 
to 
pkb(zk)kθ1 π
(k)(θ1|zk).	 (4.35) 
It is intuitive to expect that the optimal solution is for zk to be in the futility zone 
for the lowest values, the continuation zone for intermediate values, and in the eﬃcacy 
zone for high values. In this case these deﬁnitions agree with the form of boundary 
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speciﬁed and the same ak and bk values are ideal for all zk. In fact, this is what we have 
found for all the cases that we have considered. The critical value ak can then be found 
as the root of zk where (4.33) equals (4.34) and bk as the root of zk where (4.34) equals 
(4.35). Further details for how this can be achieved are discussed in Section 4.6.4. 
4.6.3 Finding the optimal critical values at all analyses 
In Section 4.6.2 we showed how to ﬁnd the critical values ak and bk by assuming the 
critical values at all other analyses to be known. Mathematically, the knowledge gained 
in Section 4.6.2 can be expressed in terms of functions φk and ψk. We  have  
ak = φk(a1, b1, . . . , ak−1, bk−1, ak+1, bk+1, . . . , aK , bK ) 
and 
bk = ψk(a1, b1, . . . , ak−1, bk−1, ak+1, bk+1, . . . , aK , bK ) 
where aK is added for notational convenience and is equal to bK . By assuming starting 
values 
{a(0), b(0)}K−1 = a(0), b(0), . . . , a(0) , b(0) 1 1 1 K−1 K−1, 
(1)we can ﬁnd the optimal solution bK at analysis K, for a given set of starting values 
{a(0), b(0)}K−1 . The optimal decision rule at analysis K − 1 can thereafter be found 1 
using {a, b}K−2, as well as  the  solution  b(1) that was just derived. For general k, the  0 K 
critical values are found using {a(0), b(0)}k−1 and {a(1), b(1)}K . This procedure can be 1 k+1
used iteratively to create a sequence of solutions 
(1), b(1)}K{a 1 , . . . , {a(m), b(m)}K .1 
For each iteration, we can improve on the previous solution. At iteration i we have 
a
(i) = φ({a(i−1), b(i−1)}k−1 , {a(i), b(i)}K )k 1 k+1
and 
b
(i) = ψ({a(i−1), b(i−1)}k−1 , {a(i), b(i)}K ).k 1 k+1
When 
K ( ) 
(ak 
(i+1) − ak (i))2 + (bk (i+1) − bk (i))2 < ,  
k=1 
where  ≈ 10−6 , we consider the method to have converged. This typically happens 
after fewer than ten iterations. In principle there is a risk that the method has 
not converged to a global minimum, but we have not found any such problems. In 
Section 4.6.4 we will discuss sensitivity checks that can be performed to assess further 
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whether the solution could be improved upon. 
To solve the more general problem of ﬁnding the optimal solution a1, b1, . . . , aK , bK , 
we had to calculate the conditional probabilities in equations (4.27) and (4.28). These 
calculations require knowledge of critical values at earlier interim analyses that are 
unknown, which is why we need to assume starting values and use the iterative 
procedure. All of this is done assuming a set of starting points {a(0), b(0)}K−1. We  1 
know from Barber and Jennison (2002) how to ﬁnd the optimal boundary when the 
futility boundary is binding. When solving our problem with a non-binding futility 
boundary, we have found it convenient to use the critical values of the solution to the 
corresponding binding problem as starting values. 
4.6.4 Implementation and sensitivity checks 
When implementing this method computationally, it is useful to deﬁne and store the 
expected cost of setting zk in the futility zone, eﬃcacy zone or continuation zone. It 
is clear from (4.32) that the conditional probabilities, pkc(zk) in (4.27) and pkb(zk) in  
(4.28), are needed to derive the optimal decision rule at each stage. As knowledge about 
the critical values a1, b1, . . . , ak−1, bk−1 at previous analyses are needed to calculate 
pkc(zk) and  pkb(zk), it is not obvious that it would be beneﬁcial to start by ﬁnding the 
optimal decision at analysis K. One could in principle start by deriving the critical 
values at any analysis k, conditional on some assumed starting values for the critical 
values at other analyses. We have nevertheless found it convenient to start at the ﬁnal 
analysis and work backwards. 
We calculate pkc(zk) and  pkb(zk) through a forward calculation, storing the sub-
densities at each analysis on a grid of values for zk. We are typically interested in the 
ratio pkc(zk)/pkb(zk), which does not depend on θ. So this calculation can be done 
for any value of θ, θ = 0 say. When it is necessary to calculate pkc(zk)/pkb(zk) for  a  
speciﬁc Zk = zk that was not included in the grid, we can make use of the sub-densities 
that have been stored and only have to calculate the transition from analysis k − 1 to  
analysis k. 
We have described a method to ﬁnd the optimal decision rule. It has been found, 
in all cases, to satisfy the natural property that for k = 1, . . . ,K  − 1, there is an 
interval (−∞, ak] where it is optimal to put zk in the futility zone, followed by an 
interval (ak, bk) where it is optimal to put zk in the continuation zone, and that ﬁnally 
there is an interval [bk,∞) where it is optimal to put zk in the eﬃcacy zone. This 
appears to be a reasonable assumption, but one might ask if another pattern could 
be possible. Numerical checks have been built into our computer program to assess 
whether this is the case, but no examples that violate these assumptions have been 
found. 
We start by assuming starting values for {a(0), b(0)}K−1, so that the root bK at1 
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the ﬁnal analysis can be calculated. The other critical values can thereafter be 
calculated recursively, working backwards from analysis K−1: at analysis k we use the 
stage k+ 1 critical values, the functions pkc(zk) and  pkb(zk) calculated for the starting 
values as well as the expected costs of setting zk+1 in the futility zone, continuation 
zone or eﬃcacy zone, previously calculated on a grid of zk+1 values. To cope with 
discontinuities, the points ak+1 and bk+1 are added to the grid. 
The integrals in (4.32) can be calculated by numerical integration using Simpson’s 
rule. At each analysis k, the roots where equation (4.33) equals equation (4.34) and 
where equation (4.34) equals equation (4.35), are found by a numerical search, and 
these two roots deﬁne the stopping boundaries. When searching for a root, bk say, we 
make use of the grid for zk that is available from the numerical integration. The root 
bk is found by searching for when the expression 
pkc(zk)kθ3 π
(k)(θ3|zk) 
× Pθ3 (Zk+1 ∈ Ck+1, . . . , Zj−1 ∈ Cj−1, Zj ≤ aj , for some j = k + 1, . . . ,K|Zk = zk) 
+ pkb(zk)kθ1 π
(k)(θ1|zk)Pθ1 (Zj ≥ bj for some j = k + 1, . . . ,K|Zk = zk) 
3 
+ pkc(zk) π
(k)(θi|zk)Eθi (Ifinal  − Ik)|Zk = zk) 
i=1 
− pkb(zk)kθ1 π(k)(θ1|zk) (4.36) 
changes value between two grid points. We then perform a numerical search for the 
root where (4.36) equals zero. Other grid points are found in a similar way. 
We are relying on starting values and an iterative procedure to ﬁnd our optimal 
solution. It is then important to perform sensitivity checks and assess the robustness of 
our results. One sensitivity check that has been performed is to solve the unconstrained 
decision problem by performing a direct numerical search over the set of boundary 
points, using the simplex method of Nelder and Mead (1965). Our experience is that 
for reasonable starting values, the direct search method typically ﬁnds the same solution 
as our method. Another sensitivity check has been performed by using the solution 
derived in Section 4.6.2 as starting value and applying the direct numerical search to 
see if an improvement is possible. In no case has the direct search method provided a 
solution that improves on our optimisation method. 
We have now outlined the general principles for ﬁnding the critical values 
a1, b1, . . . , aK , bK that solve the unconstrained Bayes decision problem deﬁned in (4.18), 
given ﬁxed costs kθ1 and kθ3 . It remains to perform a search for the costs kθ1 and kθ3 
that give the desired error probabilities α and β. The standard Lagrangian argument 
then implies that our optimal solution minimises F˜ among all rules satisfying the same 
constraints. 
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Joint planning of phase II and phase III 
5.1 Introduction 
The problems considered in previous chapters all deal with the design of separate trials. 
In this chapter we move beyond the individual trial and consider the joint planning 
of phase II and phase III trials. We consider how to approach the design of both 
stages, with a focus on what one stage contributes to the design of the other. We 
deﬁne a utility function that includes a reward if regulatory approval is achieved after 
phase III, and the costs of the phase II and phase III trials. The objective is to design 
one phase II trial and one phase III trial, in a way that maximises the expected utility. 
The phase II trial is assumed to be a ﬁxed sample trial, while the phase III trial will 
be either a ﬁxed sample trial or group sequential. We shall be focusing on two-arm 
phase II trials comparing one experimental drug and a control, thus not addressing the 
issue of dose-ﬁnding. 
We assume that diﬀerent endpoints are used in phase II and phase III. The 
relationship between the means of the phase II and phase III endpoints is modelled 
within a Bayesian framework. As phase III trials are typically more expensive and 
complex to run, it is natural to consider the role of phase II as a possibility to choose 
which drugs are really worth this investment, and which should be discontinued. This 
is likely to be of particular value if the information gathered in phase II can be obtained 
more cheaply and in a shorter time frame, while still being able to predict the phase III 
outcome with adequate accuracy. 
While the design of phase II and phase III clinical trials has attracted a lot of 
interest in the statistical literature, most publications primarily focus on one of the 
phases. Schoenfeld (1980) provides statistical considerations for phase II trials, with 
a particular focus on applications in oncology. He emphasises that the decision rule 
for progress to phase III should be speciﬁed in the study protocol and taken into 
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account when deciding the phase II sample size. Whitehead (1985) discusses the role 
of the phase II trial in a clinical development programme. He considers the situation 
where several treatments are tested in phase II, and one of these is selected to progress 
to phase III. Taking the phase III sample size as ﬁxed, Stallard (1998) uses explicit 
cost and gain functions to derive optimal group sequential phase II designs for binary 
outcomes. This method is generalised by Stallard et al. (1999), to consider both eﬃcacy 
and toxicity. A good overview about diﬀerent approaches to the design of phase II trials 
is given by Stallard et al. (2001). 
Other publications take the design of phase II as given, but discuss how to use the 
results in phase II to guide the design of phase III. Wang et al. (2006) consider the 
problem of choosing sample size for phase III based on phase II data, when the same 
endpoint is used in the two phases. They note that simply assuming that the treatment 
eﬀect in phase III is equal to the point estimate of the treatment eﬀect in phase II may 
be too optimistic. Instead, it is advocated to take a more conservative approach. One 
possibility that is mentioned by Wang et al. (2006) is to use the point estimate of the 
treatment eﬀect minus one standard error, as the treatment eﬀect in the sample size 
calculation for the new trial. Pezeshk et al. (2009) focus on how to design phase III 
using a mixed Bayesian and frequentist approach. They consider the design of a single 
phase III trial and assume that the treatment eﬀect has a certain prior distribution. 
They do not discuss the design of phase II but the prior distribution for the phase III 
treatment eﬀect can be thought of as being derived after incorporating the phase II 
results. A frequentist hypothesis test is performed at the end of phase III. 
A more holistic approach is taken in so-called seamless phase II/III trials, where 
data from phase II and phase III are combined in the ﬁnal analysis. Diﬀerent approaches 
for how to design such trials have been proposed by Bauer and Kieser (1999) and 
Stallard and Todd (2003), among others. The papers by Bretz et al. (2006) and 
Schmidli et al. (2006) describe a method for data combination that is based on the 
p-value combination tests of Bauer and Ko¨hne (1994). The latter of the two papers 
also includes practical considerations for how the method can be applied in practice. 
The duration of phase II trials is often too short to be able to observe the long-term 
clinical endpoint at the end of the trial. Jenkins et al. (2011) give an example of how 
long-term follow-up data for the phase II patients can be combined with the phase III 
data, despite not being available at the end of phase II. They ensure control of the 
type I error rate by using the combination rule of Bauer and Ko¨hne (1994), and letting 
the long-term follow-up of the phase II subjects contribute to the stage 1 p-value. A 
diﬀerent approach is used by Stallard (2010), who suggests controlling the type I error 
by adjusting the group sequential boundary in the conﬁrmatory phase. 
We shall however focus on the more conventional situation, where data from 
diﬀerent phases are not combined in the ﬁnal analysis. It is then only the phase III 
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data that contribute to the ﬁnal hypothesis test in phase III. Whitehead (1986) and 
Antonijevic et al. (2010), among others, consider the joint planning of phase II and 
phase III in this situation. Whitehead (1986) provides an integrated approach to 
phases II and III in the situation where several treatments are available in phase II. 
Several choices of phase III sample size are considered, but the phase III sample size 
is not optimised. Antonijevic et al. (2010) discuss how dose selection strategies in 
phase II aﬀect the probability of success in phase III. While the phase III sample 
size is held ﬁxed, diﬀerent choices for phase II sample size are compared. Our model 
diﬀers from Whitehead (1986) and Antonijevic et al. (2010) in that the sample sizes 
for both phase II and phase III are optimised. Furthermore, we consider the possibility 
of running a group sequential design in phase III, and investigate how this impacts the 
phase II sample size. 
In this chapter we shall consider the joint planning of one phase II trial and one 
phase III trial, comparing a single treatment to a control in both trials. We seek to 
optimise the phase II and phase III sample sizes, n2 and n3. In two-arm phase II clinical 
trials, comparing an experimental drug to a control, the most important decision is 
arguably whether to progress the drug under investigation to phase III. In addition, 
the phase II results may help to guide the design of phase III. Hence, we shall also 
consider how to ﬁnd an optimal decision rule for the go/no go decision, and how to 
choose the phase III sample size, based on phase II data. We will start by assuming 
ﬁxed sample trials in both phase II and phase III, but later move on to consider the 
possibility of a group sequential phase III trial. 
In Section 5.2, we describe the Bayesian framework that is used in this chapter. 
Section 5.2 is also where the expected utility that we seek to maximise is deﬁned. 
Thereafter, the optimisation of phase II, for a given phase III design, is studied in 
Section 5.3. In Section 5.4 it is shown how the concept of optimally purchasing 
information can be applied, for example to guide a decision about which biomarker 
to use in phase II. In Section 5.5 we discuss the joint optimisation of both phases, 
including the case when phase III is group sequential. A numerical example is provided 
in Section 5.6, while discussion and conclusions are provided in Section 5.7. Finally, 
further details of how the model is derived and implemented numerically are given in 
Section 5.8. 
5.2 Model 
5.2.1 Introduction 
As we are interested in designing a phase II trial in which the endpoint is diﬀerent 
from that measured in phase III, we need a model for how the phase II and phase III 
outcomes relate to each other. Hence, this section starts with a short discussion about 
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diﬀerent types of endpoints and their use in drug development. Thereafter, we present 
the deﬁnition of our model and discuss what is required for regulatory approval. Finally, 
the costs of conducting the trials and the gain from obtaining regulatory approval are 
introduced and brought together into a formula. This formula deﬁnes the expected 
utility that we seek to optimise. 
5.2.2 Biomarkers, surrogate endpoints and clinical endpoints 
Lesko and Atkinson (2001) give a comprehensive overview of biomarkers and surrogate 
endpoints. They deﬁne a biomarker as a physical sign or laboratory measurement 
that occurs in association with a pathological process and that has putative diagnostic 
and/or prognostic utility. A surrogate endpoint is, according to the same authors, a 
biomarker that is intended to serve as a substitute for a clinically meaningful endpoint 
and is expected to predict the eﬀect of a therapeutic intervention. Finally, a clinical 
endpoint is deﬁned as a clinically meaningful measure of how a patient feels, functions 
or survives. 
According to the deﬁnitions of Lesko and Atkinson (2001), a biomarker is a 
surrogate endpoint only if certain criteria are met. These criteria vary between 
diﬀerent authors, but the rather restrictive deﬁnition of Prentice (1989) is one that 
is frequently cited. Prentice (1989) requires that the endpoint is correlated with the 
true clinical outcome in individual subjects. In addition, the surrogate endpoint should 
capture the net eﬀect of the treatment on the clinical endpoint so that ﬁnding a 
treatment eﬀect, relative to placebo say, on the surrogate endpoint implies a strong 
likelihood of a treatment eﬀect on the clinical endpoint. Fleming and DeMets (1996) 
describe situations where the latter condition does not apply and how this has led 
to disappointing results once the long term eﬀect on the clinical endpoint could be 
evaluated in clinical trials. The view expressed by ICH (1998) reﬂects the importance 
of the issues raised by Prentice (1989) and Fleming and DeMets (1996). ICH (1998) 
recommends the following criteria for establishing the strength of evidence for an 
endpoint to act as a surrogate: 
•	 biological plausibility of the relationship, 
•	 the demonstration in epidemiological studies of the prognostic value of the 
surrogate endpoint, 
•	 evidence from clinical trials that treatment eﬀects on the surrogate correspond 
to eﬀects on the clinical outcome. 
If a surrogate endpoint is well established, it may no longer be necessary to 
demonstrate eﬃcacy for the clinical endpoint in conﬁrmatory phase III trials. This is 
the case for conditions such as hypertension and hypercholesterolemia, where regulatory 
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authorities have typically accepted the use of reduction in blood pressure or LDL-
cholesterol respectively, as surrogate endpoints. When a surrogate endpoint replaces 
the clinical endpoint as the primary endpoint in phase III, it is sometimes the case 
that the eﬀect on clinical endpoints such as death, myocardial infarction and stroke are 
studied in phase IV trials, carried out after regulatory approval. 
For conditions where the regulatory authorities approve drugs only if eﬃcacy on 
the long-term clinical endpoint has been demonstrated, biomarkers still have a role to 
play. As we have already pointed out, it may be very costly and time-consuming to 
measure the clinical endpoint in phase II. We will in this chapter study, among other 
things, when it could be beneﬁcial to study a biomarker in phase II. The option of 
using the biomarker in phase II may be particularly appealing if the response can be 
obtained within a short time frame and is less costly to measure. 
5.2.3 Model for phase II and phase III 
Suppose that the variable X is measured in a phase II clinical trial, with n2 
patients randomised to each of the treatment groups A and B. The observations 
are conditionally independent given θ2B and θ2A and normally distributed with 
XAi ∼ N(θ2A, σ22) and  XBi ∼ N(θ2B , σ22), where the common variance σ22 is known. 
The parameter of interest in the phase II trial is θ2 = θ2B − θ2A. Learning  about  
θ2 can be beneﬁcial if the knowledge gained can be translated into information about 
the clinical endpoint Y , measured in phase III. In the phase III trial with treatment 
groups A and B, there  are  n3 observations per group that are conditionally independent 
given θ3B and θ3A and normally distributed according to YAi ∼ N(θ3A, σ32) and  
YBi ∼ N(θ3B , σ32), with known common variance σ32 . At the end of phase III, we 
are interested in testing the null hypothesis θ3 = θ3B − θ3A ≤ 0. Hence, it is important 
to know how θ2 relates to θ3, when evaluating diﬀerent options for how to design 
phase II. The joint prior distribution of (θ2, θ3) is assumed to be multivariate normal 
according to 
t2 rt1τ1(θ2, θ3) ∼ N (m1, μ1), 1 , (5.1) 
rt1τ1 τ1
2 
where m1 and μ1 are the prior means and t21 and τ1
2 the prior variances, of θ2 and θ3 
respectively. The correlation between θ2 and θ3 is denoted r and plays an important 
role in our model. If (5.1) holds, the conditional distribution 
(θ3|θ2) ∼ N(C + Dθ2, τ2) (5.2) 
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is obtained, where C = μ1 −rm1τ1/t1, D = rτ1/t1 and τ 2 = (1−r2)τ12. The correlation 
r thus determines to what degree the uncertainty of θ3 can be reduced by learning 
about θ2. 
After the phase II trial, we are interested in updating the prior distribution with 
the new information obtained from the phase II trial. Let us ﬁrst deﬁne 
Z2 = X¯ n2 n2/(2σ2
2), 
where X¯ n2 = X¯ B − X¯ A is based on n2 observations per treatment group. We make the 
modelling assumption that Z2 is conditionally independent of θ3 given θ2, so for  the  
pdf of Z2 given θ2 and θ3 we have 
fZ2|θ2,θ3 (z2|θ2, θ3) =  fZ2|θ2 (z2|θ2), (5.3) 
where 
Z2|θ2 ∼ N(θ2 n2/(2σ2), 1).2 
Once the phase II results are available, we can given Z2 = z2 calculate the posterior 
distribution of θ2. As shown in standard textbooks about Bayesian Statistics, such as 
the book by Gelman et al. (2004), it follows a normal distribution according to 
θ2|Z2 = z2 ∼ N(m2, t2),2
where the mean m2 and the variance t22 can be  written as  
m1/t
2 + ¯ n2/(2σ2) m1/t2 n2/(2σ2) 
m2 = 1/t
1
2
1 + 
x
n
n
2
2 
/(2σ2
2) 
2 =
1/t
1 
2
1 
+
+ 
z2 
n2/(2σ2
2) 
2 , (5.4) 
t2
2 = (1/t21 + n2/(2σ2
2))−1 . (5.5) 
No observations of the phase III endpoint are observed in phase II, but we would still 
like to update the prior distribution of θ3 with the results for the phase II endpoint X. 
If follows immediately from (5.3) that 
πθ3|θ2,Z2 (θ3|θ2, z2) =  πθ3|θ2 (θ3|θ2), (5.6) 
since θ3 is conditionally independent of Z2 given θ2. We show in Section 5.8.1 that (5.6) 
in combination with (5.2) can be used to ﬁnd the posterior distribution for θ3 after 
phase II. It is normally distributed according to 
θ3|Z2 = z2 ∼ N(μ2, τ  2), (5.7)2 
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where the mean μ2 and the variance τ2
2 can be written as 
μ2 = μ2(n2, z2) =  C + Dm2 (5.8) 
τ2
2 = τ2
2(n2) =  τ 
2 + D2t22. (5.9) 
After phase II, the phase III sample size n3 can in the most general version of our 
model be chosen based on the observed value of Z2 and the phase II sample size n2. 
The phase III sample size is then a function of Z2 = z2 and n2, so when appropriate 
we shall write n3(z2, n2) to make this explicitly clear. In phase III, the standardised 
statistic 
Z3 = Y¯ n3 n3/(2σ3
2), (5.10) 
where Y¯ n3 = Y¯ B − Y¯ A is based on n3 observations per group, is compared against 
a critical  value  z1−α. We make the modelling assumption that Z3 is conditionally 
independent of θ2 given θ3 and Z2. Hence, for the probability density function of Z3 
given θ3, θ2 and z2, we  have  
fZ3|θ3,θ2,Z2 (z3|θ3, θ2, z2) =  fZ3|θ3,Z2 (z3|θ3, z2), (5.11) 
where the observed value of Z2 eﬀects the distribution of Z3 through n3. The  
distribution of Z3 given θ3 and Z2 = z2 is normal according to 
Z3|θ3, Z2 = z2 ∼ N(θ3 n3(z2, n2)/(2σ2), 1).3 
Since θ3 denotes the diﬀerence in means between the two treatment groups in phase III 
it is appropriate to plan phase III based on the posterior distribution of θ3 after phase II, 
given in equation (5.7). 
Figure 5-1 illustrates how t22 and τ2
2 decrease with increasing phase II sample size 
n2, for the case when r = 0.8, σ2
2 = 1,  t1
2 = 0.04 and τ1
2 = 0.04. By running a large 
enough phase II trial, the uncertainty about θ2 can be completely eliminated. The 
prior variance of θ3 can however only be reduced from τ1
2 to a minimum of (1 − r2)τ12 , 
achieved as n2 →∞. We  see  that  r2 appears in the expression for the posterior variance 
of θ3 after phase II. In the remainder of this chapter we shall focus on correlations that 
are positive, i.e. r ∈ [0, 1]. We note however that biomarkers with correlation −r would 
be just as useful in reducing the posterior variance as biomarkers with correlation of r. 
Yin (2002) models the phase II and phase III outcomes in a Bayesian framework 
that bears similarities with our model. One diﬀerence between Yin’s model and ours is 
that we consider the joint optimisation of the sample sizes to be used in phase II and 
phase III. In Yin’s model, the focus is on the sample size of the phase II trial, while 
the phase III sample size is taken as ﬁxed. Another diﬀerence is that in the model of 
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Figure 5-1: Posterior variance of θ (dashed line) and θ2 (dot-dashed line) after phase II, 3
when r = 0.8, σ22 = 1,  t21 = 0.04 and τ21 = 0.04. The solid horizontal line shows τ2 = (1  − r2)τ21 . 
Yin (2002), the long-term phase III outcome depends on the short-term outcome in 
phase III on a patient level. The uncertainty of the short-term outcome in phase III 
and its relationship with the short-term outcome in the phase II trial is expressed in 
a Bayesian model, which is updated after the phase II trial. Inoue et al. (2002) and 
Todd and Stallard (2005) also consider a change of endpoint between the two stages, 
in the context of seamless phase II/III designs. 
5.2.4 Requirements for regulatory approval 
Two independent phase III trials, each with a statistically signiﬁcant result, typically 
p < 0.025 one-sided, are often required for regulatory approval. This requirement 
is sometimes referred to as the two trials rule. Senn (1997) and Bauer (2003) have 
commented on the fact that one phase III trial with a one-sided type I error probability 
of α2 would give the same risk of an ineﬃcacious drug being approved, as applying the 
two trials rule with a one-sided type I error probability of α. Bauer (2003) also considers 
the increase in false-positive rate if two positive trials out of a total of three or four are 
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required. Senn (1997) argues that if the two trials rule is rigorously applied and fully 
taken into account at the planning stage, several aspects of drug development may have 
to change. Power may have to be set higher for individual trials, while the conduct of 
group sequential trials would also be aﬀected. 
Senn (1997) refers to the approach of focusing on one trial with a lower type I error, 
rather than the two trials rule, as the pooled trials rule. A solution that will be used in 
this paper is, instead of requiring two trials that both are signiﬁcant at the α = 0.025 
level, to focus on one trial with type I error probability α = 0.0005 < 0.0252. If  
α = 0.0252 is allowed for a one-sided test, it is reasonable to allow 2 × 0.0252 = 0.00125 
for a two-sided test. For a two-sided test, 0.00125 can be suitably rounded downwards 
to 0.001, which would give us 0.0005 for a one-sided test. In practice there should be 
very little diﬀerence between using a type I error probability of 0.0005 and 0.000625. 
Considering only one trial makes it easier to account for potential savings with group 
sequential designs. Achieving a result that is statistically signiﬁcantly diﬀerent from 
control, at the 0.0005 level one-sided, will be the threshold for regulatory approval 
in our model. We do not make any requirement for safety, even though in practice a 
positive beneﬁt/risk assessment of the new drug would be required to obtain regulatory 
approval. 
It is important to note that our model of replacing two phase III trials with one 
phase III trial must be viewed as an approximation. Even though the type I error is 
adjusted to be the same for the two procedures, there are other diﬀerences that are 
worth mentioning. Consider the case with ﬁxed sample two-arm trials, either one trial 
with type I error probability α2 and n3 patients per group, or two trials, each with 
type I probability α and n3/2 patients per treatment group. It then follows from the 
Neyman-Pearson lemma that it must be more eﬃcient to base decisions on the suﬃcient 
statistic for the whole sample, rather than calculating separate statistics for the two 
independent trials and requiring Z ≥ z1−α for both of these sub-samples. 
Let us illustrate this point with a numerical example. For the two procedures to 
have the same power 1 − β at θ3 = δ, the two independent trials with type I error α √ 
must each have power 1 − β at θ3 = δ. Suppose that we have normal response with 
unit variance of the type described in Section 5.2.3, and that one phase III trial with 
type I error 0.0005 and 90% power at θ3 = 0.2 will be run. The sample size required for 
90% power at θ3 = 0.2 then  equals  n3 = 1046 per treatment group. If this sample size 
is instead equally divided between two independent trials, each with 523 patients per √ 
group, these trials would for type I error of 0.0005 each have 89% power at θ3 = 0.2, 
which gives about 79% probability of both trials achieving statistical signiﬁcance. It √ 
would of course be possible to increase the sample size so that each trial has power 0.9 
at θ3 = 0.2, to achieve an overall power of 90%, but such an approach would still be 
ineﬃcient compared to running one trial with n3 = 1046 patients per treatment group 
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and type I error probability 0.0005. 
5.2.5 Utility function 
An important step in decision analysis is to deﬁne a utility function. We shall be using 
a utility function that describes the monetary gain that can be obtained from the sales 
of a drug, while also taking into account the costs of running the clinical trials needed 
to get a drug approved. Our model thus takes the perspective of the trial sponsor, for 
example a pharmaceutical company, and seeks to maximise the expected proﬁts that 
the drug can deliver. It is however important to note that other views, such as the 
patient and public health perspectives, are also important. Burman et al. (2007) point 
out that ethics must be given priority over proﬁt, and several authors have proposed 
to optimise utilities that are not based on monetary gain. When solving the problem 
of optimising the phase III sample size for a given prior distribution for the treatment 
eﬀect, Gittins and Pezeshk (2000b) consider both a public health beneﬁt function, and 
a gain function based on future sales of the drug. The public health beneﬁt function 
is assumed to be proportional to the treatment eﬀect, θ3 in our notation. Anscombe 
(1963) introduced the so-called horizon problem, where the results of a clinical trial are 
used to select one of two treatments, that will be used to treat M future patients with 
the same condition. Here, the objective is to minimise the expected number of patients 
that are treated with the inferior drug, taking into account both the patients treated 
in the trial and future patients. Eales and Jennison (1992) studied this problem in the 
context of a group sequential test. Let E(N) be the expected number of patients who 
receive the inferior treatment in the group sequential trial. The expected number of 
patients who receive the inferior treatment, either in the clinical trial or in the future, 
will then be E(N)+  peM , where  pe is the probability of choosing the wrong treatment 
for the future patients. The objective is to minimise the expected number of patients 
who receive the wrong treatment, taking into account both the patients in the clinical 
trial and future patients. 
The utility function in our Bayes problem includes a start-up cost a2 and a cost 
per patient c2 in the phase II trial, a start-up cost a3 and a cost per patient c3 in the 
phase III trial, and a gain g obtained for a statistically signiﬁcant result, p < 0.0005 
one-sided, in the phase III trial. We shall be focusing on a constant g in our numerical 
examples, while acknowledging that a more sophisticated model for g may be useful 
in some situations. A very natural extension, that will considered in Section 5.6, is 
to let g depend on the phase III sample size n3. It is then implicitly assumed that 
the duration of phase III increases with increasing n3, which gives a shorter remaining 
patent life once the drug is approved. Liu et al. (2004) consider this type of model to 
derive group sequential and adaptive designs for a phase III clinical trial. It would be 
straightforward to make a similar extension for phase II, and let g depend on both n2 
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and n3. In Section 5.8 we also discuss how the assumption that the gain function g is 
independent of θ3 and z3 can be relaxed. 
The process of designing our two trials can be outlined as follows. We ﬁrst design 
a two-arm phase II trial comparing a candidate drug to a control, with n2 patients per 
treatment group. Once the phase II results are available, a decision about whether to 
progress to phase III is made. We progress to phase III if z2 ≥ z2  and stop otherwise. 
If the candidate drug is progressed to phase III, the phase III sample size per group 
n3(z2, n2) is chosen based the phase II results. After phase III, regulatory approval is 
achieved if z3 ≥ z1−α. Given the threshold z1−α for regulatory approval, deﬁned in 
Section 5.2.4, and z2 
, the  value  of  Z2 that deﬁnes the go/no go decision, the utility of 
the clinical trial program can be written as 
U(n2, z2, n3, z3) =  −a21n2>0 − c2n2 + 1Z2≥z g1Z3≥z1−α − a3 − c3n3(n2, z2) , (5.12)2 
where n2 is the within-group sample size of the phase II trial and n3 is the within-
group sample size of the phase III trial. Taking the expectation of equation (5.12), the 
expected utility that we seek to maximise with respect to n2, n3 and z2 
 can, given our 
modelling assumptions in (5.3) and (5.11), be written as 
∫ ∞ ∫ ∞ ∫ ∞ ∫ ∞ 
E(U) =  dθ2dθ3dz2dz3πθ2,θ3 (θ2, θ3)fZ2|θ2 (z2|θ2) −∞ −∞ −∞ −∞ 
×fZ3|θ3,Z2 (z3|θ3, z2))U(n2, z2, n3(z2, n2), z3). (5.13) 
The unconditional probability of rejecting the null hypothesis θ3 ≤ 0, averaged over the 
prior distribution of the treatment eﬀect before phase III, is sometimes referred to as 
the assurance. As the pdf of Z3 depends on θ3, an integral over the prior distribution 
of θ3 before the phase III trial would generally be required to calculate the assurance. 
Suppose that conditional on Z2 = z2 and n2, the  posterior  for  θ3 after phase II, which 
is also the prior for θ3 before phase III, is normally distributed according to 
θ3 ∼ N(μ2(z2, n2), τ22(n2)). 
O’Hagan et al. (2005) show that the assurance can be written as 
∫ ∞ ∫ ∞ 
γ(z2, n2, n3) =  dz3 dθ3π (θ3|z2)fZ3|θ3,Z2 (z3|θ3, z2)θ3|Z2 
z1−α −∞ 
μ2(z2, n2) n3(z2, n2)/(2σ3
2) − z1−α= Φ  √ . (5.14)
1 +  n3(z2, n2)τ2
2(n2)/(2σ3
2) 
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In Section 5.8.1 we show how this expression for the assurance γ can be used to 
simplify (5.13) to obtain 
∫ ∞ 
E(U) =  −a21n2>0 − c2n2 + dz2fZ2 (z2) 
z2 
×{γ(z2, n2, n3(z2, n2))g − a3 − c3n3(z2, n2)} , (5.15) 
where f (z2) =  
∫ ∞ 
dθ2π (θ2)fZ2|θ2 (z2|θ2) is  the  marginal  pdf of  Z2.Z2 −∞ θ2 
In practice, it can be diﬃcult to know which value of g to use in (5.15). One 
interpretation is that g is the expectation of a random variable G, which depends 
on many uncertain factors, such as unexpected safety problems of the drug that may 
prevent regulatory approval, or the number of competitor drugs that will be on the 
market if the drug is approved. Suppose that the trial sponsor’s prior beliefs about 
these uncertain factors can be expressed as prior distributions. The expected value of 
G can then be obtained by integrating over these prior distributions. Let us illustrate 
how this could be done with a very simple example. Assume that the prior belief is 
that independently of the treatment eﬀect, a safety problem that prevents regulatory 
approval will occur with probability 0.1. Suppose that g = M would be  used  in the  
expression for the expected utility, if the prior probability of a safety problem were 
zero. If the prior probability of a safety problem is 0.1 instead of zero, it is appropriate 
to replace g = M with g = 0.9M . 
We consider the design of one phase II trial and one phase III trial. The objective is 
to design these two trials in a way that maximises the expected utility deﬁned in (5.15). 
We thus seek to ﬁnd the optimal phase II sample size, n
2,  as well  as the  threshold,  z
2 , 
for the go/no go decision rule for progressing to phase III based on phase II data. It 
follows from equations (5.4) and (5.8) that μ2, the posterior mean of θ3 after phase II, 
is linear in z2. Hence, given prior information and phase II sample size, there is a 
one-to-one correspondence between z2 and μ2. Consequently, we shall sometimes be 
referring to the cut-oﬀ as μ
2, rather than z
2 . 
In some cases the model will be evaluated in the context of a ﬁxed phase III sample

size n3f. We shall however also consider ﬁnding n2 and μ when n3 is not taken to be 2 
ﬁxed, but is a function n3(z2, n2) of the phase II trial results. Derivation of how to 
optimally choose n3 is then also part of the optimisation procedure. In addition, we will 
discuss how the properties of the model change if phase III is made group sequential. 
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5.3	 Optimisation of phase II given ﬁxed sample phase III 
design 
5.3.1	 Basic assumptions 
In this section we consider the situation when the phase III sample size n3 is ﬁxed 
and the phase II sample size n2 is optimised given this phase III design. Although 
not a crucial assumption for the model to work, we consider trials with two treatment 
groups of equal size, in both phase II and phase III. All the sample sizes referred to are 
per-group sample sizes, so the total sample size will be 2n2 in the phase II trial and 
2n3 in the phase III trial. 
Two diﬀerent approaches to choosing a ﬁxed phase III sample size n3 will be 
considered in this section. In neither case is n3 allowed to depend on the results 
from phase II. The ﬁrst approach will be to assume that the phase III sample size takes 
a ﬁxed value  n3f. This value may be motivated by achieving a certain power at a given 
eﬀect size that is thought be of clinical relevance. There may also be other reasons 
for n3 taking a ﬁxed value, for example the requirement to collect a minimal amount 
of safety data. The second approach is to choose the phase III sample size n3
 
f that 
maximises the expected utility. This phase III sample size is optimal within the class 
of designs where the phase III sample size is not allowed to depend on the phase II 
results. 
It is clear that the phase II results will be available before starting the phase III 
trial. So one may ask if there is a practical reason to insist on searching for n 3f, 
without using the knowledge gained from the phase II data. One answer is that for 
planning purposes, it can be useful to have a phase III sample size in mind before the 
phase II results are available. With a working assumption about what the phase III 
sample size will be, planning for how to deal with issues such as patient recruitment 
and drug supply can start. There is also a theoretical interest in assessing the beneﬁt of 
adaptively choosing the phase III sample size based on phase II data. This assessment 
bears similarities with the comparison of adaptive and non-adaptive group sequential 
tests for superiority and non-inferiority, addressed in Chapter 2. We shall come back 
to this question in Section 5.5, where the phase III sample size is allowed to depend on 
phase II data. 
Even though the focus will be on general conclusions, it is useful to assume some 
numerical values for the diﬀerent parameters included in our model. We can without 
loss of generality set the within-group sample variances in both phase II and phase III 
to unity, so σ2
2 = σ3
2 = 1. For simplicity, we assume no start-up costs for now, 
i.e. a2 = a3 = 0. The three parameters c2, c3 and g, which all have the same 
unit, can be described by two degrees of freedom. We can write the expected utility 
as c3 × f(c2/c3, g/c3), so to maximise the expected utility it is enough to specify the 
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ratios c2/c3 and g/c3. Hence, we can without loss of generality set c3 = 1,  and  the  
expected utility will be displayed for this case in our numerical examples. The optimal 
choices of n2, n3 and z2 will however apply also for other choices of c3, provided that 
c2/c3 and g/c3 remain ﬁxed. 
It should be possible to determine c2/c3 with reasonable accuracy, while g/c3 may 
be more diﬃcult to estimate precisely. We shall assume a constant ratio g/c3 = 12000, 
so the proﬁt from a phase III trial is 12000 times the cost of one phase III subject per 
treatment arm. Our choice of g/c3 = 12000 is mainly for illustrative purposes. It would 
appear to be a reasonable assumption and lies within the range published by Gittins 
and Pezeshk (2000a), where Bayesian decision analysis is used to design phase III trials 
of six diﬀerent drug projects. In a practical situation it is important to consider the 
uncertainty around each parameter and perform sensitivity analyses, to assess how 
robust the model is to misspeciﬁcation of parameters, such as for example g/c3. 
5.3.2 Proportion of resources in phase II and phase III 
Let us now consider the problem of maximising the expected utility in (5.15), for the 
case when n3 is not allowed to depend on the phase II results. We seek to ﬁnd n2, 
both for the case when n3 = n3f and for n3 = n
3f. Let us ﬁrst consider the case when

n3f is not optimised, but is instead based on other considerations, for example power 
requirements. Suppose that for the condition that is being investigated, it is found 
appropriate to set power at a clinically relevant diﬀerence of θ3 = δ. To obtain 90% 
power at δ = 0.2, we set 
2σ2(Φ−1(1 − α) + Φ−1(1 − β))2 
n3f = 
3 
δ2 
= 1046. 
We further assume 
0.04 0.04r
(θ2, θ3) ∼ N (0, 0), , (5.16)
0.04r 0.04 
so that power is set one standard deviation, of the prior distribution of θ3, away  from  
the prior mean of θ3. The assumption of μ1 = 0 may be regarded as a bit pessimistic, in 
particular for comparisons against placebo. It is however an interesting case to study, 
as before phase II it is far from certain whether the drug will progress to phase III, and 
the phase II trial can play an important role in the go/no go decision. A more optimistic 
prior distribution for θ3 will be considered in Section 5.6. A prior distribution for θ3 
centred at μ1 = 0 may be particularly realistic in a development program where the 
experimental drug is compared to an active control. If superiority over the active control 
is required for regulatory approval, this ﬁts very nicely within our current framework. 
Our model could also handle the situation when establishing non-inferiority for a pre­
114

Chapter 5. Joint planning of phase II and phase III 
speciﬁed non-inferiority margin of δN is deemed suﬃcient. In the latter case, the null 
hypothesis for θ3 in phase III would be θ3 ≤ −δN , rather than θ3 ≤ 0. 
When evaluating the amount of resources spent in phase II and phase III 
respectively, it is natural to consider the sample size ratio n2/n3. Apart  from  the  
proportion of patients, it is also of interest to assess the relative costs of the two 
phases. Denote the investment in phase II by 
C2 = a2 + c2n2 
and the investment in phase III by 
C3 = a3 + c3n3. 
We deﬁne the phase II/phase III investment ratio as 
C2 a2 + n2c2 = . (5.17)
C3 a3 + n3c3 
Once we know the choices of phase II and phase III sample sizes, it is straightforward 
to calculate the investment and sample size ratio for diﬀerent choices of c2/c3. 
We have used the methods described in Section 5.8 to solve this decision problem, 
for both n3 = 1046 and n3 = n3
 
f. The problem has been solved for various values of the 
correlation r and three speciﬁc values of the ratio c2/c3, assuming g/c3 = 12000 and 
the prior distribution in equation (5.16). The optimal phase II and phase III sample 
sizes, sample size ratios and investment ratios are shown in Figure 5-2. The results are 
qualitatively similar for the two ways of choosing phase III sample size that have been 
considered. We see in Figure 5-2 that n 2 increases monotonically with increasing r. 
This is not surprising, as more information about θ3 is obtained for larger r. It  is  
perhaps less obvious that there would be a cut-oﬀ r, so  that  n 2 = 0  for  r < r
. The  
implication of the latter is that we would move directly to phase III, without ﬁrst 
running a phase II trial. The reason for this discontinuity in the choice of n2 will be 
further discussed in Section 5.4, where we focus on the value of information and the 
decisions that are based on the information gathered in phase II. 
In practice it can be diﬃcult to know which value to use for the correlation r in the 
prior distribution for θ2 and θ3. Figure 5-2 can however be used to give an assessment 
of whether a certain pair of planned sample sizes n2 and n3 seem reasonable. Suppose 
that c2/c3 can be estimated with reasonable accuracy. If c2/c3 ≥ 0.2, we can for 
example see that a plan with n2/n3 ≥ 0.4 does not make sense, unless the correlation 
between θ2 and θ3 is close to one. 
The case r = 1  and  c2 = c3 = 1, which can be observed in Figure 5-2, is of special 
interest as it can be interpreted as running a pre-study with the same endpoint that is 
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Figure 5-2: Optimal phase II and phase III sample sizes, sample size ratios and investment 
ratios for diﬀerent values of the correlation r and diﬀerent cost ratios c2/c3. In  the  three  panels  
to the left the phase III sample size is ﬁxed at n3 = 1046, while in the three panels to the right 
the phase III sample size is chosen to maximise the expected utility. The designs have been 
optimised for g/c3 = 12000 and prior distribution for (θ2, θ3) according to (5.16). 
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later used in phase III. The phase II observations are cheap and can provide information 
about θ3, so one may ask why the phase II sample size is not higher for r = 1.  The  
reason is that the phase II observations are not used in the ﬁnal hypothesis test in 
phase III. 
So why are some resources spent in phase II rather than phase III, when the 
observations in phase II are not included in the ﬁnal analysis? Another option would be 
to instead use these resources in phase III. The latter would appear to be advantageous, 
as the observations then can also contribute to increasing the power to reject the null 
hypothesis in the conﬁrmatory trial. The beneﬁt of the observations in phase II is that 
after phase II, you get a chance to stop development of drugs that do not appear to be 
eﬃcacious. Since phase III is a ﬁxed sample trial rather than group sequential, this is 
not possible in phase III. 
A ﬁnal observation is related to the seamless phase II/III trials that were brieﬂy 
discussed in Section 5.1. We said that we would not consider seamless phase II/III 
trials in this chapter, but note that such designs would be particularly advantageous if 
the same endpoints could be used in phase II and phase III. 
5.3.3 Sensitivity to speciﬁcation of gain function 
We have already mentioned that the gain g may be diﬃcult to establish with high 
accuracy and that in practical situations, it is important to assess how robust the 
proposed design is to uncertainties about g and the ratio g/c3. In  Figure  5-3  we  set  
c2/c3 = 0.2 and show how the investment in phase II and the resource allocation 
between phase II and phase III depend on g/c3. 
Let us ﬁrst consider the case when n3 is ﬁxed, based on power or other 
considerations, and does not change depending on g/c3. For small g/c3, the  case  for  
investing in phase II increases for increasing g/c3. But there comes a point when g/c3 
is so large that the phase II trial is unlikely to change the decision about whether to 
run the phase II trial. The phase II trial then becomes less important for the go/no go 
decision, as clearly illustrated in the curve for r = 0.7, where n
2 = 0 for large enough

g/c3. We would expect to eventually see the same behaviour for r = 0.8 and  r = 0.9, 
even though these cases are not shown in Figure 5-3. It might be expected that a 
small investment in phase II should help, as it saves the cost of phase III trials that 
are unlikely to give positive outcomes. For low enough Z2 = z2, the drug would not be 
progressed to phase III. But as g/c3 increases, the threshold z2 for progress to phase III

shifts in the negative direction, and the probability that phase II makes a diﬀerence 
gets smaller. 
The situation is diﬀerent for n3 3f when, as illustrated in the right panel of 
and n3f are monotonically increasing in g/c3. 
= n

Figure 5-3, n
 23f varies with g/c3. Both  n
For small g/c3, the phase II sample size initially increases more rapidly than n3. As  g/c3 
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Figure 5-3: Optimal phase II and phase III sample sizes and sample size ratios, for diﬀerent 
values of the correlation r and ratios g/c3. In the three panels to the left the phase III sample 
size is ﬁxed at n3 = 1046, while in the three panels to the right the phase III sample size is 
chosen to maximise the expected utility. The designs have been optimised for c2/c3 = 0.2 and  
prior distribution for (θ2, θ3) according to (5.16). 
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increases however, it becomes more important to allocate resources to the phase III trial

and ensure success there. The ratio n2/n3f thus increases initially, to a level of about 
0.25-0.3, but soon starts to increase. Unlike when n3 = 1046, the optimal phase II 
sample size does not go down to zero. We believe that this is because the investment 
in phase III continues to increase, with increasing g/c3. Even though the probability 
of not running phase III decreases, the associated cost of phase III is getting very high. 
The go/no go decision then becomes more important, which motivates an increasing 
investment in phase II. 
5.3.4 Choice of phase II sample size and impact on expected utility 
We have studied how the optimal phase II sample size
 n
2 depends on various

combinations of c2/c3, g/c3 and r, as well as diﬀerent ways of choosing the phase III 
sample size. Let us now consider an example of how the expected utility and probability 
of success (PoS) actually depend on the choice of phase II sample size. We choose to 
focus on r = 0.8 and  r = 0.45, as they represent two qualitatively diﬀerent cases. In 
the former, the biomarker can provide useful information about the phase III endpoint 
while in the latter, sampling in phase II is a rather ineﬃcient way of learning about 
θ3. We further assume g/c3 = 12000, c2/c3 = 0.2 and prior distribution according to 
equation (5.16). We shall refer to the case with 
g/c3 = 12000 
c2/c3 = 0.2 ( ( )) 
(θ2, θ3) ∼ N (0, 0), 0.04 
0.04r 
0.04r 
0.04 
(5.18) 
as our core example, and return to it at various points during this chapter. 
Let us ﬁrst consider our core example for the case when the correlation r = 0.8. The 
upper left panel of Figure 5-4 shows the expected utility for diﬀerent values of n2. When  
r = 0.8, running a phase II trial with sample size n2 = n
2 gives substantial beneﬁts,

compared to when n2 = 0. For the two diﬀerent ways of choosing n3f that we have 
considered, there is a value n
2 that maximises the expected utility. It is noteworthy

that the expected utility actually decreases slightly in n2 for very small n2, and reaches 
a local minimum before it starts to increase. There is then a second change in the sign 
of the ﬁrst derivative at the local maximum of our expected utility, which occurs at 
the optimal phase II sample size n
2. Compared to the option of not running a phase II

trial, shown by n2 = 0, there is a substantial beneﬁt in running a phase II trial with 
n2 = n2. 
The situation is diﬀerent when we consider another variation of our core example, 
with r = 0.45 instead of r = 0.8. For n3f = 1046 it is actually beneﬁcial to move 
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Figure 5-4: Expected utility and probability of success (PoS), conditional and unconditional 
on progress to phase III, for r = 0.8 (solid line), r = 0.45 (dashed line) and diﬀerent values 
of n2. The panels to the left show results for n3 = 1046 and the panels to the right show 
results for n3 = n3
 
f. The designs have been optimised for our core example, i.e. g/c3 = 12000, 
c2/c3 = 0.2 and prior distribution for (θ2, θ3) according to (5.16). 
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directly to phase III, i.e. setting n2 = 0. There is a local maximum for just under 60 
observations per treatment group, but the expected utility at this local maximum is 
smaller than for n2 = 0.  For  n3f = 1254, it is optimal to run a phase II trial with

just under 100 patients per treatment group. The impact of the phase II trial on the 
expected utility is however very modest, as illustrated in the dashed line in Figure 5-4. 
In fact, we believe the most important conclusion for r = 0.45 to be that it is not very 
helpful to run a phase II trial when the correlation is this low. 
Figure 5-4 also shows the probability of success, conditionally and unconditionally 
on progressing to phase III. For the cases that we have considered, there is typically an 
initial small decrease in the unconditional PoS, as some paths to a successful result 
in phase III are now stopped after the phase II trial. While the impact on the 
unconditional PoS is minor, there is a considerable increase in the PoS conditional 
on progressing to phase III. This increase is however much smaller for r = 0.45 than for 
r = 0.8. Given that the phase III sample size is not allowed to depend on the phase II 
results, the role of the phase II trial is to identify whether a treatment should be brought 
forward to phase III. As the probability of success in phase III is substantially increased, 
it would appear that for r = 0.8, the phase II trial is successful in identifying treatments 
that should not be brought forward. This should be reassuring to investigators and 
trial sponsors, who are keen to avoid costly failures at the last hurdle. 
5.3.5 Threshold for progress to phase III 
When phase II is not used to choose the phase III sample or for dose-ﬁnding, its main 
purpose is to enable a well informed go/no go decision. It is thus of interest to assess 
how μ
2, the minimum of the posterior mean of θ3 after phase II that is required for 
progress to phase III, depends on the other parameters in the model. Our decision rule

is to progress the drug to phase III if μ2 ≥ μ2 and stop development otherwise. It should

be recognised that in practice, many other aspects will have an impact on the go/no go 
decision. The size of the phase III investment, the degree to which other treatments for 
the condition exist and the safety proﬁle of the compound are examples of other features 
that are likely to be important, resulting in a multi-dimensional problem. Ideally, these 
additional features should be included in the model. Nevertheless, our simpliﬁed model 
provides a useful quantitative assessment of how to proceed. 
For a ﬁxed phase III sample size n3, we can use the assurance γ, as deﬁned by 
O’Hagan et al. (2005), to calculate μ
2. For the expected utility, conditional on Z2 = z2 
and n2, to be positive it is necessary that 
γg ≥ a3 + c3n3. 
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The limiting case, when the expected reward of running a phase III trial equals the 
cost, occurs when 
γ = 
a3 + c3n3 
.	 (5.19) 
g 
O’Hagan et al. (2005) show that if 
θ3|Z2 = z2 ∼ N(μ2, τ2),2 
the assurance γ can be calculated directly from the standard normal cumulative 
distribution function according to 
μ2 n3/(2σ3
2) − z1−α
γ = Φ  √ . 
1 +  n3τ2
2/(2σ3
2) 
The next step is to insert this expression for γ into (5.19) and solve for μ2. We  then  
ﬁnd that the threshold μ 2 must satisfy 
μ = 
z1−α − Φ−1(1 − (a3 √ + c3n3)/g) 1 +  n3τ22/(2σ32) (5.20)2 
n3/(2σ3
2) 
We would intuitively expect to progress only if μ2 is positive, but will now show that 
this property holds only if certain conditions apply. It follows from (5.20) that μ 2 = 0  
if and only if 
Φ−1(1 − (a3 + c3n3)/g) =  √ z1−α 
1 +  n3τ2
2/(2σ3
2) 
g	 1 ⇔	 = √ (5.21) 
a3 + c3n3 Φ(−z1−α/ 1 +  n3τ22/(2σ32)) 
If τ2
2 = 0, (5.21) holds when 
g 1 
= . 
a3 + c3n3 α 
In our model, with a one-sided type I error of 0.0005, a ratio g/(a3 +c3n3) ≥ 2000 would 
thus be necessary to obtain a negative threshold μ 2 in this case. Hence, n3 ≤ 6 would  
be required in our core example with g/c3 = 12000 and a3 = 0. This is re-assuring, as 
a trial with so few observations is unlikely to be convincing to regulatory authorities 
and the wider scientiﬁc community. 
Let us now consider the case τ2
2 > 0. For τ2
2 > 0, 
g 1 ≥ 
a3 + c3n3 α 
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is a suﬃcient but not a necessary condition for obtaining μ 2 < 0. In most practical 
situations we will have n3τ2
2 >> 2σ3
2, so  for  μ 2 to be positive we must have 
g 1 
< . 
a3 + c3n3 
The situation is diﬀerent from when τ2
2 = 0, as the probability mass for positive values 
of θ3 may make it worthwhile to run the phase III trial. 
In summary, we have shown that μ 2 can be found analytically when n3 is not allowed 
to depend on the phase II sample size. The threshold depends on the gain function 
g, the cost of the phase III trial, the prior distribution for θ3 before phase III and the 
threshold z1−α for regulatory approval. If the assumption that n3 is ﬁxed is relaxed, 
the threshold becomes smaller than if n3 is ﬁxed, as there are more options for how to 
design phase III. The situation when n3 is allowed to depend on the phase II results is 
further discussed in Section 5.5.2. 
5.4 The value of information 
5.4.1 Information about θ3 
Before moving on to the more complicated problem of optimising the phase III design 
based on phase II data, it may be useful to take a step back and think about the role 
of the phase II trial in our model. To this end, we will be following the framework 
described in Section 5.2.3. According to our model a certain investment is made in 
phase II, with the hope to gain information about the clinical endpoint used in phase III. 
Assuming a2 = 0,  we  invest  C2 = c2n2 in the phase II trial, where we wish to learn as 
much as possible about θ3, the mean of the phase III endpoint. Learning in phase II 
can be particularly beneﬁcial if the information is cheaper than purchasing the same 
information in phase III. The observations in phase II have the possibility to contribute 
to the go/no go decision before phase III, while the observations in phase III are used 
for the ﬁnal hypothesis test in phase III. 
Before phase II, θ3 has prior variance τ1
2, while after phase II the posterior variance 
of θ3 is denoted τ2
2 . It is deﬁned in equation (5.9) and can be written as 
τ2
2 = τ1
2(1 − r 2(1 − t22/t21)). 
Taking the posterior information as the inverse of the posterior variance of θ3, it  is  
natural to focus on the information gain 
α 
1 1 1 1 − = − . (5.22)
τ2 τ2 τ2(1 − r2(1 − t2/t2)) τ2 2 1 1 2 1 1 
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For a given phase II sample size n2, we can insert the expression for t22 in (5.5) into 
equation (5.22) to obtain 
1 1 r2(1 − t22/t21)− = 
τ2 τ2 τ2(1 − r2(1 − t2/t2))2 1 1 2 1
r2n2t1
2/(2σ2
2)
= 
τ1
2(1 + (1 − r2)n2t12/(2σ22)) 
= 
r2C2t1
2/(2σ2
2c2) 
, (5.23)
τ1
2(1 + (1 − r2)C2t21/(2σ22c2)) 
as a measure of the information about θ3 obtained due to the phase II trial. We see in 
(5.23) that if it were possible to sample a biomarker with r = 1, it would simplify to 
C2t
2
1/(2σ2
2τ1
2c2). The information about θ3 obtained from such a biomarker increases 
linearly in C2, as the term in the denominator that involves C2 disappears. Another 
beneﬁt with using the phase III endpoint in phase II would be that combining data from 
the two phases could be more easily accomplished. In many situations it is however 
rather unrealistic to have a biomarker whose mean has correlation r = 1  with  θ3. Even  
if it is possible to collect the phase III endpoint in phase II, there are likely to be other 
issues, such as diﬀerences in patient population, that give a correlation below one. A 
more realistic option may be to measure the same variable in phase II as in phase III, 
but with a much shorter follow-up time. The correlation will then be below one, but 
the need for a high correlation can be balanced with the time and cost of collecting the 
data. 
Equation (5.23) can be written as 
1 1 1 r2t21/(2σ2
2c2)− = . (5.24)
C2 τ2
2 τ1
2 τ1
2(1 + (1 − r2)C2t21/(2σ22c2)) 
We can interpret the left-hand side of equation (5.24) as the information obtained per 
unit cost. Initially, when C2 ≈ 0, the right-hand side of equation (5.24) is approximately 
r2t21/(2σ2
2c2) 
τ2 1 
If an investment of the same size is made in phase III, the information obtained per 
unit cost can be written as 
1 
2σ3
2c3 
. 
We can compare these two expressions to get an idea about the information gained 
per unit cost, depending on whether it is purchased in phase II or phase III. The two 
expressions are however not directly comparable, as the information obtained have 
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diﬀerent roles in our model. The information obtained in phase II can be used to make 
a decision about progression to phase III, but is not included in the ﬁnal hypothesis test 
in phase III. The role of the phase III observations is the opposite. They are included 
in the ﬁnal hypothesis test but, since phase III is a ﬁxed sample trial, cannot be used 
to make a decision to stop development of the drug. 
5.4.2 Choice of biomarker 
We continue to follow the framework described in Section 5.2.3 and further discussed 
in Section 5.4.1. Suppose that we are considering two biomarkers, with means θ21 and 
θ22 respectively, for potential use in a phase II clinical trial. In some situations, it may 
be possible to use both biomarkers, in which case it would be necessary to model the 
correlation structure between θ3, θ21 and θ22. We shall however consider the situation 
when one of the two biomarkers must be chosen, so for each biomarker we need to 
specify the parameters introduced in the model description in Section 5.2.3. Let θ21 
and θ22 have correlations r1 and r2 with θ3 respectively, where 0 < r1 < r2. The  
costs per observation are c21 and c22, with  c21 < c22. It is then far from obvious which 
biomarker will be more eﬃcient for learning about θ3, as  θ22 is more strongly correlated 
with θ3, while the cost per observation is lower for biomarker 1. Suppose θ21 and θ22 
are the means of the same variable, but measured after a diﬀerent follow-up time. It 
is then reasonable to expect that if θ22 represents the mean after a longer follow-up 
than θ21, it will be more costly to measure, but also more strongly correlated with θ3. 
So this is an example of a situation where it is not straightforward to choose which 
biomarker to use. 
When analysing which biomarker to use in the phase II trial, it is of interest to ﬁnd 
the levels of phase II investment, where one of the biomarkers is to be preferred over 
the other. Assume that θ21 and θ22 have prior variances t211 and t
2
12, while the response 
2 2variances are σ21 and σ22. It then follows from (5.23) that the two biomarkers give 
equal amount of information if 
2 2 2r1C2t11/(2c21σ21) 
τ2(1 + (1 − r2)C2t2 /(2c21σ2 ))1 1 11 21
2 2 2r2C2t21/(2c22σ22)= 2 2 2τ1
2(1 + (1 − r2)C2t21/(2c22σ22)) 
2(c 2 2 2 − c 2 2 2 ) ⇔ C2 = 0  or  C2 = C2  = 22
σ22r
2
1t12
2 2
21σ
2
21r2t11 . (5.25)
(r2 − r1)t11t12 
Solutions where C2 < 0 are of no interest, but the knowledge that learning about θ21 
delivers more information if 
0 < C2 < C2 
 
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provides some useful insights. For phase II investments smaller than C2 
 , θ21 will 
dominate, while for larger investments than C2 
 , θ22 is to be preferred. 
It is natural to ask how much cheaper biomarker 1 must be, to compensate for the 
fact that the mean of biomarker 2 is more strongly correlated with θ3. We  can  solve  
equation (5.25) for c21 to ﬁnd that running a phase II trial with biomarker 1 as opposed 
to biomarker 2, for a ﬁxed level of investment C2, gives more information about θ3 if 
2c22r1
2σ2
2t11
2 + C2t12
2 t11
2 (r1
2 − r22) c21 < 2 2 2 . (5.26)2r2σ1 t12 
The right hand side of the inequality in (5.26) thus depends linearly on C2, the  level  
of phase II investment. Since r1 < r2, the most favourable situation for biomarker 1 
occurs when C2 = 0. In the limit, as C2 → 0+, we ﬁnd that the increase in information 
is higher for θ21 only if 
2 2 2c21 r1t11σ22< 2 2 2 . (5.27) c22 r2t12σ21 
Unless (5.27) holds, we can directly dismiss a biomarker with a mean that is less strongly 
correlated with θ3, as the purchase of information will only become less favourable as 
C2 increases. As C2 →∞, we ﬁnd that biomarker 1 is more eﬃcient if 
2 2r r1 2

1 − r12 
>
1 − r22 
,

which for r1  2 = 1  and  r = 1 is equivalent to 
2 2 r1 > r2. 
If one of the biomarkers has correlation r = 1 and the other not, the biomarker with 
correlation r = 1 will be more eﬃcient as C2 → ∞. It remains to consider the case 
r1 = r2 = 1, in which case biomarker 1 is more eﬃcient as C2 →∞, if  
2 2c21σ21 c22σ22< . 
t2 t2 11 12 
Figure 5-5 shows the information obtained for θ3 for three diﬀerent biomarkers, 
with means θ21, θ22 and θ23. In some situations it might be possible to use more than 
one biomarker in the phase II trial, but that is not our focus here. The condition in 
(5.25) can be used to decide which biomarker to use in a certain situation. The three 
biomarkers are assumed to have diﬀerent costs per observation, but the same sample 
variance σ2
2. The  means  θ21, θ22 and θ23 have the same prior variance t1
2, but diﬀerent 
correlations with θ3. To ﬁnd the roots of C2 where two biomarkers give equal amount 
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of information for θ3 we can use (5.25), which simpliﬁes to 
2σ2
2(c22r1
2 − c21r22)C2  = t2(r2 − r2) . 1 2 1
We can for t21 = 0.04 and σ2
2 = 1 predict that the curves in Figure 5-5 will cross at 
investment levels of 
2 × 12(0.5 × 0.72 − 0.2 × 0.82)
C2 = = 39.00 (5.28)0.04(0.82 − 0.72) 
2 × 12(0.72 − 0.2 × 0.92)
C2 = = 51.25 (5.29)0.04(0.92 − 0.72) 
2 × 12(0.82 − 0.5 × 0.92)
C2 = = 69.12, (5.30)0.04(0.92 − 0.82) 
respectively, as is indeed the case in Figure 5-5. 
In summary, it is clear that if it turns out to be optimal to run a large phase II 
trial, the endpoint whose mean is most strongly correlated with θ3 is likely to be an 
attractive choice. For investments above a certain threshold, it dominates against all 
biomarkers with lower correlation. There may however also be situations where it is 
found optimal to run a small phase II trial. A less strongly correlated, but cheaper, 
biomarker may then provide an eﬃcient alternative. 
5.4.3 Information and decision-making 
We have discussed how to evaluate and choose between diﬀerent ways of purchasing 
information that may be available from biomarkers. But purchasing information in 
optimal fashion is of little value if the information is not used in an adequate way. 
Let us focus on the information needed for the decision about whether to progress 
to phase III. One important question is whether a phase II trial is needed to make 
this decision. A related topic is discussed by Ades et al. (2004), who describe a general 
approach to deciding whether an experiment should be carried out. They use a quantity 
referred to as the expected value of sample information, which is the diﬀerence between 
the expected value of the optimal decision made after data have been collected, and 
the expected value of an optimal decision made immediately, without collecting new 
data. For the experiment to be carried out, the expected value of sample information 
must be larger than the cost of sampling. In our setting, such an approach could be 
used to decide whether it is worth to run a phase II trial with a certain investment, 
instead of moving directly to phase III. 
As pointed out by Burman and Senn (2003), a decision point such as a phase III 
go/no go decision gives an option to discontinue a treatment that is not promising 
enough to justify further investment. As discussed in Section 5.3.5, the expected utility 
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Figure 5-5: Information obtained for θ3 depending on the choice of biomarker. All biomarkers 
have t21 = 0.04 and sample variance σ22 = 1.  
is maximised if we continue to phase III whenever the expected utility of such a decision, 
conditional on Z2 = z2 and n2, is positive. The value of the phase II trial is that it 
provides the option not to run the phase III trial if the expected utility after phase II 
turns out to be negative. If the expected utility after the phase II trial, conditional on 
Z2 = z2 and n2, is positive with probability close to 1, the probability of running the 
phase III trial will also be close to 1. The phase II trial then has a negligible impact 
on the go/no go decision, and may turn out to be redundant. 
These properties can help to explain the results seen in graphs such as Figure 5-4, 
where the expected utility typically has a minor local minimum in n2. To  be  useful,  
the phase II trial has to be large enough to be able to sway the investigator’s mind 
about running the phase III trial. If the probability of progressing to phase III does not 
change much regardless of the results, the phase II trial is of limited value. As there is 
also a cost per observation c2 > 0 in phase II, this cost may sometimes outweigh the 
contribution that the phase II trial can make to the decision-making process. 
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Similar considerations can help to explain the discontinuity seen in Figure 5-2, 
where the choice of n2 jumps from 0 to a positive value as the correlation r passes 
a certain threshold. Suppose that for a given decision problem with ﬁxed r, it  is  
optimal to make an investment C2 
 in the phase II trial. We know from (5.23) that 
the information obtained about θ3 for a given phase II investment is increasing in r. 
We also know from Figure 5-2 that the optimal phase II sample size is monotonically 
increasing in r. When solving the decision problem for a smaller r, we will thus get 
a smaller phase II sample size, and due to smaller r and n2, less information about 
θ3. Eventually, as r continues to decrease, there comes a point when the increase in 
information about θ3 is very small. The phase II trial is then unlikely to have any 
impact on the decision about whether to run the phase III trial. The value of the 
option described by Burman and Senn (2003) decreases, and the information that has 
been purchased no longer compensates for the cost of sampling. This results in the 
situation shown in the upper left panel of Figure 5-4, for n3f = 1046 and r = 0.45. The 
ﬁgure shows that the expected utility at the local maximum, obtained for just under 
60 observations in phase II, is smaller than the expected utility at n2 = 0.  
5.5 Joint optimisation of phase II and phase III 
5.5.1 Adapting phase III sample size based on phase II results 
We will now discuss the problem of optimising the phase III sample size for a given 
posterior distribution of θ3 after phase II, as well as assumptions about g/c3 and 
σ3
2 . This posterior distribution can also be viewed as the prior distribution of θ3 
before phase III. Suppose that the prior distribution of θ3 before phase III is normally 
distributed according to 
θ3 ∼ N(μ2, τ22), 
with μ2 = 0  and  τ2
2 = 0.04. For now, we are not concerned with how this distribution 
has been derived, and simply take it as given. We will use it to illustrate the general 
method of optimising the phase III sample size, for a given prior distribution of θ3 
before phase III. To this end we consider three speciﬁc ratios for g/c3 and set σ3
2 = 1.  
As for the moment we are not concerned with the design of phase II, no assumptions 
are needed for c2/c3, r, or the prior distribution of θ2. Pezeshk et al. (2009) have solved 
this problem for a more general gain function, so our situation with a constant g/c3 
can be viewed as a special case of their more general framework. A description of how 
to ﬁnd the optimal phase III sample size, for a given prior distribution of θ3 before 
phase III and assumptions about g/c3 and σ3
2, is given in Section 5.8.2. 
The left panel of Figure 5-6 shows an example of how the assurance, as deﬁned 
in equation (5.14), depends on the phase III sample size n3. The centre panel shows 
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Figure 5-6: The left panel shows the assurance for diﬀerent values of n3. The centre panel 
shows the expected utility for diﬀerent values of n3 and diﬀerent ratios g/c3. The right panel 
shows the derivative of the expected utility with respect to the phase III sample size n3. The  
prior distribution for θ3 is assumed to be normal with mean zero and variance 0.04. 
the expected utility as a function of n3, for three speciﬁc choices of g/c3 and c3 = 1.  
For g/c3=12000 and g/c3=4000, the expected utility has a global maximum for our 
optimal phase III sample size n3
 . Perhaps more surprisingly, all three curves have a 
local minimum for small n3. This can be explained mathematically by treating n3 as 
continuous, and evaluating the ﬁrst derivative of the expected utility with respect to 
n3 numerically. The result is displayed in the right panel of Figure 5-6, where we see 
that each curve has two roots where the derivative equals zero. We would then expect 
each curve in the left panel of Figure 5-6 to have two stationary points, as is indeed 
the case. 
The curve for g/c3 = 2400 shows that the optimal phase III sample size may be 
obtained as n3 → 0+ . The expected utility of running such a phase III trial would 
be just above zero. We note that for n3 = 0, the probability of rejecting the null 
hypothesis equals 0.0005, so the expected utility of running a phase III trial with 
n3 = 0  equals  0.0005 × 2400 = 1.2. As the phase III sample size is increased the 
expected utility decreases and soon becomes negative. In practical applications we 
would however not choose to run a very small phase III trial for this reason of optimality. 
In fact, such an approach would be similar to running a very small study with no 
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treatment eﬀect and hoping for a type I error. Hence, it may be useful to put a lower 
bound on the phase III sample size, for example n3 ≥ n3,min, where  n3,min is driven 
by the requirement to collect a minimal amount of safety data for the drug to be 
approved. Regulatory authorities frequently make such demands, to be able to make 
an appropriate beneﬁt/risk assessment of the drug under investigation. The possibility 
of imposing a lower constraint on the maximal sample size will be further discussed 
in Section 5.5.2, where the choice of phase II sample size is also considered. Another 
alternative, which will not be considered in this chapter, could be to require that the 
assurance of the phase III trial must not be below a certain threshold. Such a constraint 
would avoid solutions of the type seen for the curve for g/c3 = 2400, where n3 
 → 0+ . 
5.5.2 Optimisation of both phase II and phase III sample sizes 
Choice of phase III sample size 
In Section 5.3, we discussed the design of phase II trials given a ﬁxed phase III sample 
size n3. Even though a posterior distribution π (θ3|z2) is available after phase II, θ3|Z2 
n3 was not allowed to depend on phase II data. Rather than using the phase III 
designs described in Section 5.3, it is natural to ask if there is a way to make use of the 
additional information obtained in phase II when designing the phase III trial. The 
aim is to ﬁnd the optimal phase III sample size, given the prior π (θ3|z2) that has  θ3|Z2 
arisen from phase II. 
Suppose that phase II is run with sample size n2. After having observed the phase II 
results, the posterior distribution π (θ3|z2) can be calculated according to (5.7), θ3|Z2 
using the expressions for μ2 in (5.8) and for τ2
2 in (5.9). From Section 5.5.1, we have 
a method to ﬁnd the optimal phase III sample size n3 
 for a given prior for θ3 before 
phase III. This method can be used for any phase II result and sample size. The 
phase III sample size is then a function n3(Z2, n2) of the phase II sample size and 
results. We note that μ2 and τ2
2 are completely determined by Z2 = z2, n2 and the 
prior distributions before phase II. We shall be writing n3(Z2, n2), even though ﬁgures 
will sometimes display n3 as a function of μ2 rather than Z2. 
After a phase II trial with sample size n2 we can, given the joint prior distribution 
πθ2,θ3 (θ2, θ3), Z2 = z2 and n2, calculate  μ2, the posterior mean of θ3 after phase II. 
Consider again our core example, with g/c3 = 12000, c2/c3 = 0.2 and prior distribution 
for (θ2, θ3) before phase II according to (5.16) with r = 0.8. For selected values of the 
phase II sample size n2, Figure 5-7 shows how to optimally choose the phase III sample 
size based on μ2, the prior mean of θ3 after phase III. The three curves for diﬀerent 
n2 have a similar shape and as we would expect, μ2 is more important for determining 
the phase III sample size than n2. To better understand the discontinuities seen for a 
certain value of μ2, we can again consider Figure 5-6. The curves in Figure 5-6 that 
display the expected utility as a function of n3 typically have two local maxima, one 
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Figure 5-7: Optimal phase III sample size depending on prior mean of θ3 before phase III, for 
diﬀerent choices of phase II sample size n2. The phase III sample size has been optimised for 
our core example, with g/c3 = 12000, c2/c3 = 0.2 and prior distribution for (θ2, θ3) according 
to (5.16) with r = 0.8. 
for n3 = 0  and  one  for  n3 > 0. As we in Figure 5-7 move towards a more negative μ2, 
there will for each curve come a point where the local maximum for n3 = 0  is  higher  
than the maximum for n3 > 0. If there is no lower constraint on the phase III sample 
size the optimal solution will then be to set n3 = 0, as was the case for the curve with 
g/c3 = 2400 in Figure 5-6. 
Choice of phase II sample size 
We now have a method for how to choose phase III sample size, given a certain result 
Z2 = z2 in a phase II trial with n2 observations per treatment group. The next step is 
to use this method to optimise the phase II sample size. To illustrate how the design of 
phase II changes when we allow optimisation of n3 based on the results in phase II, we 
return to our core example in Section 5.3. To this end we assume a correlation r = 0.8, 
reﬂecting a situation where the phase II results can have substantial impact on the 
phase III sample size. Further details for how to solve this type of decision problem, 
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where we seek to ﬁnd both the optimal phase II sample size n2 
 and an optimal rule 
for choice of phase III sample size based on the results in phase II, are provided in 
Section 5.8.2. 
The expected utility for the optimal solution is displayed with a solid line in the 
left panel of Figure 5-8. The phase II trial now plays the role of guiding the phase III 
sample size, in addition to providing the go/no go decision for progress to phase III. We 
see that the expected utility is slightly higher than when n3 was not allowed to depend 
on phase II data. Some improvement of the expected utility is then to be expected, 
as an optimal rule for choosing n3 based on Z2 is used. The right panel of Figure 5-8 
shows the optimal rule for how to choose n3 based on the results in phase II, for the case 
when the phase II sample size is optimally chosen. For comparison, the ﬁxed sample 
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= 1046sizes and n n3 3f = 1610 are also displayed. The optimal phase III sample size 
varies with μ2, the prior mean of θ3 after phase II, and can depending on μ2 be both 
higher or smaller than n
3f = 1610. 
It is also of interest to revisit the rule for how to choose phase II sample size based 
on the correlation r, now  that  n3 is allowed to depend on phase II data. We saw in 
Figure 5-2 that there was a cut-oﬀ, so that for r < r, the optimal phase II sample size 
equals zero. Figure 5-9 shows how our core example changes when n3 is allowed to n

depend on phase II data. The behaviour is similar, but there is also a key diﬀerence

compared to when n3 = 1046 or n3f. While there is still a cut-oﬀ r
 below which it

is not worthwhile to run a phase II trial, there is no longer a discontinuity in n
2 as a

function of r. Likewise, we saw in the left panel of Figure 5-8 that the expected utility, 
displayed with a solid line, no longer has a local minimum for small n2. This reﬂects the 
additional role of the phase II results, as they are now also used to ﬁnd an appropriate 
phase III sample size. Both of these changes, compared to when n3 was not allowed to 
depend on phase II data, are related to the discussion in Section 5.4 about the local 
minima and discontinuities seen for ﬁxed phase III samples. Since phase II data now 
play a role in deciding the phase III sample size, even a small amount of information 
can make a diﬀerence to the decision. So for the purpose of ﬁne-tuning the phase III 
sample size, the beneﬁts of a small phase II trial can justify the costs. In contrast, 
a larger amount of information would be required to change the investigator’s mind 
about whether to progress to phase III. 
Lower bound on phase III sample size 
When seeking the optimal phase III sample size for a given prior mean μ2, we have  so  
far not imposed a lower bound n3,min on the phase III sample size. In practice there 
is however likely to be such a constraint, as regulatory authorities typically require 
a minimum amount of safety data. Solutions with n3 close to zero are theoretically 
interesting, but of little practical use in the drug development process. Furthermore, 
a trial with a very small number of patients is unlikely to be acceptable to the wider 
scientiﬁc community. Hence, we will now present some results for the case when n3 
has a lower bound. With a lower constraint for n3, it is according to our model still 
possible to set n3 = 0 and not run the phase III trial. It is however not possible to run 
a phase III trial with n3 = 0, type I error probability α = 0.0005 and constant power 
function equal to 0.0005 for all values of θ3. 
When solving the decision problem for the case when n3 has a lower constraint, we 
can proceed in a similar away as when n3 is allowed to take any value. Further details 
of how to solve the problem are provided in Section 5.8.2. Table 5.1 shows the expected 
utility that can be maintained for a given value of n3,min. It is re-assuring to know 
that unless the constraint imposed is very high, the impact on the expected utility is 
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Figure 5-9: Phase II sample size depending on correlation r, for three diﬀerent approaches to 
determining phase III sample size. The designs have been optimised for our core example, with 
g/c3 = 12000, c2/c3 = 0.2 and prior distribution for (θ2, θ3) according to (5.16), with r = 0.8. 
limited. 
Figure 5-7 shows that the optimal phase III sample size varies with μ2, and  that  
μ2 was more important for the choice of phase III sample size than n2. Hence, it is 
somewhat surprising that the loss incurred from imposing a lower constraint on the 
phase III sample size is not larger than that shown in Table 5.1. One reason is that 
the very small phase III trials that are allowed when there is no lower constraint, with 
a low cost and probability of success, only have a small impact on the expected utility. 
Another reason has to do with the prior distribution of θ3 before phase II, which is 
normal with mean μ1 = 0 and variance τ1
2 = 0.04. The phase II results, which in 
Figure 5-8 give an optimal phase III sample size that falls below a given constraint, 
may under this prior occur with only a small probability. This will in turn limit the 
impact on the expected utility, in particular for the cases in Table 5.1 where the lower 
bound is not very high. 
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P (Progress E(C3| Progress PoS| Progress E(U) 
to phase III) to phase III 
n3,min n2 
to phase III)

0 354 1.00 967 0.267 2169

1 354 1.00 967 0.267 2168

200 354 0.63 1545 0.426 2167

1046 353 0.62 1568 0.431 2166

1610 359 0.59 1717 0.455 2149

2000 380 0.57 2000 0.486 2113

3000 441 0.51 3000 0.570 1877

4000 476 0.46 4000 0.636 1558

Table 5.1: Optimal phase II sample size, probability of progress to phase III, expected 
phase III investment C3 given progress to phase III, probability of success (PoS) given progress 
to phase III and expected utility of designs with lower constraint n3,min on phase III sample 
size n3. The designs have been optimised for our core example, with g/c3 = 12000, c2/c3 = 0.2 
and prior distribution for (θ2, θ3) according to (5.16), with r = 0.8. 
Threshold for progress to phase III 
Let us now revisit the problem of ﬁnding a decision rule for progress to phase III. After 
the phase II trial, we have 
θ3 ∼ N(μ2, τ22) 
and as before, we proceed to phase III if μ2 ≥ μ2 and stop otherwise.  In Section  5.3 

2we  derived an analytical  expression  for  μ
 , for the case when n3 was ﬁxed. Let us 
2now consider how to derive the threshold μ
 for the case when n3 is allowed to depend 
on the phase II results. We must ﬁrst know the phase III sample size that is optimal 
for a given phase II result Z2 = z2 and phase II sample size n2, or equivalently for a 
certain prior mean μ2 and prior variance τ2
2 for θ3 after phase II. From the results in 
Section 5.3, we know that μ
2 can be calculated as the solution to

2 
z1−α − Φ−1(1 − (n (μ
 ) × c3 + a3)/g) 1 +  n3(μ
2, τ22)τ22/(2σ32)
3 2, τ22 μ
 =
 .

(μ
2, τ2
2)/(2σ3
2)
n
3
2, τ2
2), we have As there is not a simple analytical expression for how to calculate n3(μ
to ﬁnd μ
2 numerically in this case. When searching for μ
2, it is helpful to know that

conditional on τ2
2, the expected utility is monotonically increasing in μ2. For  ﬁxed  n3, 
it follows from the deﬁnition of assurance in (5.14) that this must be the case. We show 
in Section 5.8.2 that the expected utility, conditional on τ2
2, is monotonically increasing 
in μ2, also when  n3 is optimally chosen based on phase II data. To ﬁnd the optimal 
go/no go decision, it then remains to perform a one-dimensional search for μ
2. 
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Even though μ 2 has to be found numerically, we can prove a simple property that 
relates to the analytical solution obtained when n3 is not allowed to depend on phase II 
data. We know that there are now more options for how to choose n3 than when n3 is 
ﬁxed, so the best phase III design must consequently be better or at least as good as 
when n3 is ﬁxed. Because of the increased ﬂexibility for how to choose n3, the  posterior  
mean cut-oﬀ μ 2 must be smaller than when n3 is ﬁxed. 
5.5.3 Group sequential phase III design 
Introduction 
So far we have assumed that phase III is run as a ﬁxed sample trial with n3 patients 
per treatment group, either chosen based on phase II results or according to some 
other criteria. In many areas of clinical research, for example in oncology and 
the cardiovascular area, phase III trials are often monitored using group sequential 
methodology. It is thus of interest to assess how the properties of the phase II and 
phase III designs change, if the phase III trial is instead made group sequential. As 
discussed in Chapter 4, regulatory authorities may question the practice of buying back 
type I error in one-sided group sequential tests. Consequently, the one-sided group 
sequential tests considered in this section will all have non-binding futility boundaries. 
We know from Chapter 4 that group sequential designs with non-binding futility 
boundaries have attained type I error rate < α and hence, are a little conservative. 
We refer to Chapter 4 for further details about such designs. 
We know from Chapter 4 that ρ family error spending designs with non-binding 
futility boundaries are eﬃcient and close to optimal. We shall therefore restrict our 
attention to this class of group sequential designs. The parameter ρ decides the amount 
of early stopping, with the probability of early stopping being monotonically decreasing 
in ρ. To give a substantial probability of early stopping, we set ρ = 1  for both  the  
upper and the lower boundary. This gives boundaries that are broadly similar to those 
proposed by Pocock (1977). Compared to a more conservative boundary, O’Brien and 
Fleming (1979) say, our stopping rule gives a low expected sample size, at a price of a 
higher maximal sample size. 
The number of analyses K has an important eﬀect on the eﬃciency of a group 
sequential design. We know from publications such as Barber and Jennison (2002), 
that the biggest eﬃciency gains are achieved when moving from K = 1 to  K = 2, while 
the eﬃciency gains achieved by increasing the number of groups beyond 5 are typically 
modest. Hence, we will consider the cases K = 1, 2, 3 and 5. Eales and Jennison 
(1992) found that while some additional eﬃciency could be achieved by optimising the 
group sizes of a K-group sequential tests, equally spaced analyses are rather eﬃcient. 
Assuming K equally spaced analyses, the only parameter that has yet to be decided is 
the maximal sample size n3,max. We shall be considering three approaches to deciding 
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the maximal sample size n3,max of group sequential designs: 
1. Choosing	 n3,max to obtain power 1 − β at the clinically relevant diﬀerence of 
θ3 = δ = 0.2. To ﬁnd n3,max, we search for the maximal sample size needed to 
satisfy the power requirements. For nﬁx = 1046, ρ = 1,  α = 0.0005 and β = 0.1, 
we have R = 1.13 and n3,max = 1183 for K = 2,  R = 1.19 and n3,max = 1243 
for K = 3  and  R = 1.22 and n3,max = 1281 for K = 5.  
2. Choosing n3,max = n to maximise the expected utility, without letting 3,max 
n3,
 
max depend on phase II data. The optimal maximal sample size of this ρ = 1  
error spending design depends on the number of groups K. 
3. Choosing n3,max = n (Z2, n2) to maximise the expected utility, based on 3,max
phase II data. The optimal maximal sample size of this ρ = 1 error spending 
design also depends on the number of groups K. 
No other group sequential designs than the ones stated above will be considered. 
Given the results in Chapter 4, we don’t expect that further optimisation of the 
group sequential boundary in phase III would have a signiﬁcant eﬀect. Setting ρ = 1  
gives boundaries with substantial possibilities of early stopping and, compared to less 
aggressive boundaries with a higher ρ, rather high maximal sample sizes to get a certain 
power at a given eﬀect size. It is appropriate to consider this type of boundaries in 
the absence of a threshold for n3,max, above which it is diﬃcult to recruit patients or 
handle other logistical aspects of the trial. If it is expected that patient recruitment 
will be diﬃcult it may well be useful to consider group sequential boundaries that are 
derived for a higher value of ρ, which require a smaller maximal sample size to achieve 
a speciﬁc power. 
Many of the qualitative results shown in previous sections apply also when phase III 
is group sequential, so we shall not repeat all of the sensitivity analyses performed 
for the case when phase III is a ﬁxed sample trial. Rather, we have identiﬁed three 
qualitative features of our model that change when phase III becomes group sequential: 
1. The phase II trial becomes less important,	 as the group sequential design in 
phase III can provide an eﬃcient stopping rule based on θ3. There  are  now  
several go/no go decisions at the interim analyses in phase III, which partly can 
replace the go/no go decision for proceeding to phase III based on phase II data. 
2. The maximal sample size in a group sequential phase III trial is often considerably 
larger than the sample size of a ﬁxed sample trial, as early stopping lowers the 
expected sample size and cost. We can aim for high power at small values of θ3, 
as the early stopping makes it possible to avoid increases in expected sample size 
at high values of θ3. 
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3.	 Adding additional interim analyses to a non-adaptively chosen phase III design 
increases the expected utility more than updating the choice of sample size based 
on the phase II results. 
Illustrating these concepts will be the focus of this section about group sequential 
designs. 
Optimising phase II sample size given group sequential phase III design 
We shall now return to our core example to illustrate how some of the key features of the 
phase II and phase III designs change when the phase III trial is group sequential. For 
a given group sequential phase III design we can, in a similar fashion as in Section 5.3, 
perform a one-dimensional search for the phase II sample size that maximises the 
expected utility. Further discussion about how to solve the decision problem are 
provided in Section 5.8.2. In Figure 5-2, we illustrated how the proportion of resources 
spent in phase II depends on the correlation r and the cost ratio c2/c3. Figure  5-10  
shows a similar illustration for the case when phase III is group sequential, where two 
diﬀerent approaches have been used to choose n3,max. The two panels to the left show 
designs with 90% power at θ3 = 0.2. In the two panels to the right, n3,max is chosen to 
maximise the expected utility, without being allowed to depend on phase II data. The 
results shown for K = 1 in Figure 5-10 are the same that were shown in Figure 5-2, 
when the ratio c2/c3 = 0.2. An important observation is that for ﬁxed correlation r, 
the proportion of resources used in phase II is lower for K = 2  than  for  K = 1.  This  is  
likely to be because part of the role of the phase II trial, a go/no go decision rule, can 
now be played by the interim analyses in the phase III trial. 
The point that phase II becomes less important when phase III is group sequential is 
illustrated even more clearly in the left panel of Figure 5-11, which shows the expected 
utility depending on phase II sample size, for designs with 90% power at θ3 = 0.2. We 
see that despite the rather high correlation of r = 0.8, the optimal phase II sample 
size n 2 = 0  for  K = 5, and beneﬁts of a phase II trial are very modest for K = 2.  In  
the right panel it is shown that there is a stronger case for a phase II trial when the 
phase III sample size is larger, as a result of being chosen to maximise the expected 
utility. The beneﬁt of phase II decreases with K, but also for K = 5  we  obtain  n2 
 > 0. 
The value shown for n2 = 0 refers to moving directly to phase III, without a phase II 
trial. We also note that just like the ﬁxed sample designs, all the group sequential 
designs in Figure 5-11 have a minor local minimum for small n2. 
Things could be diﬀerent, in both the left and right panel of Figure 5-11, if c2 << c3. 
Making phase III group sequential may then have less of an impact on the phase II 
sample size, which could then still be substantial. The observations collected in 
phase III on the other hand have the advantage that regardless of the cost ratio c2/c3, 
they can contribute to the ﬁnal hypothesis test. 
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Figure 5-10: Optimal choices of phase II sample size, maximal phase III sample size and 
sample size ratio, for ﬁxed sample phase III designs and ρ = 1,  K = 2 error spending designs. 
The left panel shows results for when the phase III sample size is chosen to obtain 90% power at 
θ3 = 0.2. In the right panel, the phase III sample size is chosen to maximise the expected utility, 
without being allowed to depend on phase II data. Results for K = 1 are shown with solid line 
and for K = 2 with dashed line. The designs have been optimised for our core example, with 
g/c3 = 12000, c2/c3 = 0.2 and prior distribution for (θ2, θ3) according to (5.16), with r = 0.8. 
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Figure 5-11: Expected utility versus phase II sample size, for two diﬀerent approaches to 
choosing the maximal sample size n3,max of the phase III trial: The left panel shows designs 
with 90% power at θ3 = 0.2. The right panel shows designs with maximal sample size n3,max 
chosen to maximise the expected utility, when n3,max is not allowed to depend on phase II 
data. The K-group, ρ = 1 error spending designs have been optimised for our core example, 
i.e. for g/c3 = 12000, c2/c3 = 0.2 and prior distribution for (θ2, θ3) according to (5.16), with 
r = 0.8. 
Optimising the maximal sample size of group sequential phase III design 
based on phase II results 
For a K-group sequential design, with equally spaced analyses say, we can now in a 
similar way to what was done for ﬁxed sample trials in Section 5.5.1, search for the value 
of n3,max that is optimal, given n2 and Z2 = z2, from a decision-analytic perspective. 
For our core example, with r = 0.8, Figure 5-12 shows how this maximal sample size 
n3,max(Z2, n2) depends on μ2, the prior mean before phase III. Also displayed are the 
ﬁxed sample sizes n3 = 1046 and n3 = 1610, where the former is chosen to achieve 90% 
power at θ3 = δ and the latter to maximise the expected utility. Finally, the optimal 
maximal sample sizes n3,max, when the maximal sample sizes has not been chosen based 
on phase II data, are shown for K = 2,  K = 3  and  K = 5. It is noteworthy that for all 
the group sequential designs displayed in Figure 5-12, the optimal maximal sample size 
is highly dependent on the number of groups in the group sequential design. All the 
designs give good opportunity to stop with a fairly small sample size, if a boundary is 
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maximal sample size for two group sequential designs. The designs have been optimised for our 
core example, with g/c3 = 12000, c2/c3 = 0.2 and prior distribution for (θ2, θ3) according to 
(5.16), with r = 0.8. 
crossed. 
As the sample size increases, the probability of rejecting H0 for small eﬀect sizes √
decreases. The power for a given value of θ3 depends on θ3 n3 and there is, taking 
into account the inﬂation factor of the group sequential boundary of R = 1.22, roughly 
a threefold increase in n3,max, from  n3 = 1046 for K = 1 to  n3,max = 3866 for 
K = 5. The optimal 5-group sequential design, when n3,max is not allowed to depend 
on phase III data, thus achieves a certain power at an eﬀect size that is smaller by a √ 
factor of approximately 3, compared to the ﬁxed sample phase III trial which achieves 
90% power at θ3 = 0.2. 
Optimising the phase II sample size and the maximal sample size of a group 
sequential phase III design 
Given that we know how to choose the maximal sample size n3,max of the group 
sequential design for a given prior, we can use the approach from Section 5.5.2 to ﬁnd 
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Figure 5-13: Expected utility versus phase II sample size n2, for two diﬀerent approaches to 
choosing the maximal sample size n3,max of the phase III trial: For the black lines, n3,max 
is not allowed to depend on phase II data, while for the blue lines, n3,max is chosen based 
on phase II data. The K-group, ρ = 1 error spending designs have been optimised for our 
core example, with g/c3 = 12000, c2/c3 = 0.2 and prior distribution for (θ2, θ3) according to 
(5.16), with r = 0.8. 
the optimal phase II sample size n2
,  as well  as the  rule  n3,max(Z2, n2) for  how  to  
choose the maximal sample size of the group sequential design in phase III. We have 
done this for our core example, with r = 0.8. We see in Figure 5-13, where the black 
lines show the same results as the right panel in Figure 5-11, that the phase II sample 
size becomes less important to the expected utility as we increase K, the  number  of  
groups in the group sequential design. The optimal phase II sample decreases with K 
for the results displayed with blue lines in Figure 5-13, from over 350 observations for 
K = 1 to slightly below 230 observations for K = 5. The trend is similar when the 
optimal phase II sample size is decreased from just under 350 observations for K = 1  
to about 220 observations for K = 5. There is however some scope for increasing the 
expected utility by running a phase II trial also when phase III is group sequential, in 
particular when phase II is also used to guide the phase III sample size. For K = 5,  the  
expected utility can for example be increased by about 3%, compared to when moving 
directly to phase III without a phase II trial. Adding interim analyses to the phase III 
design appears to be much more important than updating the phase III sample size 
based on phase II results. Adding one interim analysis to the ﬁxed sample design (black 
solid line) increases the expected utility by about 18%. This can be compared with an 
improvement of just over 1% that is achieved by running a ﬁxed sample trial, where the 
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sample size is allowed to depend on phase II data. The expected utility is improved by 
37% for the K = 5 design compared to the K = 1 design. An improvement of 38% is 
possible if in addition the maximal sample size of the group sequential design is chosen 
based on the phase II results. These results are broadly in agreement with what we 
found earlier in this thesis, about choosing future group sizes based on the observed 
treatment eﬀect within a single study. For group sequential designs for simultaneous 
testing of superiority and non-inferiority, non-adaptive 3-group sequential designs were 
found to be more eﬃcient than 2-group adaptive designs. In the present problem it 
is worth remembering that it should be a drawback that the adaptation is based on a 
biomarker for θ3, rather than the phase III endpoint. 
5.6 A numerical example 
We will now illustrate how our model can be used with a numerical example. We are 
interested in using our model to assess the potential beneﬁts of ﬁrst running a smaller 
phase II study, before embarking on a phase III trial. We shall let the phase III sample 
size be guided by the phase II results. At ﬁrst, a ﬁxed sample phase III trial will be 
assumed. To achieve the beneﬁts of early stopping we will thereafter be considering 
group sequential designs, with one interim analysis before the ﬁnal analysis. 
Gittins and Pezeshk (2000b) cite a clinical trial that was carried out by a UK-based 
pharmaceutical company, where the drug concerned was already on the market. We 
will use some of the numerical values in their example to illustrate how our model 
could be applied. The aim of the clinical trial was to broaden the indication for the 
drug in question and thus increase the sales of the product. To assess the feasibility 
of running such a trial, one low estimate and one high estimate for future annual sales 
had been established. It was assumed that the new broader indication would result 
in between 5% (low estimate) and 50% (high estimate) increase in annual proﬁt. The 
gain obtained in case of regulatory approval, £15 million for the low estimate and £150 
million for the high estimate, were obtained by discounting the resulting cash ﬂow of 
the future annual sales. The cost per patient in the phase III trial was estimated to 
be c3 = £4000, which in our notatation implies g/c3 = 3750 for the low sales estimate 
and g/c3 = 37500 for the high sales estimate. Gittins and Pezeshk (2000b) comment 
that a more careful analysis would include a start-up cost, a3 in our notation, for the 
phase III trial, in addition to the cost per patient. We shall start by setting a3 = 0,  
but will later in this section get back to the implications of introducing a start-up cost 
in phase III. 
Before any trials on the broader indication, the prior beliefs about θ3 could be 
summarized by the prior distribution 
θ3 ∼ N(μ1, τ12) 
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with μ1 = 0.41 and τ1
2 = μ21/4. This prior distribution has most of its probability 
mass at positive values of θ3, and is more optimistic than the prior distribution centred 
at zero considered in the previous sections. Moreover, σ3
2 = 2 was thought to be a 
reasonable assumption for the common within-group sample variance of the phase III 
endpoint. We shall also be making the slightly simpliﬁed assumption that the ratios 
g/c3 = 3750 and g/c3 = 37500 are achieved whenever the null hypothesis is rejected 
at the α = 0.0005 level. In the model of Gittins and Pezeshk (2000b), g depends also 
on z3, in such a way that the full gain functions that we have speciﬁed are obtained 
only if z3 is suﬃciently high. We show in Section 5.8 how our decision problem can be 
approached for this more sophisticated gain function. 
Once the posterior distribution for θ3, as well  as assumptions for  g/c3 and σ3
2, are  
available, it is straightforward to use our model to decide how to design the phase III 
trial. We now make some additional assumptions that were not speciﬁed in the problem 
solved by Gittins and Pezeshk (2000b). We follow the approach in Table 5.1 and impose 
a lower bound, in this case 100 patients per treatment group, on the phase III sample 
size. This is a very sensible feature, as it has a negligible impact on the expected utility, 
but avoids designs with phase III sample size close to zero. 
As before, a biomarker is used in phase II to obtain information about θ3. Suppose 
that two diﬀerent biomarkers are available for use in the phase II study, both with 
sample variance σ2
2 = 1 but with diﬀerent costs per observation, c21 = 0.1c3 for 
biomarker 1 and c22 = 0.5c3 for biomarker 2. The means of the two biomarkers have the 
same prior variance t21 = 0.25, but diﬀerent correlations with θ3, r1 = 0.8 and  r2 = 0.9, 
respectively. Let us now consider the possibility of using either of these biomarkers in 
a pre-study, preceding our phase III trial. We know from Section 5.4, that since the 
biomarkers have the same prior variance t21 and sample variance σ2
2, the  two  biomarkers  
will deliver the same amount of information about θ3, for a given investment C2, if  
2σ2
2(c22r1
2 − c21r22) = 2(0.5c3 × 0.8
2 − 0.1c3 × 0.92) = 11.2c3 = £44800. (5.31)2 2C
 2 =
 t2 1(r
 )
 0.25(0.92 − 0.82)− r
2 1
Figure 5-14 shows how the expected utility depends on the phase II investment and the

choice of biomarker. We see from Figure 5-14 that the curves for the expected utility

cross at C
2 = £44800 for both the low and high sales estimate, which is in agreement

with the result in (5.31). This condition about the eﬃciency of the biomarkers applies

regardless of the phase III sample size and which sales estimate is assumed to be the

most appropriate. We also see that the expected utility is considerably larger if the

phase II investment is increased to a level C2 > C2 . Biomarker 1 would be the better

option if the phase II investment were constrained according to C2 ≤ C2 .  If  this is not 

the case, biomarker 2 is to be preferred. 
We see in Figure 5-14 that for g/c3 = 37500, the optimal phase II investment is 
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Figure 5-14: Expected utility for diﬀerent choices of phase II sample size n2 and two diﬀerent 
biomarkers, when n2 is used to guide the phase III sample size. The decision problem has 
been solved assuming that the prior distribution for θ3 is normal with mean 0.41 and variance 
0.412/4, a prior variance for θ2 of 0.25, σ2
2 = 1  and  σ3
2 = 2.  
considerably higher than when g/c3 = 3750. When g/c3 = 3750, about 4%, or £0.3 
million pounds, can be gained by running a pre-study, compared to moving directly 
to a ﬁxed sample phase III trial. For g/c3 = 37500, about 3%, or £4 million, can be 
gained. 
It has been shown in previous sections that substantial beneﬁts can be achieved 
by making phase III group sequential. We therefore consider running a ρ = 1 error 
spending design with two equally spaced analyses. We do not expect the choice of 
biomarker to change in the group sequential setting, as biomarker 1 is more eﬃcient 
than biomarker 2 only for very small investment levels. Hence, we will focus on 
biomarker 2 for the remainder of this section. We will now focus our attention on 
running a phase II trial with this biomarker, and assess the impact on the choice of 
phase III sample size, as well as the go/no go decision. 
The two upper panels of Figure 5-15 show how the phase III sample size depends 
on the phase II results, for the case when biomarker 2 is used in phase II. The results 
for a ﬁxed sample phase III trial are shown with a solid line, while the results for a 
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Figure 5-15: Phase III sample size for ﬁxed sample trial (solid line) and maximal phase III 
sample size for K = 2,  ρ = 1 error spending design (dashed line), depending on the prior 
mean of θ3 before phase III. The six subplots show results for diﬀerent assumptions about gain 
function, cost per patient and start-up cost. The decision problem has been solved assuming a 
prior distribution for θ3 ∼ N(0.41, 0.412/4), a prior variance for θ2 of 0.25, r = 0.9, c2/c3 = 0.5, 
σ2
2 = 1  and  σ3
2 = 2.  
group sequential design are shown with a dashed line. The maximal sample size is 
increased by a higher amount than what a typical inﬂation factor for an error spending 
design with K = 2 analyses would motivate. Hence, the group sequential design aims 
at achieving a higher power at a given eﬀect size. The cut-oﬀ μ
2, which deﬁnes the

go/no go decision rule, is somewhat higher for a ﬁxed sample trial than when phase III

is group sequential. For g/c3 = 3750, we have μ2 = 0.13 for K = 1  and  μ
2 = 0.10

for K = 2. We would expect this behaviour, as the possibility of early stopping in the 
group sequential design makes it feasible to run a phase III trial with a lower expected 
cost. We also note that for both K = 1  and  K = 2, the cut-oﬀ is considerably higher 
for g/c3 = 3750, than for g/c3 = 37500. This property of the go/no go decision rule is 
consistent with what we observed in previous sections about the threshold for progress 
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to phase III. It reﬂects the increased conﬁdence in the compound that is required to 
pursue a phase III trial, when the forecasts for future sales are less optimistic. 
Figure 5-15 also shows results for two sensitivity analyses that we shall now consider. 
The ﬁrst is related to the question of including a start-up cost a3 > 0 in the model for 
the cost structure phase III trial. So far it has been assumed that a3 = 0, letting the cost 
of the phase III trial be proportional to the number of patients. In the group sequential 
setting, it is however very realistic to think that there is some additional start-up cost 
that is not directly proportional to the number of patients at the time of the interim 
analysis. The two panels in the centre of Figure 5-15 show that including a start-up 
cost a3/c3 = 500, rather than a3 = 0, has a notable impact on the decision rule for 
progress to phase III. The start-up cost will sometimes mean that the expected utility 
of running phase III becomes negative, when it otherwise would have been positive. 
The impact is more pronounced for the low sales estimate, when the start-up cost is 
a higher proportion of the total gain g. The cut-oﬀs for μ2 previously cited, 0.13 for 
K = 1 and  0.10 for K = 2, are now shifted to 0.18 and 0.15, respectively. If the 
expected utility of running the phase III trial is positive, the optimal phase III sample 
size is however very similar to when a3 = 0.  
The two panels in the centre of Figure 5-16 show how the expected utility is aﬀected 
by the start-up cost. As there was some change in how to choose n3 based on μ2, 
we would expect the start-up to have an impact on the properties of our model, in 
particular when g/c3 = 3750 and the start-up costs eliminates a substantial proportion 
of the potential gain. We see in Figure 5-16 that the relative beneﬁt of phase II trial 
is increased, from 4% to 7%, when a start-up cost for phase III is included for the 
lower sales estimate. Like in previous examples, it is also noteworthy that the group 
sequential phase III design delivers important eﬃciency gains compared to the ﬁxed 
sample phase III trial. Overall, the impact of the start-up cost on the expected utility 
is less substantial than the impact on the decision rule for progress to phase III. 
An important feature of this example is that the prior mean is set two standard 
deviations of the prior distribution for θ3 above zero. Based on the prior information it 
is thus very probable that the drug has a positive treatment eﬀect compared to control. 
It is thus to be expected that the relative increase in expected utility, about 3 − 4%, 
is rather modest, as the go/no go decision rule should be less uncertain. It is however 
worth remembering that a modest increase on the relative scale may correspond to an 
important diﬀerence in absolute numbers, especially if the sponsor has diﬃculties to 
fund the trial. 
Our ﬁnal sensitivity analysis concerns the situation where the gain function depends 
on the number of patients accrued in the phase III trial. This is a very reasonable 
assumption, as the number of patients in phase III has an impact on the duration of 
the trial and time of patent life left when the drug is approved. For the low sales 
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Figure 5-16: Expected utility for diﬀerent choices of phase II sample size n2, when  n2 is used 
to guide the phase III sample size. Results are shown for a ﬁxed sample trial phase III trial 
(solid line) and for K = 2,  ρ = 1 error spending design (dashed line). The six subplots show 
results for diﬀerent assumptions about gain function, cost per patient and start-up cost. The 
decision problem has been solved assuming a prior distribution for θ3 ∼ N(0.41, 0.412/4), a 
prior variance for θ2 of 0.25, r = 0.9, c2/c3 = 0.5, σ2
2 = 1  and  σ3
2 = 2.  
estimate, we shall consider the case g(n3) = max((7500 − n3)c3, 0), where n3 is the 
number of subjects on termination, while the cost c3 = £2000. Compared to our 
previous model, the cost per patient in phase III is reduced from £4000 to £2000. 
The potential gain if the drug is approved is however also decreased, by £2000 per 
patient. For the high sales estimate, the cost per patient remains c3 = £2000, while 
g/c3 = max((75000 − 10n3)c3, 0), as we ﬁnd it reasonable to assume that the time 
component will be proportional to the potential gain that will be achieved if the new 
indication of the drug is approved. In this sensitivity analysis, the gain function is zero 
if  the sample size at termination  n3 ≥ 7500, for both the low and high sales estimate, 
so it would not make sense to schedule interim analyses for n3 ≥ 7500. Deﬁning the 
gain function in this manner thus gives a deﬁnitive upper constraint for the maximal 
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sample size. We see in the bottom right panel of Figure 5-15, that for both K = 1  and  
K = 2, the phase III sample size is decreased considerably when this model for g is used 
for the high sales estimate. The situation is diﬀerent for the low sales estimate, where 
the cost structure for the phase III observations has become more favourable to the 
trial sponsor. To see why this is the case, we note that £2000(1 + I(z3 ≥ z1−α)) is now 
charged for having one patient per treatment group, instead of c3 = £4000 regardless 
of the result in the phase III trial. 
The two lower panels in Figure 5-16 show how the expected utility depends on 
the phase III sample size, when the gain function depends on n3. We see a largely 
similar pattern as before, even though things diﬀer slightly between the low and high 
sales estimate. In the former case, the new cost structure makes it possible to increase 
the expected utility, as the cost per patient in phase III is decreased from £4000 to 
£2000. In the latter case, the dependence of the gain function on n3 means that the 
expected utility is lower, even though c3 is decreased by a half. It is not surprising 
that the results for the high and low sales estimate vary, as the high sales estimate 
assumes a tenfold increase compared to the low sales estimate. A diﬀerent approach 
would have been to assign a prior probability to these sales estimates and work with 
the expectation under this prior. A third possibility would be to let the gain function 
depend explicitly on θ3 and z3, so that the diﬀerent sales forecasts are built in to the 
deﬁnition of g. 
5.7 Discussion 
We have seen that the correlation between θ2, the mean of the biomarker, and θ3, the  
mean of the clinical endpoint, as well as the cost of sampling, are crucial when deciding 
the phase II sample size. The prior uncertainty of θ2 and θ3 is also important. We have 
derived an expression for the information obtained for a certain investment, which can 
be used to assess if a biomarker is appropriate to use in the phase II trial. Suppose 
that it turns out to be optimal to make a large investment in phase II. A biomarker 
that is expensive but strongly correlated with the mean of the phase III endpoint is 
then likely to be more useful than a cheaper biomarker that is less strongly correlated. 
If only a small investment is made in phase II, a cheaper biomarker, which still has a 
substantial correlation, may provide a useful option. 
Our model can be used to ﬁnd the optimal phase II sample size, and hence, the 
amount of resources spent in phase II. We have found that the resources spent in 
phase II increase when the phase III investment is high, and there is uncertainty about 
whether the drug will progress to phase III. The phase II trial can however become 
redundant, if for example the ratio g/c3 is so high that the phase III trial will be carried 
out with probability close to one. The possibility to stop a project is important, in 
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particular when there is no group sequential monitoring in phase III. This can, in 
combination with the fact that the information in phase II may be cheaper than in 
phase III, justify an investment in phase II even though the observations in phase II 
are not used in the the ﬁnal hypothesis test in phase III. 
In the most general version of our model, n3 is allowed to depend on phase II data. 
The importance of this adaptation can be assessed by comparing with the situation 
when n3 is optimised, but not allowed to depend on the phase II data. The eﬃciency 
gains of the ﬁrst approach compared to the latter are rather modest, but we would still 
recommend making use of the information gathered in phase II. In practice, it may be 
useful to have a working assumption for the phase III sample size before the phase II 
results are obtained. If desirable, the phase III sample size can then be updated once 
the phase II results are available. We would recommend to use a lower bound for the 
phase III sample size, as it was shown in Table 5.1 that the eﬃciency loss from such 
an approach is small. Using a very small phase III sample size, because of promising 
results for a biomarker in phase II, may on the other hand be a risky strategy that may 
undermine the credibility of trial results. 
When a group sequential design is used in phase III, the expected utility can be 
improved by increasing the number of groups K. Another result of the possibility of 
early stopping is that the optimal maximal sample size of the group sequential design 
increases with K. We have found that increasing K, for example from K = 1  to  K = 2,  
has a more pronounced impact on the expected utility than adaptively choosing the 
phase III sample size based on phase II data. In Section 5.5.3 an improvement of 18 
% was observed when moving from K = 1  to  K = 2, while running a ﬁxed sample 
phase III trial with sample size updated based on phase II data gave an improvement 
of just 1%. The most eﬃcient design is obtained when a group sequential design is 
used in phase III and the maximal sample size is chosen based on the phase II results. 
It is not surprising that several aspects of the model change when a group sequential 
design is used in phase III. When phase III is group sequential, there is a possibility 
of early stopping. Hence, the early stopping in the phase III trial can partly replace 
the role that the phase II trial has in the go/no go decision. When the phase III 
sample size is chosen based on the phase II results, there is, provided that the cost and 
correlation structure of the biomarker is favourable, some use of phase II even when 
phase III is group sequential. This beneﬁt does however decrease with the number of 
interim analyses K. It may however not be entirely realistic that the expected sample 
size reﬂects the entire cost of a group sequential phase III trial. In practice it may be 
more reasonable to include a start-up cost, which cannot be recovered through early 
stopping. We have seen in Section 5.6 that when this is the case, the importance of 
the phase II trial increases slightly. 
In Section 5.6, we also experimented with introducing a gain function that was 
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decreasing in the phase III sample size n3. It is then implicitly assumed that an 
increased number of patients will increase the duration of the trial, with a shorter 
remaining patent life once the drug is approved. Results were largely similar, but 
typically with a slightly smaller optimal phase III sample size. An even more careful 
analysis would make the gain function depend also on the phase II sample size n2. 
It would be straightforward to extend our model to let g depend on n2. As  we  are  
assuming that the biomarker in phase II can be rapidly observed, it would appear 
to be a reasonable approximation to let g be independent of n2. The approximation 
will be particularly appropriate if there is not a big increase in recruitment time when 
increasing the phase II sample size. Moreover, it may be the case that even though 
the duration of the phase II trial is far from insigniﬁcant, other activities that are run 
simultaneously mean that the duration of the phase II does not in isolation decide when 
phase III can start. For the phase III trial that is the ﬁnal activity before submission for 
regulatory approval, it is more obvious that an increase in the number of observations 
will delay a potential launch of the drug. 
It is noteworthy that also for the rather modest ratios g/c3 that we have considered, 
it is often worthwhile to move forward to phase III even if the posterior distribution 
of the treatment eﬀect after phase II is not that impressive. There may be several 
ways to extend the model to make the decision rule for progress to phase III more 
conservative. Firstly, we have only required a statistically signiﬁcant result, p <  0.0005 
one-sided, for regulatory approval. In practice many phase III trials fail due to other 
issues such as unexpected safety problems. So if the assurance before embarking on a 
phase III trial according to our model is γ, the actual probability of regulatory approval 
is almost certain to be less than γ. A very simple model for safety could be that there 
is a risk of unexpected toxicity in phase III, that is independent of the eﬃcacy of the 
drug. In such a situation, discounting the assurance by a factor to account for issues 
other than eﬃcacy that may lead to the drug not being approved, would lead to a gain 
function g×P(Safe) instead of g. Such an approach is unlikely to change the qualitative 
behaviour of our model. 
A second extension could be to account for the fact that a pharmaceutical company 
can only run a limited number of late stage drug projects at the same time. A similar 
issue has been studied by Stallard (2003), who considered diﬀerent drug projects 
competing for the same limited resource. The competition for resources between 
diﬀerent projects may mean that some projects with positive expected utility may have 
to be parked if others are more promising. On the other hand, it could be argued that 
in such situations it might be possible to temporarily increase the volume of projects 
that can be run simultaneously, for example through cooperation with external contract 
research organisations. 
A third extension could be to consider other prior distributions than our choice of 
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bivariate normal prior distribution. Even for a drug with a not so impressive prior 
mean, there is due to the tails of the normal distribution some probability mass at 
values of the treatment eﬀect that make a phase III trial attractive. Perhaps a diﬀerent 
choice of prior, for example with a point mass of zero treatment eﬀect compared to 
control, would be an interesting extension to the model. We have nevertheless shown 
that phase II can be useful, in particular in identifying which treatments should be 
discontinued after phase II and increasing the probability of success conditional on 
progressing to phase III. 
5.8 Derivation and implementation 
5.8.1 Model derivation 
Derivation of posterior distribution of θ3 after phase II 
In this section we will provide further details about the methods used to derive phase II 
and phase III designs that maximise the expected utility. We will be using the model 
assumptions in equations (5.3) and (5.11) as well as the fact that the property 
πθ3|θ2,Z2 (θ3|θ2, z2) =  πθ3|θ2 (θ3|θ2) (5.32) 
follows immediately from (5.3). Let us now use (5.32) to derive the posterior 
distribution of θ3|Z2 = z2. We  have  ∫ ∞ 
πθ3|Z2 (θ3|z2) =  dθ2πθ3|θ2,Z2 (θ3|θ2, z2)πθ2|Z2 (θ2|z2), −∞ 
and using the fact that θ3 is conditionally independent of Z2 given θ2, we obtain  ∫ ∞ 
πθ3|Z2 (θ3|z2) =  dθ2πθ3|θ2 (θ3|θ2)πθ2|Z2 (θ2|z2). (5.33) −∞ 
Recall from Section 5.2.3 that the conditional distribution of θ3 given θ2 is normal with 
mean C + Dθ2 and variance τ 2, while the posterior distribution of θ2 given Z2 = z2 
is normal with mean m2 and variance t22. After  θ2 has been integrated out, it follows 
that the posterior distribution of θ3|Z2 = z2 is normal with mean μ2 and variance τ22 , 
where μ2 = C + Dm2 and τ2
2 = τ 2 + D2t22. 
Expected utility to be maximised 
We will now derive the simpliﬁed expression for the expected utility, shown in (5.15). 
Taking the expectation of U as deﬁned in (5.12), the expected utility in (5.13) can, 
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when g is allowed to depend on θ3, z3 and n3, be written as ∫ ∞ ∫ ∞ ∫ ∞ ∫ ∞ 
E(U) =  −a21n2>0 − c2n2 + dz2dz3dθ2dθ3fZ2,Z3,θ2,θ3 (z2, z3, θ2, θ3) −∞ −∞ −∞ −∞ 
×I(z2 > z){−a3 − n3(z2, n2)c3 + I(z3 > z1−α)g(θ3, z3, n3(z2, n2))}2 
∫ ∞ ∫ ∞ ∫ ∞ ∫ ∞ 
= −a21n2>0 − c2n2 + dz2dz3dθ3dθ2πθ3|θ2 (θ3|θ2)πθ2 (θ2)fZ2|θ2,θ3 (z2|θ2, θ3) −∞ −∞ −∞ −∞ 
×fZ3|θ3,θ2,Z2 (z3|θ3, θ2, z2)I(z2 > z2 ){−a3 − n3(z2, n2)c3 + I(z3 > z1−α)g(θ3, z3, n3(z2, n2))} 
∫ ∞ ∫ ∞ ∫ ∞ ∫ ∞ 
= −a21n2>0 − c2n2 + dz2dz3dθ3dθ2πθ3|θ2 (θ3|θ2)πθ2 (θ2)fZ2|θ2 (z2|θ2) −∞ −∞ −∞ −∞ 
×fZ3|θ3,Z2 (z3|θ3, z2)I(z2 > z){−a3 − n3(z2, n2)c3 + I(z3 > z1−α)g(θ3, z3, n3(z2, n2))},2 
(5.34) 
where the last equality follows from the modelling assumptions in (5.3) and (5.11). We 
can combine (5.32) and (5.33) with the identity 
πθ2 (θ2)fZ2|θ2 (z2|θ2) =  πθ2|Z2 (θ2|z2)fZ2 (z2), 
to obtain ∫ ∞ ∫ ∞ 
dθ2πθ3|θ2 (θ3|θ2)πθ2 (θ2)fZ2|θ2 (z2|θ2) =  dθ2πθ3|θ2,Z2 (θ3|θ2, z2)πθ2|Z2 (θ2|z2)fZ2 (z2) −∞ −∞ 
= π (θ3|z2)f (z2),θ3|Z2 Z2 
which inserted into (5.34) gives 
∫ ∞ ∫ ∞ ∫ ∞ 
E(U) =  −a21n2>0 − c2n2 + dz2f (z2)I(z2 > z) dz3 dθ3πθ3|Z2 (θ3|z2)Z2 2 −∞ −∞ −∞ 
×fZ3|θ3,Z2 (z3|θ3, z2){−a3 − c3n3(z2, n2) +  I(z3 > z1−α)g(θ3, z3, n3(z2, n2))} 
∫ ∞ ∫ ∞ 
= −a21n2>0 − c2n2 + dz2f (z2){−a3 − c3n3(z2, n2) +  dz3Z2 
z2 z1−α ∫ ∞ 
× dθ3πθ3|Z2 (θ3|z2)fZ3|θ3,Z2 (z3|θ3, z2)g(θ3, z3, n3(z2, n2))}. (5.35) −∞ 
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Here, π (θ3|z2) denotes the pdf of the posterior distribution of θ3, after having θ3|Z2 
observed Z2 = z2 in a phase II trial with n2 patients per treatment group. When 
g = g(n3(z2, n2)) and does not depend on z3 and θ3, (5.35) reduces to ∫ ∞ 
E(U) =  −a21n2>0 − c2n2 + dz2fZ2 (z2) 
z2 
×{γ(z2, n2, n3(z2, n2))g(n3(z2, n2)) − a3 − c3n3(z2, n2)} . 
If g is independent also of n3, which is assumed for most of this chapter, the formula 
displayed in equation (5.15) is obtained. Suppose that g does depend on n3 and z3, 
and is linear in θ3, 
g(θ3, z3, n3) =  g1(z3, n3(z2, n2)) + g2(z3, n3(z2, n2)) θ3, 
say. The expected utility can then be written as 
∫ ∞ 
E(U) =  −a21n2>0 − c2n2 + dz2fZ2 (z2) 
z2 ∫ ∞ 
×{−a3 − c3n3(z2, n2) +  dz3f (z3|z2)Z3|Z2 
z1−α 
×(g1(z3, n3(z2, n2)) + g2(z3, n3(z2, n2))μ3(z3, n3(z2, n2)))}, 
where fZ3|Z2 (z3|z2) =  ∞ dθ3πθ3|Z2 (θ3|z2)fZ3|θ3,Z2 (z3|θ3, z2) and  μ3(z3, n3(z2, n2)) is the −∞ 
posterior mean of θ3 after phase III. This type of gain function bears similarities with 
the public health beneﬁt function used by Gittins and Pezeshk (2000b). 
We have focused our derivation on a very general case, where the gain function is 
not a constant and n3 can be chosen based on the phase II results. The situation when 
we simplify to having g and n3 as constants can be viewed as a special case of our 
derivation, which applies in these cases too. 
The situation is very similar when, like in Section 5.5.3, phase III is group sequential. 
Instead of calculating the probability of exceeding z1−α under the prior distribution of 
θ3, the probability of stopping and continuing at each interim analysis has to be taken 
into account. When the gain function depends on n3, it is important to note that 
the gain function takes diﬀerent values depending on at which interim analysis the 
null hypothesis is rejected. The other important diﬀerence is that when the sample 
size depends on the amount of early stopping, we need to take this into account when 
calculating the cost per patient. For a group sequential phase III design, we are only 
charged c3 times the expected sample size under the posterior distribution for θ3 after 
phase II, as opposed to c3 × n3 for a ﬁxed sample phase III trial. 
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5.8.2 Implementation 
Optimisation of phase III sample size 
Sample size of phase III trial without interim analyses 
In Section 5.5.1 we consider the problem of ﬁnding the optimal phase III sample size 
, given a prior distribution for θ3 and assumptions about g/c3 and σ3
2 . We will now n

provide further details of how to solve this problem. Suppose that 
θ3|Z2 = z2 ∼ N(μ2, τ2).2 
This is equivalent to having observed Z2 = z2 in a phase II trial with n2 patients per 
group, for some z2, n2 and prior distribution. For given z2 and n2, we can calculate the 
expected utility of running a ﬁxed sample phase III study with maximal sample size n3. 
The next step is to perform a numerical search for the value n
3(Z2, n2) that  gives  the  
optimal phase III design for given Z2 = z2 and n2. For a ﬁxed sample phase III trial 
with sample size chosen based on the phase II results, n
3 and the type I error probability

α = 0.0005 deﬁne the design of the phase III trial. If we instead are interested in n
3f, 
which is not allowed to depend on the phase II results, we perform a two-dimensional 
search for the pair of sample sizes n2, n3 that maximise the expected utility. 
Maximal sample size when phase III trial is group sequential 
When, like in Section 5.5.3, a group sequential design is used in phase III, we have by 
choosing a ρ family error spending design already determined the shape of both the 
upper and lower boundary. If we are aiming for 90% power at θ = δ, it is straightforward 
to derive the maximal sample size n3,max, through a one-dimensional numerical search. 
If the maximal sample size is chosen based on decision-analytic considerations, the 
problem is one-dimensional. If n3,max is allowed to depend on the phase II results, we 
can ﬁnd the maximal sample size in a similar way as described above for a ﬁxed sample 
trial. If we instead are interested in the ﬁxed value of n
3,max that does not depend on

the phase II results, we search for the pair of sample sizes n2, n3,max that maximise

the expected utility. 
Decision rule for progression to phase III 
We saw in Section 5.3 that when the phase III sample size is not allowed to depend 
on phase II data, the cut-oﬀ μ
2 for progress to phase III can be found analytically. As

explained in Section 5.5.1, this is not the case when the phase III sample size is chosen 
based on phase II data. When n3 is allowed to vary depending on μ2, we can still ﬁnd 
μ
 through a one-dimensional search, provided that the expected utility, for ﬁxed τ2
2 , 
is monotonically increasing in μ2. We show this in two steps: 
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1. We ﬁrst make use of the fact that in all these designs, the expected utility must, 
for ﬁxed τ2
2 and n3, be monotonically increasing in μ2, the prior mean of θ3 after 
phase II. This follows from the deﬁnition of assurance in equation (5.14). 
2. To see what happens when n3 is allowed to vary, consider two prior means, with 
μ21 < μ22, and suppose that n3(μ21, τ2
2) =  n31. Using the same sample size n31 
when the prior mean equals μ22 must for μ22 > μ21 and ﬁxed τ2
2, according to 
the deﬁnition in (5.14), give a higher assurance and consequently higher expected 
utility. If n
3(μ22, τ2
2)  n31, this must be because another choice of phase III = 
sample size gives an even higher expected utility, conditional on μ22 and τ2
2, than  
n31. 
As the expected return is monotonically increasing in μ2, a go/no go decision rule can 
be calculated by searching for μ
2, the  value of  μ2 that gives an optimal phase III design 
with expected utility equal to zero. 
Finding the optimal phase II sample size 
Once we know the optimal phase III sample size n
3(z2, n2), for a given combination of 
Z2 = z2 and n2, the next step is to ﬁnd the phase II sample size n2 that maximises the

expected utility. Given the results of a phase II design with n2 observations, we can 
calculate π (θ3|z2). With this posterior distribution available, we have a rule for θ3|Z2 
how to choose the optimal phase III design. For any combination of n2, Z2 = z2, the  
optimal phase III design can thus be regarded as known, regardless of whether phase III 
is a ﬁxed sample design or group sequential. For some combinations n2, Z2 = z2, the  
optimal design may be not to proceed to phase III and stop development of the drug 
in question. 
To assess the optimal choice of n2, we can integrate over the marginal distribution 
of Z2 and obtain the expected utility as deﬁned in (5.15), for diﬀerent choices of n2. 
Methods for numerical integration that are based on Simpson’s rule are suitable in these 
situations, and are further described in Jennison and Turnbull (2000, Chapter 19). 
Provided that we know how to calculate the integral numerically, it remains to perform 
a one-dimensional search for n
2, the  value of  n2 that maximises (5.15). 
157

CHAPTER 6

Discussion and conclusions 
6.1 A broader drug development perspective 
An important objective in drug development is to get drugs approved in areas where 
there is an unmet medical need. There are many areas where there is no satisfactory 
treatment available, or where the current standard treatment could be improved upon. 
There are consequently several players who have an interest in getting new, eﬀective 
medicines approved. Patients and regulatory authorities are aﬀected if fewer eﬀective 
medicines are available, and the pharmaceutical industry is facing challenges such 
as expiring patents of existing drugs, increased costs of running clinical trials and 
diﬃculties with getting new drugs approved. There is a growing demand for novel, 
innovative approaches to how new medicines can be developed. Adaptive design of 
clinical trials is one new area that has received considerable attention. While it would 
be unrealistic to expect this class of designs to provide a solution to all the issues 
mentioned in this paragraph, it is hoped that it can be helpful in improving important 
aspects of clinical trial design. 
This thesis deals with sequential and adaptive methods for clinical trials, and how 
such methods can be used to achieve eﬃcient clinical trial designs. The eﬃciency 
gains that can be achieved through non-adaptive group sequential methods are well 
established, while the newer adaptive methods seek to combine the best of the group 
sequential framework with an approach that gives more ﬂexibility. Within the context 
of a clinical development programme, both classes of designs can also be helpful in 
identifying which treatments should be progressed for further testing. 
The increased costs of drug development, described by DiMasi et al. (2003), 
emphasise the need for designing development programmes that are more eﬃcient. 
More eﬃcient development programmes would make it possible to test larger number 
of promising candidate drugs. Adequately designed clinical trials can also be helpful in 
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identifying which treatments should be progressed to the later, more costly, stages of 
development. Hence, the eﬃcient design of group sequential and trials can contribute 
to improving the drug development process and making more eﬀective drugs available 
to patients. The four problems that have been studied in this thesis all relate to how 
clinical trials can me made more eﬃcient and ﬂexible, while maintaining the credibility 
of trial results. We will now brieﬂy discuss the main results. 
6.2 Summary of results 
6.2.1	 Optimal group sequential designs for simultaneous testing of 
superiority and non-inferiority 
Conﬁrmatory clinical trials, comparing the eﬃcacy of a new treatment with an active 
control, typically aim at demonstrating either superiority or non-inferiority. We 
consider non-adaptive and adaptive group sequential designs that combine the two 
objectives. The diﬀerence between the two classes is that in adaptive group sequential 
designs, the future group sizes may be chosen based on the observed treatment eﬀect. 
For both classes of designs, we derive group sequential designs meeting error 
probability constraints which minimise the expected sample size, averaged over a 
set of values of the treatment eﬀect. These optimised designs provide an eﬃcient 
means of reducing expected sample size under a range of treatment eﬀects, even when 
the separate objectives of proving superiority and non-inferiority would require quite 
diﬀerent ﬁxed sample sizes. 
We also present error spending versions of the non-adaptive sequential designs, 
which are easily implementable and can handle unpredictable group sizes or information 
levels. The adaptive choice of group size yield some modest eﬃciency gains. Further 
reduction can however be achieved by adding another interim analysis to a non-adaptive 
group sequential design. 
6.2.2	 Control of type I error when applying the CRP principle in an 
error spending design 
Error spending tests are eﬃcient and can cope with unpredictable information 
sequences with exact control of the type I error rate. Since the conditional rejection 
probability (CRP) principle gives ﬂexibility beyond what is available in error spending 
designs, it would be very beneﬁcial to be able to combine the two approaches. We 
have investigated how to apply the CRP principle in a clinical trial with unpredictable 
information levels and present numerical examples of how the type I error can be 
inﬂated. A method that ensures protection of the type I error, by using a pre-speciﬁed 
combination rule, is discussed. It is found that such methods can lead to unequal 
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weighting of equally informative observations and thus some loss of eﬃciency. If it is 
very important to be able to adapt, it may well be that the increased ﬂexibility that is 
provided compensates for the eﬃciency loss, which is often small. The conclusion from 
Chapter 3 is that care is needed when applying the CRP principle. The type I error 
can be inﬂated when applying the CRP principle in an error spending design, unless 
the conditional type I error is well deﬁned in all situations when a re-design can occur. 
6.2.3 Group sequential designs with non-binding futility boundaries 
The eﬃciency gains that can be achieved through one-sided group sequential tests 
are well documented (Barber and Jennison, 2002; Jennison and Turnbull, 2006a). In 
Chapter 4 we address a problem that arises whenever there is a futility boundary in a 
one-sided group sequential test, but has sometimes been overlooked in the statistical 
literature. A new method to derive optimal group sequential designs with non-binding 
futility boundaries is presented and the results are compared against currently available 
designs with non-binding futility boundaries. The new optimisation method extends 
the method of dynamic programming, used in Chapter 2. 
Using tests with non-binding futility boundaries should be re-assuring to regulators. 
They can be conﬁdent that the type I error is controlled, even if the futility boundary 
is not always applied. From the point of view of the trial sponsor, the boundaries 
are a little conservative, with an attained type I error that is smaller than α and a 
small loss of power as a result. By making comparisons with optimal group sequential 
designs with binding futility boundaries, we can quantify the eﬃciency loss incurred 
by the additional requirement that futility boundaries must be non-binding. Group 
sequential designs with non-binding futility boundaries nevertheless deliver substantial 
eﬃciency gains compared to ﬁxed sample designs. It is found that both error spending 
designs and futility stopping based on predictive power give eﬃciency close to that of 
the optimal designs. The comparisons with the optimal group sequential designs means 
that we have two methods that are easy to use, with close to optimal eﬃciency. 
6.2.4 Joint planning of phase II and phase III 
In Chapter 5 we move beyond the individual trial, to consider the joint planning of one 
phase II trial and one phase III trial. We present a method to ﬁnd the phase II and 
phase III sample sizes, as well as a decision rule for progress to phase III, that maximise 
the expected utility. We consider both the situation when the phase III sample size is 
ﬁxed, and when it is optimally chosen based on phase II data. 
In our model, with diﬀerent endpoints in phase II and phase III, the utility of the 
phase II trial varies depending on the cost of sampling and the correlation with the 
mean of the phase III endpoint. Given a certain prior distribution, cost and correlation, 
we derive an expression for the utility of using a certain biomarker in phase III. This 
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expression can be used to choose between diﬀerent biomarkers, with diﬀerent cost and 
correlation structures. 
The impact of running an error spending design, of the type used in Chapter 4 
with a non-binding futility boundary, in phase III is also considered. It is found that 
running a group sequential design in phase III reduces the importance of the phase II 
trial. Each interim analysis of the group sequential design can be thought of as a 
new go/no go decision. Hence, the go/no go decision between phase II and phase III 
becomes less important. 
We also assess what eﬃciency gains can be achieved, by adaptively choosing 
phase III sample size based on phase II data. To this end, a simpliﬁed version of 
the model, where the phase III sample size is not allowed to depend on phase II data, 
is compared to an optimal adaptation rule. It is found that adding an interim analyses 
to the phase III trial is more important to the expected utility than adaptively choosing 
the phase III sample size based on phase II data. 
6.3 Discussion 
6.3.1 Adapting future sample size based on observed data 
Our results show that adaptive methods can provide some additional eﬃciency 
compared to classical group sequential designs, as well as increased possibilities to 
respond to new internal and external information. Care is however needed when 
applying adaptive methods. The conduct of clinical trials is important, and the 
logistical challenges of implementing adaptive methods can be considerable. Eﬃcient 
non-adaptive group sequential designs are often easier to implement in practice, and 
have in the cases we have considered been quite competitive in terms of eﬃciency. 
The eﬃciency of non-adaptive and adaptive group sequential tests for a two-decision 
problem has been compared by Tsiatis and Mehta (2003), Brannath et al. (2006) 
and Jennison and Turnbull (2006a), among others. Our results for the three-decision 
problem in Chapter 2 are largely in agreement with their ﬁndings. 
The problem of adaptively choosing the second group size, considered in Chapter 2, 
bears similarities with adaptively choosing phase III sample size based on phase II 
data, considered in Chapter 5. In both cases we ﬁnd that the beneﬁts of adaptation 
are modest, while greater eﬃciency can be achieved by increasing the number of groups 
in the non-adaptive group sequential designs. The adaptive group sequential designs 
in Chapter 2 are optimal from a theoretical perspective, but would in practice be 
diﬃcult to implement for an unpredictable information sequence. We would prefer a 
pre-planned, non-adaptive group sequential design, using the error spending approach 
described in Section 2.2.5 to handle unpredictable information sequences. The situation 
is diﬀerent in Chapter 5, where no adjustment to the ﬁnal analysis is necessary because 
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of the adaptation based on phase II. Hence, we recommend the approach illustrated 
in Section 5.6, using the knowledge gained in phase II to update the phase III sample 
size. 
6.3.2 Optimisation as an approach to clinical trial design 
Throughout this thesis, decision analysis has been used as a device to derive clinical 
trial designs that maximise the expected utility, or equivalently, minimise the excepted 
cost. It is however our experience that in phase III in particular, it is still more common 
to design clinical trials based on the frequentist hypothesis test framework, where the 
sample size is chosen to achieve a certain power at a given eﬀect size. Solving very 
general decision problems, involving many parameters, is diﬃcult, and this could be 
one reason for why in practice, the approach is not so often applied. To be able to solve 
a decision problem, it is often necessary to make simplifying assumptions. On a less 
technical level, decision analysis is however not so diﬀerent from what we do to make 
decisions in daily life. Diﬀerent pros and cons are weighed against each other and the 
most diﬃcult part may be to deﬁne the utility function. Even if the utility function is 
suitably deﬁned, it may be diﬃcult to specify some of the parameter values that are 
needed to solve the decision problem. This should however not be an excuse to base the 
design on ad hoc assumptions that are diﬃcult to justify. We would recommend to ﬁrst 
make an informed, conscious choice about which model and parameter values to use. 
Thereafter, it is important to perform robustness checks to assess how the uncertainty 
about the parameters in the model aﬀects the decision-making. 
The choice of prior distribution is another diﬃculty that should not be 
underestimated. O’Hagan et al. (2006) propose eliciting prior distributions based on 
the opinion of experts, but this possibility has not been considered in this thesis. It 
could be possible to use elicitation to determine the prior distribution in Chapter 5. For 
the problems in Chapter 2 and Chapter 4, the prior distribution is to a large degree 
decided by the need to control the error probability constraints at certain values of 
the treatment eﬀect. It could be argued that the choice of prior distribution is more 
subjective in the problem in Chapter 5, where it more directly reﬂects the prior belief 
about the mean of the phase II and phase III endpoints. 
6.3.3 Decision analysis in this thesis 
Let us now consider how decision analysis has been applied in Chapters 2, 4 and 5 and 
assess what the diﬀerences and similarities are. In both Chapter 2 and Chapter 4, 
decision analysis is used to solve the constrained optimisation problem of ﬁnding 
an optimal group sequential boundary, subject to suitably deﬁned frequentist error 
probability constraints. This is achieved by ﬁrst developing a method to solve the 
unconstrained Bayes problem, with ﬁxed costs for making the wrong decision about 
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the treatment eﬀect. When a method to solve the unconstrained problem is available, 
it remains to perform a numerical search for the costs that give a solution with the 
desired error probabilities. 
The problem in Chapter 5 is diﬀerent in several ways. In Chapter 5, the type I error 
probability of the phase III trial is not deﬁned by a group sequential boundary that is a 
part of the optimisation process. The threshold that deﬁnes the go/no go decision rule 
can be thought of as a futility boundary in a one-sided group sequential test, but does 
not impact the type I error probability of the phase III trial. Moreover, the general 
formulation in Chapter 5 does not require achieving a certain power at a stipulated 
eﬀect size. When the problem is re-deﬁned in this way in Section 5.3, the phase III 
sample size is constrained to take a certain value and there is one less parameter to 
optimise. 
The computational methods that have been used also diﬀer between the chapters. In 
Chapter 2 the method of dynamic programming can be used to solve the unconstrained 
decision problem, with ﬁxed costs for the type I and type II error probabilities. The 
optimisation problem in Chapter 4 was more challenging computationally, as dynamic 
programming could not be directly applied. The problem could be solved by extending 
the method of dynamic programming, as described in detail in Section 4.6. 
We did not apply the standard method of dynamic programming, illustrated in 
Chapter 2, to solve the optimisation problem in Chapter 5. There were however still 
common features with the problems in the other chapters. When the phase III sample 
size is allowed to depend on phase II data, the problem in Chapter 5 bears similarities 
with ﬁnding the adaptive group sequential designs in Section 2. When n3 is not allowed 
to depend on phase II data, there are also connections to the problem considered by 
Eales and Jennison (1992), who optimise the group sizes of an optimal group sequential 
test. 
6.4 Extensions and future work 
Chapter 5 can be viewed as an extension of the other chapters. It brings together 
methods that we have used for the design of individual trials, to solve the more complex 
problem of how to design a clinical development programme. As a clinical development 
program involves many complex decisions and parameters, it is easy to see that the 
model could be further extended. While some possible extensions were discussed at 
the end of Chapter 5, the problem of ﬁnding the right dose or set of doses to bring 
forward to phase III would be another very natural extension. In many indications, 
dose-ﬁnding plays a crucial role in the trial immediately before phase III. It would be 
useful to extend our model by including multiple doses of the experimental drug, as 
well as a control, in phase II. A very similar framework to the one used in Chapter 5 
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could be applied, with the key diﬀerence that it would be computationally challenging 
to calculate the posterior distribution of the treatment eﬀect at diﬀerent dose levels. 
The optimal phase II sample size is then likely to increase, as more information in 
phase II would make it easier to identify which dose(s) to bring forward to phase III. 
It would appear to be reasonable to use a parametric model that assumes a treatment 
eﬀect that is monotonically increasing in dose. If monotonicity is assumed, it would 
however also be necessary to model how the toxicity of the drug depends on the dose. 
Otherwise, any sensible decision rule would end up always selecting the top dose, with 
the highest eﬃcacy. 
6.5 Final words 
To summarise, this thesis presents four problems related to the design of clinical trials. 
It is natural to ask what can be gained by using the methods and designs presented 
in this thesis. We would argue that the four problems that have been solved are 
very relevant to clinical trial applications. The solutions that we present are either 
new approaches to problems that have not yet been solved, or methods that are more 
eﬃcient than the ones currently available in the literature. If the methods are applied 
in a correct way, they could ideally contribute to improved clinical trial designs and 
development programmes. Taking into account the costs of drug development estimated 
by DiMasi et al. (2003), even modest eﬃciency gains on a relative scale can translate 
to important improvements in absolute numbers. 
The error spending versions of the optimal non-adaptive group sequential designs in 
Chapter 2 and Chapter 4 should be easy to implement in practice. They can deal with 
unpredictable group sizes and could be monitored within a group sequential framework, 
where a DMC makes recommendations about whether to stop or continue. If desirable, 
the error spending designs in Chapter 2 could be made non-binding, following the 
approach used for one-sided tests in Chapter 4. Chapter 3 is also closely related 
to applications, and what can go wrong if the conditional type I error is not well 
deﬁned in all situations when a re-design can occur. Finally, the problem in Chapter 5 
is probably even closer to clinical trial applications than the others. A model that 
incorporates what is required for regulatory approval is deﬁned. Thereafter the problem 
is solved using explicit assumptions about the gains and costs in diﬀerent phases of the 
development program. As discussed in Section 6.4, it would be very appealing to make 
further extensions to the model, as well as applying it to practical examples in diﬀerent 
therapeutic areas. 
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